Document_and_Entity_Informatio
Document and Entity Information (USD $) | 12 Months Ended | ||
Dec. 31, 2013 | Mar. 07, 2014 | Jun. 28, 2013 | |
Document And Entity Information [Abstract] | ' | ' | ' |
Document Type | '10-K | ' | ' |
Document period end date | 31-Dec-13 | ' | ' |
Amendment flag | 'false | ' | ' |
Document Period Focus | 'FY | ' | ' |
Document Fiscal Year Focus | '2013 | ' | ' |
Current fiscal year end date | '--12-13 | ' | ' |
Entity central index key | '0001123494 | ' | ' |
Entity current reporting status | 'Yes | ' | ' |
Entity filer category | 'Accelerated Filer | ' | ' |
Entity registrant name | 'HARVARD BIOSCIENCE INC | ' | ' |
Entity voluntary filers | 'No | ' | ' |
Entity well known seasoned issuer | 'No | ' | ' |
Entity common stock shares outstanding | ' | 31,639,467 | ' |
Entity public float | ' | ' | $100,095,274 |
Non Affiliate Share Holding | ' | ' | 28,116,650 |
Statements_of_Financial_Positi
Statements of Financial Position (USD $) | Dec. 31, 2013 | Dec. 31, 2012 |
In Thousands, unless otherwise specified | ||
Current Assets: | ' | ' |
Cash and cash equivalents | $25,771 | $20,681 |
Accounts receivable, net of allowance for doubtful accounts of $358 and $194, respectively | 13,884 | 14,357 |
Inventories | 15,777 | 17,762 |
Deferred income tax assets - current | 1,547 | 1,553 |
Other receivables and other assets | 3,771 | 4,619 |
Total current assets | 60,750 | 58,972 |
Property, plant and equipment, net | 4,375 | 4,551 |
Deferred income tax assets - non-current | 13,116 | 10,770 |
Amortizable intangible assets, net | 19,009 | 21,225 |
Goodwill | 36,605 | 36,200 |
Other indefinite lived intangible assets | 1,289 | 1,276 |
Other assets | 316 | 490 |
Total Assets | 135,460 | 133,484 |
Current liabilities: | ' | ' |
Current portion, long-term debt | 5,000 | 0 |
Accounts payable | 4,682 | 4,680 |
Deferred revenue | 640 | 482 |
Accrued income taxes payable | 99 | 506 |
Accrued expenses | 5,078 | 3,505 |
Other liabilities - current | 586 | 728 |
Total current liabilities | 16,085 | 9,901 |
Long-term debt | 19,750 | 12,950 |
Deferred income tax liabilities - non-current | 160 | 277 |
Other liabilities- non current | 4,980 | 6,143 |
Total liabilities | 40,975 | 29,271 |
Commitments and contingencies | ' | ' |
Stockholders Equity Abstract | ' | ' |
Preferred stock, par value $0.01 per share, 5,000,000 shares authorized | 0 | 0 |
Common stock, par value $0.01 per share, 80,000,000 shares authorized; 39,384,974 and 37,123,705 shares issued and 31,639,467 and 29,378,198 shares outstanding, respectively | 390 | 370 |
Additional paid-in-capital | 202,446 | 196,634 |
Accumulated deficit | -95,039 | -77,260 |
Accumulated other comprehensive loss | -2,644 | -4,863 |
Treasury stock at cost, 7,745,507 common shares | -10,668 | -10,668 |
Total stockholders' equity | 94,485 | 104,213 |
Total liabilities and stockholders' equity | $135,460 | $133,484 |
Statements_of_Financial_Positi1
Statements of Financial Position (Parentheticals) (USD $) | Dec. 31, 2013 | Dec. 31, 2012 |
In Thousands, except Share data, unless otherwise specified | ||
CONSOLIDATED BALANCE SHEETS | ' | ' |
Allowance for doubtful accounts | $358 | $194 |
Preferred Stock Par value | $0.01 | $0.01 |
Preferred Stock - Shares Authorized | 5,000,000 | 5,000,000 |
Common stock par value | $0.01 | $0.01 |
Common Stock- Shares Authorized | 80,000,000 | 80,000,000 |
Common Stock- Shares Issued | 39,384,974 | 37,123,705 |
Common Stock- Shares Outstanding | 31,639,467 | 29,378,198 |
Treasury Stock common shares | 7,745,507 | 7,745,507 |
Statements_of_Operations
Statements of Operations (USD $) | 12 Months Ended | ||
In Thousands, except Share data, unless otherwise specified | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2011 |
CONSOLIDATED STATEMENTS OF OPERATIONS | ' | ' | ' |
Revenues | $105,171 | $111,171 | $108,864 |
Cost of product revenues | 57,475 | 58,831 | 58,672 |
Gross profit | 47,696 | 52,340 | 50,192 |
Sales and marketing expenses | 17,330 | 18,287 | 16,909 |
General and administrative expenses | 17,887 | 18,121 | 17,630 |
Research and development expenses | 4,154 | 4,344 | 3,874 |
HART transaction costs | 2,048 | 696 | 161 |
Restructuring charges | 2,150 | 310 | 467 |
Amortization of intangible assets | 2,590 | 2,752 | 2,746 |
Total Operating Expenses | 46,159 | 44,510 | 41,787 |
Operating income | 1,537 | 7,830 | 8,405 |
Other (expense) income: | ' | ' | ' |
Foreign exchange | -139 | -113 | -41 |
Interest expense | -955 | -584 | -752 |
Interest income | 43 | 46 | 65 |
Other expense, net | -51 | -287 | -809 |
Other (expense) income, net | -1,102 | -938 | -1,537 |
Income before income taxes | 435 | 6,892 | 6,868 |
Total Income Tax Expense (Benefit) | -288 | 2,398 | 1,579 |
Income from continuing operations | 723 | 4,494 | 5,289 |
Discontinued Operations [Abstract] | ' | ' | ' |
Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent | -2,553 | -2,124 | -1,477 |
Net (loss) income | ($1,830) | $2,370 | $3,812 |
Income per share: | ' | ' | ' |
Basic earnings per common share from continuing operations | $0.02 | $0.16 | $0.19 |
Discontinued operations | ($0.08) | ($0.07) | ($0.05) |
Basic earnings per common share | ($0.06) | $0.09 | $0.14 |
Diluted earnings per common share from continuing operations | $0.02 | $0.15 | $0.18 |
Discontinued operations | ($0.08) | ($0.07) | ($0.05) |
Diluted Earnings Per Common Share | ($0.06) | $0.08 | $0.13 |
Weighted average common shares: | ' | ' | ' |
Basic | 30,384,010 | 28,799,377 | 28,451,386 |
Diluted | 31,913,799 | 29,792,107 | 29,818,734 |
Statement_of_Comprehensive_Inc
Statement of Comprehensive Income (USD $) | 12 Months Ended | ||
In Thousands, unless otherwise specified | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2011 |
Consolidated Statements of Comprehensive Income [Abstract] | ' | ' | ' |
Net income | ($1,830) | $2,370 | $3,812 |
Other Comprehensive Income (Loss), Net of Tax [Abstract] | ' | ' | ' |
Foreign currency translation adjustments | 1,573 | 1,863 | -976 |
Other Comprehensive Income Derivatives Qualifying As Hedges Net Of Tax Period Increase Decrease [Abstract] | ' | ' | ' |
Loss on derivative instruments designated and qualifying as cash flow hedges | -116 | 0 | 0 |
Amounts reclassified from accumulated other comprehensive income to net income | 67 | 0 | 0 |
Derivatives qualifying as hedges, net of tax total | -49 | 0 | 0 |
Other Comprehensive Income (Loss), Pension and Other Postretirement Benefit Plans, Adjustment, Net of Tax [Abstract] | ' | ' | ' |
Amount of net loss included in net periodic pension costs, net of tax expense of $62, $57 and $40 in 2013, 2012 and 2011, respectively | 243 | 191 | 119 |
Net gain (loss), net of tax expense (benefits) of $115, ($357) and ($323) in 2013, 2012 and 2011, respectively | 452 | -1,195 | -969 |
Changes in defined benefit pension plans, net of tax, total | 695 | -1,004 | -850 |
Other Comprehensive Income (Loss), Net of Tax, total | 2,219 | 859 | -1,826 |
Total Comprehensive Income (Loss), Net of Tax, total | $389 | $3,229 | $1,986 |
Statement_of_Comprehensive_Inc1
Statement of Comprehensive Income (Parentheticals) (USD $) | 12 Months Ended | ||
In Thousands, unless otherwise specified | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2011 |
Consolidated Statements of Comprehensive Income [Abstract] | ' | ' | ' |
Other Comprehensive Income (Loss), Reclassification, Pension and Other Postretirement Benefit Plans, Net Gain (Loss) Recognized in Net Periodic Benefit Cost, Tax | $62 | $57 | $40 |
Other Comprehensive Income (Loss), Pension and Other Postretirement Benefit Plans, Net Unamortized Gain (Loss) Arising During Period, Tax | $115 | ($357) | ($323) |
Statement_of_Shareholders_Equi
Statement of Shareholders Equity (USD $) | Total | Common Stock [Member] | Additional Paid-in Capital [Member] | Retained Earnings [Member] | Accumulated Other Comprehensive Income (Loss) [Member] | Treasury Stock [Member] |
In Thousands, except Share data, unless otherwise specified | ||||||
Total stockholders' equity at begining of the year, Value at Dec. 31, 2010 | $90,248 | $361 | $187,893 | ($83,442) | ($3,896) | ($10,668) |
Balance at December 31, 2008, Shares at Dec. 31, 2010 | 36,058,000 | ' | ' | ' | ' | ' |
Stock option exercises during the year, Value | 400 | 1 | 399 | ' | ' | ' |
Stock option exercises during the year, Shares | 106,000 | ' | ' | ' | ' | ' |
Stock issued during the year, Value, Employee Stock Purchase Plan | 167 | 0 | 167 | ' | ' | ' |
Stock issued during the year, Shares, Employee Stock Purchase Plans | 49,000 | ' | ' | ' | ' | ' |
Restricted Stock Unit Issuance | 117,000 | ' | ' | ' | ' | ' |
Shares Withheld For Taxes | -41,000 | ' | ' | ' | ' | ' |
Shares Withheld For Taxes- Value | -165 | ' | -165 | ' | ' | ' |
Stock-based compensation expense | 2,863 | ' | 2,863 | ' | ' | ' |
Purchases of treasury stock | 0 | ' | ' | ' | ' | ' |
Other Comprehensive Income (Loss), Net of Tax [Abstract] | ' | ' | ' | ' | ' | ' |
Other Comprehensive Income (Loss), Net of Tax | -1,826 | ' | ' | ' | -1,826 | ' |
Net income | 3,812 | ' | ' | 3,812 | ' | ' |
Total stockholders' equity at year end, Value at Dec. 31, 2011 | 95,499 | 362 | 191,157 | -79,630 | -5,722 | -10,668 |
Shares issued at year end, Shares at Dec. 31, 2011 | 36,289,000 | ' | ' | ' | ' | ' |
Stock option exercises during the year, Value | 2,117 | 7 | 2,110 | ' | ' | ' |
Stock option exercises during the year, Shares | 648,000 | ' | ' | ' | ' | ' |
Stock issued during the year, Value, Employee Stock Purchase Plan | 192 | 1 | 191 | ' | ' | ' |
Stock issued during the year, Shares, Employee Stock Purchase Plans | 60,028 | ' | ' | ' | ' | ' |
Restricted Stock Unit Issuance | 164,000 | ' | ' | ' | ' | ' |
Shares Withheld For Taxes | -37,000 | ' | ' | ' | ' | ' |
Shares Withheld For Taxes- Value | -145 | ' | -145 | ' | ' | ' |
Stock-based compensation expense | 3,321 | ' | 3,321 | ' | ' | ' |
Other Comprehensive Income (Loss), Net of Tax [Abstract] | ' | ' | ' | ' | ' | ' |
Other Comprehensive Income (Loss), Net of Tax | 859 | ' | ' | ' | 859 | ' |
Net income | 2,370 | ' | ' | 2,370 | ' | ' |
Total stockholders' equity at year end, Value at Dec. 31, 2012 | 104,213 | 370 | 196,634 | -77,260 | -4,863 | -10,668 |
Shares issued at year end, Shares at Dec. 31, 2012 | 37,124,000 | ' | ' | ' | ' | ' |
Stock option exercises during the year, Value | 4,051 | 20 | 4,031 | ' | ' | ' |
Stock option exercises during the year, Shares | 2,135,000 | ' | ' | ' | ' | ' |
Stock issued during the year, Value, Employee Stock Purchase Plan | 194 | 0 | 194 | ' | ' | ' |
Stock issued during the year, Shares, Employee Stock Purchase Plans | 56,938 | ' | ' | ' | ' | ' |
Restricted Stock Unit Issuance | 282,000 | ' | ' | ' | ' | ' |
Shares Withheld For Taxes | -213,000 | ' | ' | ' | ' | ' |
Shares Withheld For Taxes- Value | -1,083 | ' | -1,083 | ' | ' | ' |
Stockholders Equity Note Spinoff Transaction | -15,949 | ' | ' | -15,949 | ' | ' |
Stock-based compensation expense | 2,670 | ' | 2,670 | ' | ' | ' |
Other Comprehensive Income (Loss), Net of Tax [Abstract] | ' | ' | ' | ' | ' | ' |
Other Comprehensive Income (Loss), Net of Tax | 2,219 | ' | ' | ' | 2,219 | ' |
Net income | -1,830 | ' | ' | -1,830 | ' | ' |
Total stockholders' equity at year end, Value at Dec. 31, 2013 | $94,485 | $390 | $202,446 | ($95,039) | ($2,644) | ($10,668) |
Shares issued at year end, Shares at Dec. 31, 2013 | 39,385,000 | ' | ' | ' | ' | ' |
Statements_of_Cash_Flows
Statements of Cash Flows (USD $) | 12 Months Ended | ||
In Thousands, unless otherwise specified | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2011 |
Cash flows from operating activities: | ' | ' | ' |
Net income | ($1,830) | $2,370 | $3,812 |
Adjustments to reconcile net income to net cash provided by operating activities: | ' | ' | ' |
Stock-based compensation expense | 2,670 | 3,321 | 2,863 |
Depreciation | 1,298 | 1,270 | 1,276 |
Receivable for the earn-out related to discontinued assets | 440 | 1,344 | 0 |
Gain on sales of fixed assets | 0 | -24 | -19 |
Non cash restructuring charge | -46 | -13 | 210 |
Amortization Of Catalog Costs | 101 | 184 | 307 |
Provision for allowance for doubtful accounts | 172 | -31 | 67 |
Amortization of intangible assets | 2,590 | 2,752 | 2,746 |
Amortization of deferred financing costs | 46 | 52 | 89 |
Deferrred Income Tax Expense (Benefit) | -2,441 | -731 | -849 |
Changes in operating assets and liabilities: | ' | ' | ' |
Decrease (increase) n accounts receivable | 436 | 1,154 | 232 |
Decrease (increase) in inventories | 1,921 | 1,174 | -1,705 |
(Increase) decrease in other receivables and other assets | -1,020 | -925 | -73 |
(Decrease) increase in trade accounts payable | -41 | -905 | 69 |
Increase (decrease) in accrued income taxes | 323 | 213 | -544 |
(Decrease) increase in accrued expenses | 847 | -485 | -1,368 |
(Decrease) increase in deferred revenue | 146 | -48 | 31 |
Increase (decrease) in other liabilities | -672 | 78 | -496 |
Net Cash Provided By Operating Activities | 4,060 | 8,062 | 6,648 |
Cash flows used in investing activities: | ' | ' | ' |
Additions to property, plant and equipment | -1,622 | -1,769 | -1,506 |
Additions to catalog costs | -57 | -62 | -252 |
Proceeds from sales of property, plant and equipment | 66 | 33 | 25 |
Proceeds from sale of discontinued operations | 1,784 | 0 | 0 |
Acquisitions, net of cash acquired | 0 | -2,878 | -5,465 |
Net cash provided by (used in) investing activities | 171 | -4,676 | -7,198 |
Cash flows used in financing activities: | ' | ' | ' |
Repayments of debt | -2,750 | -3,850 | -1,708 |
Net proceeds from issuance of debt | 14,550 | 500 | 0 |
Purchases of treasury stock | ' | ' | 0 |
Transfer of cash and cash equivalents to HART | -15,041 | 0 | 0 |
Payments of debt issuance costs | -312 | 0 | 0 |
Net proceeds from issuance of common stock | 3,621 | 2,287 | 567 |
Net cash provided (used in) financing activities | 68 | -1,063 | -1,141 |
Effect of exchange rate changes on cash | 791 | 442 | -97 |
Increase (decrease) in cash and cash equivalents | 5,090 | 2,765 | -1,788 |
Cash and cash equivalents at the begining of period | 20,681 | 17,916 | 19,704 |
Cash and cash equivalents at the end of period | 25,771 | 20,681 | 17,916 |
Supplemental disclosures of cash flow information [Abstract] | ' | ' | ' |
Cash paid for interest | 892 | 577 | 638 |
Cash paid for income taxes, net of refunds | $1,479 | $1,519 | $2,234 |
Organization
Organization | 12 Months Ended |
Dec. 31, 2013 | |
Organization Disclosure [Abstract] | ' |
Organization Disclosure [Text Block] | ' |
1. Organization | |
Harvard Bioscience, Inc. ( “Harvard Bioscience” or “the Company”) is a global developer, manufacturer and marketer of a broad range of scientific instruments, systems and lab consumables used to advance life science research for basic research, drug discovery, clinical and environmental testing. The Company's products are sold to thousands of researchers in over 100 countries through its global sales organization, catalogs, websites, and through distributors including GE Healthcare, Thermo Fisher Scientific Inc., VWR and other specialized distributors. The Company has sales and manufacturing operations in the United States, the United Kingdom, Germany, Sweden, Spain, France and Canada. . |
Basis_of_Presentation_and_Summ
Basis of Presentation and Summary of Significant Accounting Policies | 12 Months Ended | ||||||
Dec. 31, 2013 | |||||||
Basis of Presentation and Summary of Significant Accounting Policies Disclosure [Abstract] | ' | ||||||
Basis of Presentation and Summary of Significant Accounting Policies Disclosure [Text Block] | ' | ||||||
2. Summary of Significant Accounting Policies | |||||||
(a) Principles of Consolidation | |||||||
The consolidated financial statements include the accounts of Harvard Bioscience, Inc. and its wholly-owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. | |||||||
(b) Use of Estimates | |||||||
The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires the use of management estimates. Such estimates include the determination and establishment of certain accruals and provisions, including those for inventory obsolescence, catalog cost amortization periods, income tax and reserves for bad debts. In addition, certain estimates are required in order to determine the value of assets and liabilities associated with acquisitions. Estimates are also required to evaluate the value and recoverability of existing long-lived and intangible assets, including goodwill. On an ongoing basis, the Company reviews its estimates based upon currently available information. Actual results could differ materially from those estimates. | |||||||
(c) Cash and Cash Equivalents | |||||||
For purposes of the consolidated balance sheets and statements of cash flows, the Company considers all highly liquid instruments with original maturities of three months or less to be cash equivalents. | |||||||
(d) Allowance for Doubtful Accounts | |||||||
Allowance for doubtful accounts is based on the Company's assessment of collectability of customer accounts. The Company regularly reviews the allowance by considering factors such as historical experience, credit quality, age of the accounts receivable balances and other factors that may affect a customer's ability to pay. | |||||||
(e) Inventories | |||||||
The Company values its inventories at the lower of the actual cost to purchase (first-in, first-out method) and/or manufacture the inventories or the current estimated market value of the inventories. The Company regularly reviews inventory quantities on hand and records a provision to write down excess and obsolete inventories to its estimated net realizable value if less than cost, based primarily on historical inventory usage and estimated forecast of product demand. | |||||||
(f) Property, Plant and Equipment | |||||||
Property, plant and equipment are stated at cost and depreciated using the straight-line method over the estimated useful lives of the assets as follows: | |||||||
Buildings | 40 | years | |||||
Machinery and equipment | 3 | - | 10 | years | |||
Computer equipment and software | 3 | - | 7 | years | |||
Furniture and fixtures | 5 | - | 10 | years | |||
Automobiles | 3 | - | 6 | years | |||
Property and equipment held under capital leases and leasehold improvements are amortized using the straight line method over the shorter of the lease term or estimated useful life of the asset. | |||||||
(g) Catalog Costs | |||||||
Significant costs of product catalog design, development and production are capitalized and amortized over the expected useful life of the catalog (usually one to three years). | |||||||
(h) Income Taxes | |||||||
Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to be applied to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. | |||||||
The Company recognizes the effect of income tax positions only if those positions are more likely than not of being sustained. Recognized income tax positions are measured at the largest amount that is more than 50% likely of being realized. Changes in recognition are reflected in the period in which the judgement occurs. | |||||||
(i) Foreign Currency Translation | |||||||
The functional currency of the Company's foreign subsidiaries is generally their local currency. All assets and liabilities of its foreign subsidiaries are translated at exchange rates in effect at period-end. Income and expenses are translated at rates which approximate those in effect on the transaction dates. The resulting translation adjustment is recorded as a separate component of stockholders' equity in accumulated other comprehensive income in the consolidated balance sheets. Gains and losses resulting from foreign currency transactions are included in net income. | |||||||
(j) Earnings per Share | |||||||
Basic earnings per share is computed by dividing net income by the weighted average number of shares of common stock outstanding during the periods presented. The computation of diluted earnings per share is similar to the computation of basic earnings per share, except that the denominator is increased for the assumed exercise of dilutive options and other potentially dilutive securities using the treasury stock method unless the effect is antidilutive. Since the Company is reporting discontinued operations, it used income from continuing operations as the control number in determining whether those potential dilutive securities are dilutive or antidilutive. | |||||||
(k) Comprehensive Income | |||||||
The Company follows the provisions of Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 220, “Comprehensive Income”. FASB ASC 220 requires companies to report all changes in equity during a period, resulting from net income (loss) and transactions from non-owner sources, in a financial statement in the period in which they are recognized. The Company has chosen to disclose comprehensive income, which encompasses net income (loss), foreign currency translation adjustments, gains and losses on derivatives, the underfunded status of its pension plans, and pension minimum additional liability adjustments, net of tax, in the consolidated statements of comprehensive income. | |||||||
(l) Revenue Recognition | |||||||
The Company follows the provisions of FASB ASC 605, “Revenue Recognition”. The Company recognizes product revenue when persuasive evidence of a sales arrangement exists, the price to the buyer is fixed or determinable, delivery has occurred, and collectibility of the sales price is reasonably assured. Sales of some of its products include provisions to provide additional services such as installation and training. Revenues on these products are recognized when the additional services have been performed. Service agreements on its equipment are typically sold separately from the sale of the equipment. Revenues on these service agreements are recognized ratably over the life of the agreement, typically one year, in accordance with the provisions of FASB ASC 605-20, “Revenue Recognition—Services”. | |||||||
The Company accounts for shipping and handling fees and costs in accordance with the provisions of FASB ASC 605-45-45, “Revenue Recognition—Principal Agent Considerations”, which requires all amounts charged to customers for shipping and handling to be classified as revenues. The costs incurred related to shipping and handling is classified as cost of product revenues. Warranties and product returns are estimated and accrued for at the time sales are recorded. The Company has no obligations to customers after the date products are shipped or installed, if applicable, other than pursuant to warranty obligations and service or maintenance contracts. The Company provides for the estimated amount of future returns upon shipment of products or installation, if applicable, based on historical experience. | |||||||
(m) Goodwill and Other Intangible Assets | |||||||
Goodwill and other intangible assets include goodwill, unamortizable intangible assets and amortizable intangible assets. Amortizable intangible assets (those intangible assets with definite estimated useful lives) are initially recorded at fair value and amortized, using the straight-line method, over their estimated useful lives. At December 31, 2013, amortizable intangible assets include existing technology, trade names, distribution agreements, customer relationships and patents. These amortizable intangible assets are amortized on a straight-line basis over 7 to 15 years, 15 years, 5 years, 5 to 15 years and 5 to 15 years, respectively. | |||||||
Goodwill and unamortizable intangible assets acquired in a business combination and determined to have an indefinite useful life are not amortized, but instead are tested for impairment annually or more frequently if events or changes in circumstances indicate that the asset might be impaired, in accordance with the provisions of FASB ASC 350, “Intangibles—Goodwill and Other”. | |||||||
For the purpose of its goodwill analysis, and following the spin-off of HART, the Company has one reporting unit. The Company conducted its annual impairment analysis in the fourth quarter of fiscal year 2013. The goodwill impairment test is a two-step process. The first step of the impairment analysis compares the Company's fair value to its carrying value to determine if there is any indication of impairment. Step two of the analysis compares the implied fair value of goodwill to its carrying amount in a manner similar to a purchase price allocation for business combination. If the carrying amount of goodwill exceeds its implied fair value, an impairment loss is recognized equal to that excess. For indefinite-lived intangible assets if the carrying amount exceeds the fair value of the asset, the Company would write down the indefinite-lived intangible asset to fair value. | |||||||
At December 31, 2013, the Company compared its carrying value to its overall market capitalization, noting the fair value of the Company significantly exceeded the carrying value. The Company concluded that none of its goodwill was impaired. | |||||||
The Company evaluates indefinite-lived intangible assets for impairment annually and when events occur or circumstances change that may reduce the fair value of the asset below its carrying amount. Events or circumstances that might require an interim evaluation include unexpected adverse business conditions, economic factors, unanticipated technological changes or competitive activities, loss of key personnel and acts by governments and courts. At December 31, 2013 the Company concluded that none of its indefinite-lived intangible assets were impaired. | |||||||
(n) Impairment of Long-Lived Assets | |||||||
The Company assesses recoverability of its long-lived assets that are held for use, such as property, plant and equipment and amortizable intangible assets in accordance with FASB ASC 360, “Property, Plant and Equipment” when events or changes in circumstances indicate that the carrying amount of an asset or asset group may not be recoverable. Recoverability of assets or an asset group to be held and used is measured by a comparison of the carrying amount of an asset or asset group to estimated undiscounted future cash flows expected to be generated by the asset or the asset group. Cash flow projections are based on trends of historical performance and management's estimate of future performance. If the carrying amount of the asset or asset group exceeds the estimated future cash flows, an impairment charge is recognized by the amount by which the carrying amount of the asset or asset group exceeds its estimated fair value. At December 31, 2013 the Company concluded that none of its long-lived assets were impaired. | |||||||
(o) Derivatives | |||||||
The Company uses interest-rate-related derivative instruments to manage its exposure related to changes in interest rates on its variable-rate debt instruments. The Company does not enter into derivative instruments for any purpose other than cash flow hedging. The Company does not speculate using derivative instruments. The Company recognizes all derivative instruments as either assets or liabilities in the balance sheet at their respective fair values. For derivatives designated in hedging relationships, changes in the fair value are either offset through earnings against the change in fair value of the hedged item attributable to the risk being hedged or recognized in accumulated other comprehensive income (“AOCI”), to the extent the derivative is effective at offsetting the changes in cash flows being hedged until the hedged item affects earnings. | |||||||
The Company only enters into derivative contracts that it intends to designate as a hedge of a forecasted transaction or the variability of cash flows to be received or paid related to a recognized asset or liability (cash flow hedge). For all hedging relationships, the Company formally documents the hedging relationship and its risk-management objective and strategy for undertaking the hedge, the hedging instrument, the hedged transaction, the nature of the risk being hedged, how the hedging instrument's effectiveness in offsetting the hedged risk will be assessed prospectively and retrospectively, and a description of the method used to measure ineffectiveness. The Company also formally assesses, both at the inception of the hedging relationship and on an ongoing basis, whether the derivatives that are used in hedging relationships are highly effective in offsetting changes in cash flows of hedged transactions. For derivative instruments that are designated and qualify as part of a cash flow hedging relationship, the effective portion of the gain or loss on the derivative is reported as a component of other comprehensive income and reclassified into earnings in the same period or periods during which the hedged transaction affects earnings. Gains and losses on the derivative representing either hedge ineffectiveness or hedge components excluded from the assessment of effectiveness are recognized in current earnings. | |||||||
The Company discontinues hedge accounting prospectively when it determines that the derivative is no longer effective in offsetting cash flows attributable to the hedged risk, the derivative expires or is sold, terminated, or exercised, the cash flow hedge is de-designated because a forecasted transaction is not probable of occurring, or management determines to remove the designation of the cash flow hedge. | |||||||
In all situations in which hedge accounting is discontinued and the derivative remains outstanding, the Company continues to carry the derivative at its fair value on the balance sheet and recognizes any subsequent changes in its fair value in earnings. When it is probable that a forecasted transaction will not occur, the Company discontinues hedge accounting and recognizes immediately in earnings gains and losses that were accumulated in other comprehensive income related to the hedging relationship. | |||||||
(p) Fair Value of Financial Instruments | |||||||
The carrying values of the Company's cash and cash equivalents, trade accounts receivable and trade accounts payable and short-term debt approximate their fair values because of the short maturities of those instruments. The fair value of the Company's long-term debt approximates its carrying value and is based on the amount of future cash flows associated with the debt discounted using current borrowing rates for similar debt instruments of comparable maturity. | |||||||
Financial reporting standards define a fair value hierarchy that consists of three levels: | |||||||
Level 1 includes instruments for which quoted prices in active markets for identical assets or liabilities accessible to the Company at the measurement date. | |||||||
Level 2 includes instruments for which the valuations are based on quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable data for substantially the full term of the assets or liabilities. | |||||||
Level 3 includes valuations based on inputs that are unobservable and significant to the overall fair value measurement. | |||||||
(q) Stock-based Compensation | |||||||
The Company accounts for stock-based payment awards in accordance with the provisions of FASB ASC 718, “Compensation—Stock Compensation”, which requires it to recognize compensation expense for all stock-based payment awards made to employees and directors including stock options, restricted stock units and employee stock purchases (“employee stock purchases”) related to the Employee Stock Purchase Plan (as amended, the “ESPP”). The Company issues new shares upon stock option exercises, upon vesting of the restricted stock units and under the Company's ESPP. | |||||||
Stock-based compensation expense recognized is based on the value of the portion of stock-based payment awards that is ultimately expected to vest and has been reduced for estimated forfeitures. The Company values stock-based payment awards, except restricted stock units at grant date using the Black-Scholes option-pricing model (“Black-Scholes model”). The determination of fair value of stock-based payment awards on the date of grant using an option-pricing model is affected by its stock price as well as assumptions regarding a number of highly complex and subjective variables. These variables include, but are not limited to its expected stock price volatility over the term of the awards and actual and projected stock option exercise behaviors. | |||||||
The fair value of restricted stock units are based on the market price of the Company's stock on the date of grant and are recorded as compensation expense ratably over the applicable service period, which ranges from one to four years. Unvested restricted stock units are forfeited in the event of termination of employment with the Company. | |||||||
Stock-based compensation expense recognized under FASB ASC 718 for the years ended December 31, 2013, 2012 and 2011 consisted of stock-based compensation expense related to stock options, the employee stock purchase plan, and the restricted stock units and was recorded as a component of cost of product revenues, sales and marketing expenses, general and administrative expenses, research and development expenses and discontinued operations. | |||||||
(r) Recently Issued Accounting Pronouncements | |||||||
In July 2013, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2013-11, “Income Taxes (Topic 740): Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists”, which requires an entity to present an unrecognized tax benefit as a reduction of a deferred tax asset for a net operating loss (NOL) carryforward, or similar tax loss or tax credit carryforward, rather than as a liability when the uncertain tax position would reduce the NOL or other carryforward under the tax law. The ASU is effective prospectively for fiscal years, and interim periods within those years, beginning after December 15, 2013. The Company believes the adoption of this new guidance will not have a material impact on its consolidated financial position or results of operations. | |||||||
In February 2013, the FASB issued additional guidance in ASU 2013-02, “Reporting Amounts Reclassified Out of Accumulated Other Comprehensive Income.” The new guidance requires the presentation of effects on net income line items of significant amounts reclassified out of accumulated other comprehensive income, but only if the item reclassified is required under U.S. GAAP to be reclassified to net income in its entirety in the same reporting period. The Company shall provide this information either on the face of the statements or in the notes to the consolidated financial statements. The guidance is effective for fiscal years beginning after December 15, 2012. The adoption of this guidance, which is related to disclosure only, did not have an impact on the Company's consolidated financial position, results of operations or cash flows. | |||||||
Recently_Issued_Accounting_Pro
Recently Issued Accounting Pronouncements | 12 Months Ended |
Dec. 31, 2013 | |
Recently Issued Accounting Pronouncements [Abstract] | ' |
Recently Issued Accounting Pronouncements Disclosure [Text Block] | ' |
(r) Recently Issued Accounting Pronouncements | |
In July 2013, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2013-11, “Income Taxes (Topic 740): Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists”, which requires an entity to present an unrecognized tax benefit as a reduction of a deferred tax asset for a net operating loss (NOL) carryforward, or similar tax loss or tax credit carryforward, rather than as a liability when the uncertain tax position would reduce the NOL or other carryforward under the tax law. The ASU is effective prospectively for fiscal years, and interim periods within those years, beginning after December 15, 2013. The Company believes the adoption of this new guidance will not have a material impact on its consolidated financial position or results of operations. | |
In February 2013, the FASB issued additional guidance in ASU 2013-02, “Reporting Amounts Reclassified Out of Accumulated Other Comprehensive Income.” The new guidance requires the presentation of effects on net income line items of significant amounts reclassified out of accumulated other comprehensive income, but only if the item reclassified is required under U.S. GAAP to be reclassified to net income in its entirety in the same reporting period. The Company shall provide this information either on the face of the statements or in the notes to the consolidated financial statements. The guidance is effective for fiscal years beginning after December 15, 2012. The adoption of this guidance, which is related to disclosure only, did not have an impact on the Company's consolidated financial position, results of operations or cash flows. | |
Concentrations
Concentrations | 12 Months Ended |
Dec. 31, 2013 | |
Concentrations Disclosure [Abstract] | ' |
Concentrations Disclosure [Text Block] | ' |
3. Concentrations | |
No customer accounted for more than 10% of the revenues for the years ended December 31, 2013, 2012 and 2011. At December 31, 2013 and 2012, no customer accounted for more than 10% of net accounts receivable. |
Inventories
Inventories | 12 Months Ended | ||||||
Dec. 31, 2013 | |||||||
Inventories Disclosure [Abstract] | ' | ||||||
Inventories Disclosure [Text Block] | ' | ||||||
4. Inventories | |||||||
Inventories consist of the following: | |||||||
December 31, | |||||||
2013 | 2012 | ||||||
(in thousands) | |||||||
Finished goods | $ | 7,039 | $ | 8,023 | |||
Work in process | 752 | 731 | |||||
Raw materials | 7,986 | 9,008 | |||||
Total | $ | 15,777 | $ | 17,762 |
Property_Plant_and_Equipment
Property, Plant and Equipment | 12 Months Ended | ||||
Dec. 31, 2013 | |||||
Property, Plant and Equipment Disclosure [Abstract] | ' | ||||
Property, Plant and Equipment Disclosure [Text Block] | ' | ||||
5. Property, Plant and Equipment | |||||
Property, plant and equipment consist of the following: | |||||
December 31, | |||||
2013 | 2012 | ||||
(in thousands) | |||||
Land, buildings and leasehold improvements | $ | 3,082 | $ | 2,790 | |
Machinery and equipment | 9,471 | 8,760 | |||
Computer equipment and software | 4,927 | 4,917 | |||
Furniture and fixtures | 1,281 | 1,201 | |||
Automobiles | 59 | 194 | |||
18,820 | 17,862 | ||||
Less: accumulated depreciation | -14,445 | -13,311 | |||
Property, plant and equipment, net | $ | 4,375 | $ | 4,551 |
Acquisitions
Acquisitions | 12 Months Ended | |||
Dec. 31, 2013 | ||||
Acquisition Disclosure [Abstract] | ' | |||
Acquisitions Disclosure [Text Block] | ' | |||
6. Acquisitions | ||||
The Company's continuing operations did not complete any acquisitions during 2013, while the Company's continuing operations completed two acquisitions during 2012. | ||||
AHN Biotechnologie GmbH | ||||
On February 3, 2012, the Company acquired all issued and outstanding shares of AHN Biotechnologie GmbH (“AHN”) for approximately $2.0 million. The Company funded the acquisition from its existing cash balances. | ||||
AHN is located in Nordhausen, Germany. AHN is a manufacturer of plastic laboratory consumables which include pipettes, pipette tips, PCR tubes and spin columns. | ||||
With the assistance of an external valuation company, the aggregate purchase price for this acquisition was allocated to tangible and intangible assets acquired as follows: | ||||
(in thousands) | ||||
Tangible assets | $ | 1,500 | ||
Liabilities assumed | -1,454 | |||
Net assets assumed | 46 | |||
Goodwill and intangible assets: | ||||
Goodwill | 1,308 | |||
Customer relationships | 474 | |||
Trade name | 180 | |||
Total goodwill and intangible assets | 1,962 | |||
Acquisition purchase price | $ | 2,008 | ||
The results of operations for AHN have been included in the Company's consolidated financial statements from the date of acquisition. The financial results of this acquisition are considered immaterial for the purposes of pro forma financial statement disclosures. Goodwill recorded as a result of the acquisition of AHN is not deductible for tax purposes. | ||||
Modular SFC, Inc. | ||||
On May 31, 2012, the Company acquired substantially all of the assets of Modular SFC, Inc. (“Modular”) for approximately $0.5 million. The Company funded the acquisition from its existing cash balances. | ||||
Consideration for the acquisition comprised of the following: | ||||
(in thousands) | ||||
Cash | $ | 500 | ||
Contingent consideration | 20 | |||
Total | $ | 520 | ||
The fair value of the assets and liabilities was as follows: | ||||
(in thousands) | ||||
Tangible assets | $ | 30 | ||
Liabilities assumed | - | |||
Net assets assumed | 30 | |||
Goodwill and intangible assets: | ||||
Goodwill | 145 | |||
Customer relationships | 50 | |||
Technology | 200 | |||
Trade name | 95 | |||
Total goodwill and intangible assets | 490 | |||
Acquisition purchase price | $ | 520 | ||
The results of operations for Modular have been included in the Company's consolidated financial statements from the date of acquisition. The financial results of this acquisition are considered immaterial for the purposes of pro forma financial statement disclosures. Goodwill recorded as a result of the acquisition of Modular is deductible for tax purposes. | ||||
Direct acquisition costs recorded in other expense, net in the Company's consolidated statements of operations were $0 and $0.3 million for the years ended December 31, 2013 and 2012, respectively. |
Discontinued_Operations
Discontinued Operations | 12 Months Ended | ||||||
Dec. 31, 2013 | |||||||
Discontinued Operations [Abstract] | ' | ||||||
Discontinued Operations Disclosure [Text Block] | ' | ||||||
7. Discontinued Operations | |||||||
Genomic Solutions | |||||||
In November 2007, the Company completed the sale of the assets of its Genomic Solutions Division and the stock of its Belgian subsidiary, MAIA Scientific, both of which were part of its Capital Equipment Business Segment, to Digilab, Inc. The purchase price paid by Digilab under the terms of the Asset Purchase Agreement consisted of $1.0 million in cash plus additional consideration in the form of an earn-out based on 20% of the revenue generated by the acquired business as it is conducted by Digilab over a three-year period post-transaction. Any earn-out amounts were evidenced by interest bearing promissory notes which were due on November 30, 2012. The unpaid principal balance of the promissory notes had an interest rate of LIBOR plus 1100 basis points per annum. Digilab had delivered promissory notes of $4.6 million. The Company has recorded valuation allowances for 100% of the earn-out promissory notes as their collectability is uncertain. Going forward, the Company will continue to monitor the financial performance of Digilab and recognize any contingent consideration in discontinued operations when and if realization of earn-out amounts is probable. The Company has included the contingent consideration as sale proceeds in its income tax returns. Accordingly, the tax effect of this contingent consideration is included in the Company's deferred tax assets. | |||||||
UBI | |||||||
In September 2008, the Company completed the sale of assets of its Union Biometrica Division (“UBI”) including its German subsidiary, Union Biometrica GmbH, representing the remaining portion of its Capital Equipment Business Segment, to UBIO Acquisition Company. The purchase price paid by UBIO Acquisition Company under the terms of the Asset Purchase Agreement consisted of $1 in cash, the assumption of certain liabilities, plus additional consideration in the form of an earn-out based on the revenue generated by the acquired business as it is conducted by UBIO Acquisition Company over a five-year post-transaction period in an amount equal to (i) 5% of the revenue generated up to and including $6.0 million and (ii) 8% of the revenue generated above $6.0 million each year. During 2013, UBIO Acquisition Company made payments, including interest, of $1.8 million. UBIO Acquisition Company's final payment under the earn-out obligation was received in October 2013. | |||||||
HART | |||||||
On November 1, 2013, the previously announced spin-off of Harvard Apparatus Regenerative Technology, Inc., or HART, from the Company was completed. Through the spin-off date the historical operations of HART were reported as continuing operations in the consolidated statements of operations. Following the spin-off, the historical operations of HART have been broken out and reported as discontinued operations for all periods presented. HART became an independent company that operates the regenerative medicine business previously owned by Harvard Bioscience. The spin-off was completed through the distribution to Harvard Bioscience's stockholders of record all of the shares of common stock of HART (the “Distribution”). In the Distribution, the Company distributed to its stockholders one share of HART common stock for every four shares of Harvard Bioscience common stock outstanding as of the close of business on October 21, 2013, the record date for the Distribution. Fractional shares of HART common stock were not included in the distribution. Instead, Registrar & Transfer Company aggregated fractional shares into whole shares, sold the whole shares in the open market and distributed the aggregate net cash proceeds of the sales pro rata to each holder who otherwise would have been entitled to receive a fractional share in the Distribution. | |||||||
Effective with the spin-off, the Company contributed $15.0 million in cash to HART to fund its operations. In addition, the Company transferred approximately $0.9 million in assets, made up primarily of property, plant and equipment, to HART as part of the spin-off. | |||||||
In connection with the spin-off of HART, certain required adjustments were made to the Company's outstanding equity compensation awards under its employee benefit plans. Each outstanding option to purchase Harvard Bioscience common stock was converted on the date of the Distribution into both an adjusted Harvard Bioscience option to purchase Harvard Bioscience common stock and an option to purchase HART common stock. Black-Scholes valuation modeling was used to determine the value that each Harvard Bioscience option had lost at the time of the Distribution and to ensure the holder maintained such lost value, 80% of such lost value was provided back to the holder by making appropriate adjustments to the share amount and exercise price of the existing Harvard Bioscience option and 20% of such lost value was provided back to the holder through the issuance of an option to purchase HART common stock. Similar to the adjustment of the existing Harvard Bioscience options, with respect to each unvested Harvard Bioscience restricted stock unit outstanding at the time of the Distribution, such Harvard Bioscience restricted stock unit was converted on the date of the Distribution into both an adjusted Harvard Bioscience restricted stock unit and a HART restricted stock unit. The market prices of Harvard Bioscience and HART common stock were used to determine the value that each Harvard Bioscience restricted stock unit lost at the time of the Distribution and then to ensure the holder maintained such lost value, 80% of such lost value was provided back to the holder by making the appropriate increases of the share amount of the existing Harvard Bioscience restricted stock unit and 20% of such lost value was provided back to the holder through the issuance of a HART restricted stock unit. The share amounts and exercise prices of the adjusted Harvard Bioscience options and HART options, as well as the share amounts of the adjusted Harvard Bioscience restricted stock units and HART restricted stock units, were each adjusted and set in a manner to ensure the intrinsic value held by the holder pertaining to the existing Harvard Bioscience award was maintained immediately following the Distribution and was determined such that tax was not triggered under Section 409A of the Internal Revenue Code. As part of these required adjustments, the Company issued approximately 1.7 million options and approximately 0.1 million restricted stock units to holders of its outstanding equity compensation awards. | |||||||
In connection with the spin-off, on October 31, 2013, the Company entered into various commercial agreements with HART which contain many of the key provisions related to the Distribution. These agreements include: (i) a Separation and Distribution Agreement; (ii) an Intellectual Property Matters Agreement; (iii) a Product Distribution Agreement; (iv) a Tax Sharing Agreement; (v) a Transition Services Agreement; and (vi) a Sublease. | |||||||
Harvard Bioscience intends for the HART Distribution, taken together, to qualify as a reorganization pursuant to which no gain or loss is recognized by Harvard Bioscience or its stockholders for federal income tax purposes under Sections 355, 368(a)(1)(D) and related provisions of the Internal Revenue Code. On June 28, 2013, Harvard Bioscience received a Supplemental Ruling to the Private Letter Ruling dated March 22, 2013 from the IRS to the effect that, among other things, the spin-off will qualify as a transaction that is tax-free for U.S. federal income tax purposes under Section 355 and 368(a)(1)(D) of the Internal Revenue Code continuing in effect. Harvard Bioscience has also received an opinion from its outside tax advisor to such effect. In connection with the ruling and the opinion, Harvard Bioscience made certain representations regarding it and its business. The Company has agreed that it will not take or fail to take any action which prevents or could reasonably be expected to prevent the tax-free status of the spin-off. HART has agreed to certain restrictions that are intended to preserve the tax-free status of the contribution and the Distribution. HART may take certain actions otherwise prohibited by these covenants if Harvard Bioscience receives a private letter ruling from the IRS or if HART obtains, and provides to Harvard Bioscience, an opinion from a U.S. tax counsel or accountant of recognized national standing, in either case, acceptable to Harvard Bioscience in its sole and absolute discretion to the effect that such action would not jeopardize the tax-free status of the contribution and the Distribution. These covenants include restrictions on HART's: | |||||||
• issuance or sale of stock or other securities (including securities convertible into HART's stock but excluding certain compensatory arrangements); | |||||||
• sales of assets outside the ordinary course of business; and | |||||||
• entering into any other corporate transaction which would cause HART to undergo a 50 percent or greater change in HART's stock ownership. | |||||||
In addition, current U.S. federal income tax law creates a presumption that the spin-off of HART would be taxable to the Company, but not its stockholders, if such spin-off is part of a “plan or series of related transactions” pursuant to which one or more persons acquire directly or indirectly stock representing a 50% or greater interest (by vote or value) in the Company or HART. Acquisitions that occur during the four-year period that begins two years before the date of the spin-off are presumed to occur pursuant to a plan or series of related transactions, unless it is established that the acquisition is not pursuant to a plan or series of transactions that includes the spin-off. U.S. Treasury regulations currently in effect generally provide that whether an acquisition and a spin-off are part of a plan is determined based on all of the facts and circumstances, including, but not limited to, specific factors described in the U.S. Treasury regulations. In addition, the U.S. Treasury regulations provide several “safe harbors” for acquisitions that are not considered to be part of a plan. These rules will limit the Company's ability during the two-year period following the spin-off to enter into certain transactions that may be advantageous to the Company and its stockholders, particularly issuing equity securities to satisfy financing needs, repurchasing equity securities, disposing of certain assets, engaging in mergers and acquisitions, and, under certain circumstances, acquiring businesses or assets with equity securities or agreeing to be acquired. | |||||||
The following table sets forth the impact discontinued operations had on the Company's consolidated statements of operations. | |||||||
Year ended December 31, | |||||||
2013 | 2012 | 2011 | |||||
(in thousands) | |||||||
Gain on disposal of discontinued operations, UBI | $ | 440 | $ | 1,344 | $ | - | |
(Loss) from discontinued operations, HART | -4,861 | -4,664 | -2,326 | ||||
Income tax (benefit) | -1,868 | -1,196 | -849 | ||||
(Loss) from discontinued operations, net of tax | $ | -2,553 | $ | -2,124 | $ | -1,477 |
Goodwill_and_Other_Intangible_
Goodwill and Other Intangible Assets | 12 Months Ended | ||||||||||||||
Dec. 31, 2013 | |||||||||||||||
Goodwill And Other Intangible Assets Disclosure [Abstract] | ' | ||||||||||||||
Goodwill And Other Intangible Assets Disclosure [Text Block] | ' | ||||||||||||||
8. Goodwill and Other Intangible Assets | |||||||||||||||
Goodwill and other indefinite-lived intangible assets are subject to impairment reviews annually, or more frequently if events or circumstances indicate there may be impairment. | |||||||||||||||
For purposes of the Company's annual goodwill impairment analysis, and following the spin-off of HART, the Company has one reporting unit. As of December 31, 2013, the Company completed its annual goodwill impairment test and concluded there was no impairment to goodwill. Intangible assets consist of the following: | |||||||||||||||
Weighted | |||||||||||||||
December 31, | Average | ||||||||||||||
2013 | 2012 | Life | (a) | ||||||||||||
(in thousands) | |||||||||||||||
Amortizable intangible assets: | Gross | Accumulated Amortization | Gross | Accumulated Amortization | |||||||||||
Existing technology | $ | 13,464 | $ | -11,091 | $ | 13,258 | $ | -10,207 | 4.3 | Years | |||||
Tradename | 6,178 | -2,185 | 6,167 | -1,756 | 11 | Years | |||||||||
Distribution agreement/customer relationships | 21,827 | -9,447 | 21,699 | -7,938 | 10.6 | Years | |||||||||
Patents | 271 | -8 | 9 | -7 | 5 | Years | |||||||||
Total amortizable intangible assets | 41,740 | $ | -22,731 | 41,133 | $ | -19,908 | |||||||||
Indefinite-lived intangible assets: | |||||||||||||||
Goodwill | 36,605 | 36,200 | |||||||||||||
Other indefinite-lived intangible assets | 1,289 | 1,276 | |||||||||||||
Total goodwill and other indefinite-lived intangible assets | 37,894 | 37,476 | |||||||||||||
Total intangible assets | $ | 79,634 | $ | 78,609 | |||||||||||
(a) Weighted average life is as of December 31, 2013. | |||||||||||||||
The changes in the carrying amount of goodwill for the years ended December 31, 2013 and 2012 is as follows: | |||||||||||||||
(in thousands) | |||||||||||||||
Balance at December 31, 2011 | $ | 34,209 | |||||||||||||
Goodwill arising from business combination | 1,453 | ||||||||||||||
Effect of change in foreign currencies | 538 | ||||||||||||||
Balance at December 31, 2012 | $ | 36,200 | |||||||||||||
Effect of change in foreign currencies | 405 | ||||||||||||||
Balance at December 31, 2013 | $ | 36,605 | |||||||||||||
Intangible asset amortization expense was $2.6 million, $2.8 million and $2.7 million for the years ended December 31, 2013, 2012 and 2011, respectively. Amortization expense of existing amortizable intangible assets is currently estimated to be $2.5 million for the year ending December 31, 2014, $2.2 million for the year ending December 31, 2015, $2.1 million for the year ending December 31, 2016, $1.8 million for the year ending December 31, 2017 and $1.7 million for the year ending December 31, 2018. |
Restructuring_and_Other_Exit_C
Restructuring and Other Exit Costs | 12 Months Ended | |||||||||||
Dec. 31, 2013 | ||||||||||||
Restructuring and Related Activities [Abstract] | ' | |||||||||||
Restructuring And Other Exit Costs Disclosure [Text Block] | ' | |||||||||||
9. Restructuring and Other Exit Costs | ||||||||||||
2013 Restructuring Plans | ||||||||||||
During the fourth quarter of 2013, the management of Harvard Bioscience initiated a plan to realign global operations to create organizational efficiencies and reduce operating expenses throughout the Company. The plan included an approximately 13% reduction in the workforce, as well as the elimination of the position of Chief Operating Officer. The Company recorded restructuring charges of approximately $2.1 million representing severance payments. Additional charges related to this plan are expected to be incurred through the second quarter of 2014, and include, but are not limited to, contract termination costs, as well as moving and employee relocation costs. Payments related to this plan are expected to be made through the end of 2014. Activity and liability balances related to these charges were as follows: | ||||||||||||
Severance | ||||||||||||
and Related Costs | ||||||||||||
(in thousands) | ||||||||||||
Restructuring charges | $ | 2,100 | ||||||||||
Cash payments | -666 | |||||||||||
Restructuring balance at December 31, 2013 | $ | 1,434 | ||||||||||
During the third quarter of 2013, the management of Harvard Bioscience initiated a plan to reduce operating expenses at one of its foreign subsidiaries. Activity and liability balances related to these charges were as follows: | ||||||||||||
Severance | ||||||||||||
and Related Costs | ||||||||||||
(in thousands) | ||||||||||||
Restructuring charges | $ | 96 | ||||||||||
Cash payments | -96 | |||||||||||
Restructuring balance at December 31, 2013 | $ | - | ||||||||||
2012 Restructuring Plan | ||||||||||||
During 2012, the management of Harvard Bioscience initiated a plan to reduce operating expenses at one of its foreign subsidiaries. The Company recorded restructuring charges of approximately $0.3 million representing severance payments. No further charges are expected to be incurred on this matter. Activity and liability balances related to these charges were as follows: | ||||||||||||
Severance | ||||||||||||
and Related Costs | Other | Total | ||||||||||
(in thousands) | ||||||||||||
Restructuring charges | $ | 312 | $ | 11 | $ | 323 | ||||||
Cash payments | -179 | - | -179 | |||||||||
Restructuring balance at December 31, 2012 | $ | 133 | $ | 11 | $ | 144 | ||||||
Cash payments | $ | -84 | $ | -11 | $ | -95 | ||||||
Non-cash reversal of restructuring charges | -46 | - | -46 | |||||||||
Restructuring balance at December 31, 2013 | $ | 3 | $ | - | $ | 3 | ||||||
2011 Restructuring Plan | ||||||||||||
During 2011, the management of Harvard Bioscience initiated a plan to relocate one if its U.S. facilities as part of a business improvement initiative. The Company also developed a plan to improve operating margins at another U.S. subsidiary. The Company recorded restructuring charges of approximately $0.5 million, which included $0.3 million in fixed asset write offs, $0.1 million in severance payments and $0.1 million in other expenses. No further charges are expected to be incurred on this matter. Activity and liability balances related to these charges were as follows: | ||||||||||||
Severance and | Fixed Asset | |||||||||||
Related Costs | Write offs | Other | Total | |||||||||
(in thousands) | ||||||||||||
Restructuring charges | $ | 78 | $ | 307 | $ | 110 | $ | 495 | ||||
Cash payments | -33 | - | -180 | -213 | ||||||||
Non-cash charges | - | -307 | 70 | -237 | ||||||||
Restructuring balance at December 31, 2011 | 45 | - | - | 45 | ||||||||
Cash payments | -45 | - | - | -45 | ||||||||
Restructuring balance at December 31, 2012 | $ | - | $ | - | $ | - | $ | - | ||||
Aggregate restructuring charges relating to the 2013 Restructuring Plans, 2012 Restructuring Plan and the 2011 Restructuring Plan were as follows: | ||||||||||||
Years ended December 31, | ||||||||||||
2013 | 2012 | 2011 | ||||||||||
(in thousands) | ||||||||||||
Restructuring charges | $ | 2,150 | $ | 310 | $ | 467 |
Long_Term_Debt
Long Term Debt | 12 Months Ended | ||||
Dec. 31, 2013 | |||||
Long Term Debt Disclosure [Abstract] | ' | ||||
Long Term Debt Disclosure [Text Block] | ' | ||||
10. Long Term Debt | |||||
On August 7, 2009, the Company entered into an amended and restated $20.0 million revolving credit loan agreement with Bank of America, as agent, and Bank of America and Brown Brothers Harriman & Co as lenders. On September 30, 2011, the Company entered into the First Amendment to the Amended and Restated Revolving Credit Loan Agreement (the “First Amendment”) with Bank of America as agent, and Bank of America and Brown Brothers Harriman & Co as lenders. The First Amendment extended the maturity date of the credit facility to August 7, 2013 and reduced the interest rate to the London Interbank Offered Rate plus 3.0%. On October 4, 2012, the Company entered into the Second Amendment to the Amended and Restated Revolving Credit Loan Agreement (the “Second Amendment”) with Bank of America as agent, and Bank of America and Brown Brothers Harriman & Co as lenders. The Second Amendment extends the maturity date of the credit facility to August 7, 2014 with no changes to other terms. | |||||
On March 29, 2013, the Company entered into a Second Amended and Restated Revolving Credit Agreement (the “Credit Agreement”) with Bank of America, as agent, and Bank of America and Brown Brothers Harriman & Co as lenders. The Credit Agreement converted the Company's existing outstanding revolving advances into a term loan in the principal amount of $15.0 million (the “Term Loan”), provides a revolving credit facility in the maximum principal amount of $25.0 million (“Revolving Line”) and provides a delayed draw term loan of up to $15.0 million (the “DDTL”) to fund capital contributions to the Company's former subsidiary, HART. The maximum amount available under the Credit Agreement is $50.0 million as borrowings against the DDTL in excess of $10.0 million results in a dollar for dollar reduction in the Revolving Line capacity. The Revolving Line has a maturity date of March 29, 2016, while the Term Loan and DDTL have a maturity date of March 29, 2018. | |||||
On October 31, 2013, the Company amended the Credit Agreement to reduce the DDTL from up to $15.0 million to up to $10.0 million and allow for up to $5.0 million to instead be available for drawing as advances under the Revolving Line. | |||||
Borrowings under the Term Loan and the DDTL shall bear interest at a rate based on either the effective London Interbank Offered Rate (LIBOR) for certain interest periods selected by the Company, or a daily floating rate based on the British Bankers' Association (BBA) LIBOR as published by Reuters (or other commercially available source providing quotations of BBA LIBOR), plus in either case, a margin of 3.0%. The Revolving Line shall bear interest at a rate based on either the effective LIBOR for certain interest periods selected by the Company, or a daily floating rate based on the BBA LIBOR, plus in either case, a margin of 2.5%. The Company was required to fix the rate of interest on at least 50% of the Term Loan and the DDTL through the purchase of interest rate swaps. The Term Loan and DDTL each have interest payments due at the end of the applicable LIBOR period, or monthly with respect to BBA LIBOR borrowings, and principal payments due quarterly. The Revolving Line has interest payments due at the end of the applicable LIBOR period, or monthly with respect to BBA LIBOR borrowings. | |||||
The Loans are guaranteed by all of the Company's direct and indirect domestic subsidiaries, and secured by substantially all of the assets of the Company and the guarantors. The Loans are subject to restrictive covenants under the Credit Agreement, and financial covenants that require the Company and its subsidiaries to maintain certain financial ratios on a consolidated basis, including a maximum leverage, minimum fixed charge coverage and minimum working capital. Prepayment of the Loans is allowed by the Credit Agreement at any time during the terms of the Loans. The Loans also contain limitations on the Company's ability to incur additional indebtedness and requires lender approval for acquisitions funded with cash, promissory notes and/or other consideration in excess of $6.0 million and for acquisitions funded solely with equity in excess of $10.0 million. | |||||
As of December 31, 2013 and 2012, the Company had borrowings of $24.8 million and $13.0 million, respectively, outstanding under its Credit Agreement. As of December 31, 2013, the Company was in compliance with all financial covenants contained in the Credit Agreement; the Company was subject to a working capital borrowing restriction and had available borrowing capacity under its Credit Agreement of $17.4 million. During the year ended December 31, 2013, the Company incurred $0.3 million of debt issuance costs associated with the Credit Agreement. The costs were capitalized, reflected in the balance sheet as an asset, and will be amortized over the finite life of the underlying Credit Agreement. | |||||
As of December 31, 2013, the weighted effective interest rates on the Company's Term Loan, DDTL and Revolving Line borrowings were 3.96%, 3.55% and 3.16%, respectively. | |||||
As of December 31, 2013 and 2012, the Company's borrowings were comprised of: | |||||
December 31, | |||||
2013 | 2012 | ||||
(in thousands) | |||||
Long-term debt: | |||||
Term loan | $ | 12,750 | $ | - | |
DDTL | 9,500 | - | |||
Revolving line | 2,500 | 12,950 | |||
Total debt | 24,750 | 12,950 | |||
Less: current installments | -5,000 | - | |||
Long-term debt | $ | 19,750 | $ | 12,950 | |
The aggregate amounts of debt maturing during the next five years are as follows: | |||||
(in thousands) | |||||
2014 | $ | 5,000 | |||
2015 | 5,000 | ||||
2016 | 7,500 | ||||
2017 | 5,000 | ||||
2018 | 2,250 | ||||
Total | $ | 24,750 |
Derivatives
Derivatives | 12 Months Ended | ||||||||
Dec. 31, 2013 | |||||||||
Derivative Instruments and Hedging Activities Disclosure [Abstract] | ' | ||||||||
Derivative Instruments and Hedging Activities Disclosure [Text Block] | ' | ||||||||
11. Derivatives | |||||||||
The Company uses interest-rate-related derivative instruments to manage its exposure related to changes in interest rates on its variable-rate debt instruments. The Company does not enter into derivative instruments for any purpose other than cash flow hedging. The Company does not speculate using derivative instruments. | |||||||||
By using derivative financial instruments to hedge exposures to changes in interest rates, the Company exposes itself to credit risk and market risk. Credit risk is the failure of the counterparty to perform under the terms of the derivative contract. When the fair value of a derivative contract is positive, the counterparty owes the Company, which creates credit risk for the Company. When the fair value of a derivative contract is negative, the Company owes the counterparty and, therefore, the Company is not exposed to the counterparty's credit risk in those circumstances. The Company minimizes counterparty credit risk in derivative instruments by entering into transactions with carefully selected major financial institutions based upon their credit profile. | |||||||||
Market risk is the adverse effect on the value of a derivative instrument that results from a change in interest rates. The market risk associated with interest-rate contracts is managed by establishing and monitoring parameters that limit the types and degree of market risk that may be undertaken. | |||||||||
The Company assesses interest rate risk by continually identifying and monitoring changes in interest rate exposures that may adversely impact expected future cash flows and by evaluating hedging opportunities. The Company maintains risk management control systems to monitor interest rate risk attributable to both the Company's outstanding or forecasted debt obligations as well as the Company's offsetting hedge positions. The risk management control systems involve the use of analytical techniques, including cash flow sensitivity analysis, to estimate the expected impact of changes in interest rates on the Company's future cash flows. | |||||||||
The Company uses variable-rate London Interbank Offered Rate (LIBOR) debt to finance its operations. The debt obligations expose the Company to variability in interest payments due to changes in interest rates. Management believes that it is prudent to limit the variability of a portion of its interest payments. To meet this objective, management enters into LIBOR based interest rate swap agreements to manage fluctuations in cash flows resulting from changes in the benchmark interest rate of LIBOR. These swaps change the variable-rate cash flow exposure on the debt obligations to fixed cash flows. Under the terms of the interest rate swaps, the Company receives LIBOR based variable interest rate payments and makes fixed interest rate payments, thereby creating the equivalent of fixed-rate debt for the notional amount of its debt hedged. In accordance with its Credit Agreement, the Company was required to fix the rate of interest on at least 50% of its Term Loan and the DDTL through the purchase of interest rate swaps. On June 5, 2013, the Company entered into an interest rate swap contract with an original notional amount of $15.0 million and a maturity date of March 29, 2018 in order to hedge the risk of changes in the effective benchmark interest rate (LIBOR) associated with the Company's Term Loan. On November 29, 2013, the Company entered into a second interest rate swap contract with an original notional amount of $5.0 million and a maturity date of March 29, 2018 in order to hedge the risk of changes in the effective benchmark interest rate (LIBOR) associated with the DDTL. The Term Loan swap contract converted specific variable-rate debt into fixed-rate debt and fixed the LIBOR rate associated with the Term Loan at 0.96% plus a bank margin of 3.0%. The DDTL swap contract converted specific variable-rate debt into fixed-rate debt and fixed the LIBOR rate associated with the Term Loan at 0.93% plus a bank margin of 3.0%.The interest rate swaps were designated as cash flow hedges in accordance with ASC 815 “Derivatives and Hedging”. | |||||||||
The following table presents the notional amount and fair value of the Company's derivative instruments as of December 31, 2013. As of December 31, 2012 the Company did not have any derivative instruments outstanding. | |||||||||
31-Dec-13 | 31-Dec-13 | ||||||||
Notional | Fair | ||||||||
Amount | Value (a) | ||||||||
Derivatives designated as hedging instruments under ASC 815 | Balance sheet classification | (in thousands) | |||||||
Interest rate swap | Other liabilities-non current | $ | 17,500 | $ | -49 | ||||
(a) See note 12 for the fair value measurements related to these financial instruments. | |||||||||
All of the Company's derivative instruments are designated as hedging instruments. | |||||||||
The Company has structured its interest rate swap agreements to be 100% effective and as a result, there was no impact to earnings resulting from hedge ineffectiveness. Changes in the fair value of interest rate swaps designated as hedging instruments that effectively offset the variability of cash flows associated with variable-rate, long-term debt obligations are reported in accumulated other comprehensive income (“AOCI”). These amounts subsequently are reclassified into interest expense as a yield adjustment of the hedged interest payments in the same period in which the related interest affects earnings. The Company's interest rate swap agreement was deemed to be fully effective in accordance with ASC 815, and, as such, unrealized gains and losses related to these derivatives were recorded as AOCI. | |||||||||
The following table summarizes the effect of derivatives designated as cash flow hedging instruments on the Company's consolidated statements of operations: | |||||||||
For the Year ended December 31, 2013 | |||||||||
(In thousands) | Amount of gain or (loss) recognized in OCI on derivative (effective portion) | Location of gain or (loss) reclassified from AOCI into income (effective portion) | Amount of gain or (loss) reclassified from AOCI into income (effective portion) | ||||||
Interest rate swaps | $ | -49 | Interest expense | $ | -67 | ||||
As of December 31, 2013, $0.1 million of deferred losses on derivative instruments accumulated in AOCI are expected to be reclassified to earnings during the next 12 months. Transactions and events expected to occur over the next twelve months that will necessitate reclassifying these derivatives' losses to earnings include the repricing of variable-rate debt. There were no cash flow hedges discontinued during 2013 or 2012. | |||||||||
Fair_Value_Measurements
Fair Value Measurements | 12 Months Ended | |||||||||
Dec. 31, 2013 | ||||||||||
Fair Value Disclosures [Abstract] | ' | |||||||||
Fair Value Disclosures [Text Block] | ' | |||||||||
12. Fair Value Measurements | ||||||||||
Fair value measurement is defined as the price that would be received to sell an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. A fair value hierarchy is established, which prioritizes the inputs used in measuring fair value into three broad levels as follows: | ||||||||||
Level 1—Quoted prices in active markets for identical assets or liabilities. | ||||||||||
Level 2—Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly. | ||||||||||
Level 3—Unobservable inputs based on the Company's own assumptions. | ||||||||||
The following table presents the fair value hierarchy for those liabilities measured at fair value on a recurring basis: | ||||||||||
Fair Value as of December 31, 2013 | ||||||||||
(In thousands) | Level 1 | Level 2 | Level 3 | Total | ||||||
Liabilities: | ||||||||||
Interest rate swap agreements | $ | - | $ | 49 | $ | - | $ | 49 | ||
The Company uses the market approach technique to value its financial liabilities. The Company's financial liabilities carried at fair value include derivative instruments used to hedge the Company's interest rate risks. The fair value of the Company's interest rate swap agreements was based on LIBOR yield curves at the reporting date. | ||||||||||
Leases
Leases | 12 Months Ended | ||
Dec. 31, 2013 | |||
Leases Disclosure [Abstract] | ' | ||
Leases Disclosure [Text Block] | ' | ||
13. Leases | |||
As part of the spin-off of HART, the Company entered into a Sublease with HART for approximately 17,000 square feet of space for the next 18 months, with extended terms through May 31, 2017. The Company charges HART for sublease rent, applicable taxes and utilities. For the year ended December 31, 2013, the Company charged HART $26,000, which was recorded as a reduction to rent expense. | |||
The Company has noncancelable operating leases for office and warehouse space expiring at various dates through 2018 and thereafter. Rent expense, which is recorded on a straight-line basis, was approximately $1.3 million, $1.3 million and $1.5 million for the years ended December 31, 2013, 2012 and 2011, respectively. | |||
Future minimum lease payments for operating leases, with initial or remaining terms in excess of one year at December 31, 2013, for its continuing operations are as follows: | |||
Operating | |||
Leases | |||
(in thousands) | |||
2014 | $ | 1,228 | |
2015 | 1,073 | ||
2016 | 763 | ||
2017 | 422 | ||
2018 | 160 | ||
Thereafter | 70 | ||
Net minimum lease payments | $ | 3,716 |
Accrued_Expenses
Accrued Expenses | 12 Months Ended | ||||
Dec. 31, 2013 | |||||
Accrued Liabilities Current [Abstract] | ' | ||||
Accrued Expenses Disclosure [Text Block] | ' | ||||
14. Accrued Expenses | |||||
Accrued expenses consist of: | |||||
December 31, | |||||
2013 | 2012 | ||||
(in thousands) | |||||
Accrued compensation and payroll | $ | 1,349 | $ | 1,389 | |
Accrued legal and professional fees | 927 | 869 | |||
Accrued severance | 1,434 | 133 | |||
Warranty costs | 305 | 222 | |||
Other | 1,063 | 892 | |||
Total | $ | 5,078 | $ | 3,505 |
Income_Taxes
Income Taxes | 12 Months Ended | ||||||
Dec. 31, 2013 | |||||||
Income Tax [Abstract] | ' | ||||||
Income Taxes Disclosure [Text Block] | ' | ||||||
15. Income Tax | |||||||
Income tax (benefit) expense attributable to income from continuing operations for the years ended December 31, 2013, 2012 and 2011 consisted of: | |||||||
Year ended December 31, | |||||||
2013 | 2012 | 2011 | |||||
(in thousands) | |||||||
Current income tax expense: | |||||||
Federal and state | $ | 47 | $ | 70 | $ | 111 | |
Foreign | 413 | 1,705 | 1,156 | ||||
460 | 1,775 | 1,267 | |||||
Deferred income tax (benefit) expense: | |||||||
Federal and state | -594 | 931 | 478 | ||||
Foreign | -154 | -308 | -166 | ||||
-748 | 623 | 312 | |||||
Total income tax (benefit) expense | $ | -288 | $ | 2,398 | $ | 1,579 | |
Income tax (benefit) expense for the periods ended December 31, 2013, 2012 and 2011 differed from the amount computed by applying the U.S. federal income tax rate of 34% to pre-tax continuing operations income as a result of the following: | |||||||
Years ended December 31, | |||||||
2013 | 2012 | 2011 | |||||
(in thousands) | |||||||
Computed "expected" income tax expense | $ | 147 | $ | 2,343 | $ | 2,335 | |
Increase (decrease) in income taxes resulting from: | |||||||
Permanent differences, net | 482 | -25 | 109 | ||||
Foreign tax rate differential | -64 | -435 | -333 | ||||
State income taxes, net of federal income tax benefit | 31 | 135 | 113 | ||||
Non-deductible stock compensation expense | 1 | 254 | 345 | ||||
Impact of prior year pension deductions | -294 | - | - | ||||
Tax credits | -615 | -127 | -558 | ||||
Release of uncertain tax position liability due to | |||||||
expiration of statute of limitations | - | - | -528 | ||||
Change in valuation allowance allocated to income | |||||||
tax expense (benefit) | 31 | 281 | 63 | ||||
Other | -7 | -28 | 33 | ||||
Total income tax (benefit) expense | $ | -288 | $ | 2,398 | $ | 1,579 | |
Income tax (benefit) expense is based on the following pre-tax continuing operations (loss) income for the years ended December 31, 2013, 2012 and 2011: | |||||||
Years ended December 31, | |||||||
2013 | 2012 | 2011 | |||||
(in thousands) | |||||||
Domestic | $ | -2,549 | $ | 681 | $ | 339 | |
Foreign | 2,984 | 6,211 | 6,529 | ||||
Total | $ | 435 | $ | 6,892 | $ | 6,868 | |
The tax effects of temporary differences that give rise to significant components of the deferred tax assets and deferred tax liabilities from continuing operations at December 31, 2013 and 2012 are as follows: | |||||||
2013 | 2012 | ||||||
(in thousands) | |||||||
Deferred tax assets: | |||||||
Accounts receivable | $ | 65 | $ | 62 | |||
Inventory | 1,405 | 1,251 | |||||
Operating loss and credit carryforwards | 12,978 | 8,829 | |||||
Accrued expenses | 409 | 107 | |||||
Pension liabilities | 985 | 1,366 | |||||
Contingent consideration | 2,593 | 2,413 | |||||
Other accrued liabilities | 1,867 | 3,761 | |||||
Total gross deferred assets | 20,302 | 17,789 | |||||
Less: valuation allowance | -1,249 | -1,307 | |||||
Deferred tax assets | $ | 19,053 | $ | 16,482 | |||
Deferred tax liabilities: | |||||||
Intangible assets | $ | 4,242 | $ | 4,057 | |||
Property, plant and equipment | 70 | 115 | |||||
Other accrued liabilities | 238 | 264 | |||||
Total deferred tax liabilities | 4,550 | 4,436 | |||||
Net deferred tax assets | $ | 14,503 | $ | 12,046 | |||
The amounts recorded as deferred tax assets as of December 31, 2013 and 2012 represent the amount of tax benefits of existing deductible temporary differences and carryforwards that are more likely than not to be realized through the generation of sufficient future taxable income within the carryforward period. Significant management judgment is required in determining any valuation allowance recorded against deferred tax assets and liabilities. The Company provides valuation allowances for net deferred tax assets in several foreign jurisdictions. | |||||||
At December 31, 2013, the Company had federal and state net operating loss carryforwards available to offset future taxable income of approximately $26.6 million. The operating loss carryforwards will begin to expire in 2014. Furthermore, the Company had foreign operating loss carryforwards to offset future taxable income of approximately $3.9 million, which can be carried forward indefinitely. The Company also had federal and state general business and minimum tax credit carryforwards available to reduce future federal and state regular income taxes of approximately $5.1 million, which begin to expire in 2020. Approximately $7.2 million of net operating losses are subject to an annual limitation of $0.7 million imposed by change in ownership provisions of Section 382 of the Internal Revenue Code. As mentioned above, certain of these net operating loss and credit carryforwards have full valuation allowances set up against them. | |||||||
Undistributed earnings of the Company's foreign subsidiaries amounted to approximately $49.2 million, $46.0 million and $40.9 million at December 31, 2013, 2012 and 2011, respectively. Undistributed foreign earnings are indefinitely reinvested and, accordingly, no related provision for U.S federal and state income taxes has been provided. It is impracticable to estimate the total tax liability, if any, which would be created by the future distribution of these earnings. | |||||||
At December 31, 2013 and 2012, cash and cash equivalents held by the Company's foreign subsidiaries was $23.6 million and $19.2 million, respectively. These funds are not available for domestic operations unless the funds are repatriated. If the Company planned to or did repatriate these funds then U.S. federal and state income taxes would have to be recorded on such amounts. The Company currently has no plans and does not intend to repatriate any of its undistributed foreign earnings. The foreign earnings are considered permanently reinvested and will be used for foreign acquisitions, capital investments and operations. In July 2011, the Company acquired the assets of CMA, a Swedish manufacturer, and utilized approximately $4.4 million of foreign cash on hand to do so. In February 2012, the Company acquired all issued and outstanding shares of AHN Biotechnologie GmbH, a German manufacturer, and utilized approximately $2.0 million of foreign cash on hand. In 2013, the Company also used $0.9 million of foreign cash on hand for capital improvements at AHN. | |||||||
During 2010, the Company completed an analysis of its research and development credit carryforwards and determined that due to certain documentation requirements to substantiate the credit, an uncertain tax liability of $0.2 million should be recorded. No penalties or interest have been accrued on this liability because the credits have not yet been utilized. If payment of these amounts ultimately proves to be unnecessary, the reversal of the liabilities would result in tax benefits being recognized in the period when the Company determines the liabilities are no longer necessary. If the estimate of tax liabilities proves to be less than the ultimate assessment, a further charge to expense would result. A reconciliation of uncertain tax liabilities is as follows: | |||||||
(in thousands) | |||||||
Balance at December 31, 2011 | $ | 191 | |||||
Additions based on tax positions of prior years | - | ||||||
Balance at December 31, 2012 | 191 | ||||||
Additions based on tax positions of prior years | - | ||||||
Balance at December 31, 2013 | $ | 191 | |||||
The Company or one of its subsidiaries files income tax returns in the U.S. federal jurisdiction, and various states and foreign jurisdictions. With few exceptions, the Company is no longer subject to income tax examinations by tax authorities for years before 2009. During 2013, The Company closed its IRS audit for the 2009 and 2010 tax years. There were no material adjustments. The Company is also under audit for tax years 2009 and 2010 by the Massachusetts Department of Revenue. The Company is not aware of any tax audits in other major jurisdictions. | |||||||
During 2013, the Company spun off its HART subsidiary. All related carryforward tax attributes remained with Harvard Bioscience. |
Employee_Benefit_Plans
Employee Benefit Plans | 12 Months Ended | ||||||||
Dec. 31, 2013 | |||||||||
Employee Benefit Plans Disclosure [Abstract] | ' | ||||||||
Employee Benefit Plans Disclosure [Text Block] | ' | ||||||||
16. Employee Benefit Plans | |||||||||
The Company sponsors profit sharing retirement plans for its U.S. employees, which includes employee savings plans established under Section 401(k) of the U.S. Internal Revenue Code (the “401(k) Plans”). The 401(k) Plans cover substantially all full-time employees who meet certain eligibility requirements. Contributions to the profit sharing retirement plans are at the discretion of management. For the years ended December 31, 2013, 2012 and 2011, the Company contributed approximately $0.6 million, $0.5 million and $0.6 million, respectively, to the 401(k) Plans. | |||||||||
Certain of the Company's subsidiaries in the United Kingdom (UK), Harvard Apparatus Limited and Biochrom Limited, maintain contributory, defined benefit or defined contribution pension plans for substantially all of their employees. The provisions of FASB ASC 715-20 require that the funded status of the Company's pension plans be recognized in its balance sheet. FASB ASC 715-20 does not change the measurement or income statement recognition of these plans, although it does require that plan assets and benefit obligations be measured as of the balance sheet date. The Company has historically measured the plan assets and benefit obligations as of the balance sheet date. | |||||||||
The components of pension expense follows: | |||||||||
Year ended December 31, | |||||||||
2013 | 2012 | 2011 | |||||||
(in thousands) | |||||||||
Components of net periodic benefit cost: | |||||||||
Service cost | $ | 288 | $ | 314 | $ | 298 | |||
Interest cost | 797 | 819 | 836 | ||||||
Expected return on plan assets | -524 | -570 | -608 | ||||||
Net amortization loss | 305 | 248 | 159 | ||||||
Curtailment gain | -197 | - | - | ||||||
Net periodic benefit cost | $ | 669 | $ | 811 | $ | 685 | |||
The measurement date is December 31 for these plans. The funded status of the Company's defined benefit pension plans and the amount recognized in the consolidated balance sheets at December 31, 2013 and 2012 is as follows: | |||||||||
December 31, | |||||||||
2013 | 2012 | ||||||||
(in thousands) | |||||||||
Change in benefit obligation: | |||||||||
Balance at beginning of year | $ | 19,643 | $ | 16,866 | |||||
Service cost | 272 | 303 | |||||||
Interest cost | 797 | 819 | |||||||
Participants' contributions | 56 | 60 | |||||||
Actuarial (gain) loss | -329 | 1,547 | |||||||
Benefits paid | -431 | -663 | |||||||
Currency translation adjustment | 395 | 711 | |||||||
Balance at end of year | $ | 20,403 | $ | 19,643 | |||||
December 31, | |||||||||
2013 | 2012 | ||||||||
(in thousands) | |||||||||
Change in fair value of plan assets: | |||||||||
Balance at beginning of year | $ | 13,704 | $ | 12,006 | |||||
Actual return on plan assets | 1,125 | 944 | |||||||
Participants' contributions | 56 | 60 | |||||||
Employer contributions | 801 | 873 | |||||||
Benefits paid | -431 | -663 | |||||||
Currency translation adjustment | 285 | 484 | |||||||
Balance at end of year | $ | 15,540 | $ | 13,704 | |||||
December 31, | |||||||||
2013 | 2012 | ||||||||
(in thousands) | |||||||||
Change in benefit obligation: | |||||||||
Funded status | $ | -4,863 | $ | -5,939 | |||||
Unrecognized net loss | N/A | N/A | |||||||
Net amount recognized | $ | -4,863 | $ | -5,939 | |||||
The accumulated benefit obligation for all defined benefit pension plans was $19.5 million and $18.1 million at December 31, 2013 and 2012, respectively. | |||||||||
The amounts recognized in the consolidated balance sheets consist of: | |||||||||
December 31, | |||||||||
2013 | 2012 | ||||||||
(in thousands) | |||||||||
Deferred income tax assets | $ | 985 | $ | 1,366 | |||||
Other long term liabilities | -4,863 | -5,939 | |||||||
Net amount recognized | $ | -3,878 | $ | -4,573 | |||||
The amounts recognized in accumulated other comprehensive income, net of tax consist of: | |||||||||
December 31, | |||||||||
2013 | 2012 | ||||||||
(in thousands) | |||||||||
Underfunded status of pension plans | $ | -3,878 | $ | -4,573 | |||||
Net amount recognized | $ | -3,878 | $ | -4,573 | |||||
The weighted average assumptions used in determining the net pension cost for these plans follows: | |||||||||
Year ended December 31, | |||||||||
2013 | 2012 | 2011 | |||||||
Discount rate | 4.43% | 4.09% | 4.70% | ||||||
Expected return on assets | 3.79% | 4.02% | 4.40% | ||||||
Rate of compensation increase | 2.99% | 3.51% | 3.50% | ||||||
The discount rate assumptions used for pension accounting reflect the prevailing rates available on high-quality, fixed-income debt instruments with terms that match the average expected duration of the Company's defined benefit pension plan obligations. The Company uses the iBoxx AA 15yr+ index, which matches the average duration of its pension plan liability of approximately 15 years. With the current base of assets in the pension plans, a 0.1% increase/decrease in the discount rate assumption would decrease/increase annual pension expense by approximately $157,000. | |||||||||
The Company's mix of pension plan investments among asset classes also affects the long-term expected rate of return on plan assets. As of December 31, 2013, the Company's actual asset mix approximated its target mix. Differences between actual and expected returns are recognized in the calculation of net periodic pension (income)/cost over the average remaining expected future working lifetime, which is approximately 15 years, of active plan participants. With the current base of assets, a 0.1% increase/decrease in the asset return assumption would decrease/increase annual pension expense by approximately $94,000. | |||||||||
The fair value and asset allocations of the Company's pension benefits as of December 31, 2013 and 2012 measurement dates were as follows: | |||||||||
December 31, | |||||||||
2013 | 2012 | ||||||||
(in thousands) | |||||||||
Asset category: | |||||||||
Equity securities | $ | 7,404 | 48% | $ | 6,918 | 50% | |||
Debt securities | 6,061 | 39% | 5,049 | 37% | |||||
Cash and cash equivalents | 1,488 | 9% | 969 | 7% | |||||
Other | 587 | 4% | 768 | 6% | |||||
Total | $ | 15,540 | 100% | $ | 13,704 | 100% | |||
Financial reporting standards define a fair value hierarchy that consists of three levels. The fair values of the plan assets by fair value hierarchy level as of December 31, 2013 and 2012 is as follows: | |||||||||
December 31, | |||||||||
2013 | 2012 | ||||||||
(in thousands) | |||||||||
Quoted Prices in Active Markets for Identical Assets (Level 1) | $ | 1,488 | $ | 969 | |||||
Significant Other Observable Inputs (Level 2) | 13,465 | 11,967 | |||||||
Significant Other Unobservable Inputs (Level 3) | 587 | 768 | |||||||
Total | $ | 15,540 | $ | 13,704 | |||||
Level 1 assets consist of cash and cash equivalents held in the pension plans at December 31, 2013. The Level 2 assets primarily consist of investments in private investment funds that are valued using the net asset values provided by the trust or fund, including an insurance contract. Although these funds are not traded in an active market with quoted prices, the investments underlying the net asset value are based on quoted prices. Level 3 assets consist of an investment in a longevity fund which invests in a portfolio of physical life insurance settlements that are valued using the net asset values provided by the fund. Since June 2011, the fund has been closed to all activity. During the current year, the Company wrote down the value of this investment by $0.2 million. This is due, in part, to the illiquidity and inactivity of the fund, however, the fund has entered into premium financing contracts to ensure premium obligations on the policies are met for the foreseeable future or until maturities result in reliable liquidity. Going forward, the Company will monitor the financial condition of this fund to determine if additional write down is necessary. | |||||||||
The following table presents a summary of changes in the Company's Level 3 investments measured at fair value on a recurring basis: | |||||||||
December 31, | |||||||||
2013 | 2012 | ||||||||
(in thousands) | |||||||||
Balance at beginning of year | $ | 768 | $ | 1,042 | |||||
Purchases during the year | - | - | |||||||
Unrealized loss | -181 | -274 | |||||||
Balance at end of year | $ | 587 | $ | 768 | |||||
The Company expects to contribute approximately $0.8 million to its pension plans during 2014. | |||||||||
The benefits expected to be paid from the pension plans are $0.5 million in 2014, $0.6 million in 2015, $0.9 million in 2016, $0.7 million in 2017 and $0.9 million in 2018. The expected benefits to be paid in the five years from 2019—2023 are $4.6 million. The expected benefits are based on the same assumptions used to measure the Company's benefit obligation at December 31, 2013 and include estimated future employee service. |
Commitments_and_Contingent_Lia
Commitments and Contingent Liabilities | 12 Months Ended |
Dec. 31, 2013 | |
Commitments and Contingencies Disclosure [Abstract] | ' |
Commitments and Contingencies Disclosure [Text Block] | ' |
17. Commitments and Contingent Liabilities | |
From time to time, the Company may be involved in various claims and legal proceedings arising in the ordinary course of business. The Company is not currently a party to any such material claims or proceedings. | |
Accumulated_Other_Comprehensiv
Accumulated Other Comprehensive Income | 12 Months Ended | |||||||||||||||
Dec. 31, 2013 | ||||||||||||||||
Accumulated Other Comprehensive Income [Abstract] | ' | |||||||||||||||
Accumulated Other Comprehensive Income Disclosure [Text Block] | ' | |||||||||||||||
18. Accumulated Other Comprehensive (Loss) Income | ||||||||||||||||
Changes in each component of accumulated other comprehensive (loss) income, net of tax are as follows: | ||||||||||||||||
Foreign currency | Derivatives | |||||||||||||||
translation | qualifying as | Defined benefit | ||||||||||||||
(in thousands) | adjustments | hedges | pension plans | Total | ||||||||||||
Balance at December 31, 2012 | $ | -290 | $ | - | $ | -4,573 | $ | -4,863 | ||||||||
Other comprehensive income (loss) before reclassifications | 1,573 | -116 | 452 | 1,909 | ||||||||||||
Amounts reclassified from AOCI | - | 67 | 243 | 310 | ||||||||||||
Net other comprehensive income (loss) | 1,573 | -49 | 695 | 2,219 | ||||||||||||
Balance at December 31, 2013 | $ | 1,283 | $ | -49 | $ | -3,878 | $ | -2,644 | ||||||||
The amounts reclassified out of accumulated other comprehensive (loss) income are as follows: | ||||||||||||||||
Affected line item in the | Year Ended December 31, | |||||||||||||||
(in thousands) | Statements of Operations | 2013 | 2012 | 2011 | ||||||||||||
Amounts Reclassified From AOCI | ||||||||||||||||
Derivatives qualifying as hedges | ||||||||||||||||
Realized loss on derivatives qualifying as hedges | Interest expense | $ | 67 | $ | - | $ | - | |||||||||
Income tax | Income tax (benefit) expense | - | - | - | ||||||||||||
67 | - | - | ||||||||||||||
Defined benefit pension plans | ||||||||||||||||
Amortization of net losses included in net periodic pension costs | General and administrative expenses | 305 | 248 | 159 | ||||||||||||
Income tax | Income tax (benefit) expense | -62 | -57 | -40 | ||||||||||||
243 | 191 | 119 | ||||||||||||||
Total reclassifications | $ | 310 | $ | 191 | $ | 119 |
Capital_Stock
Capital Stock | 12 Months Ended | |||||||||||||||||
Dec. 31, 2013 | ||||||||||||||||||
Capital Stock Disclosure [Abstract] | ' | |||||||||||||||||
Capital Stock Disclosure [Text Block] | ' | |||||||||||||||||
19. Capital Stock | ||||||||||||||||||
Common Stock | ||||||||||||||||||
On February 5, 2008, the Company's Board of Directors adopted a Shareholder Rights Plan and declared a dividend distribution of one preferred stock purchase right for each outstanding share of the Company's common stock to shareholders of record as of the close of business on February 6, 2008. Initially, these rights will not be exercisable and will trade with the shares of the Company's common stock. Under the Shareholder Rights Plan, the rights generally will become exercisable if a person becomes an “acquiring person” by acquiring 20% or more of the common stock of the Company or if a person commences a tender offer that could result in that person owning 20% or more of the common stock of the Company. If a person becomes an acquiring person, each holder of a right (other than the acquiring person) would be entitled to purchase, at the then-current exercise price, such number of shares of preferred stock which are equivalent to shares of the Company's common stock having a value of twice the exercise price of the right. If the Company is acquired in a merger or other business combination transaction after any such event, each holder of a right would then be entitled to purchase, at the then-current exercise price, shares of the acquiring company's common stock having a value of twice the exercise price of the right. | ||||||||||||||||||
Preferred Stock | ||||||||||||||||||
The Company's Board of Directors has the authority to issue up to 5.0 million shares of preferred stock and to determine the price privileges and other terms of the shares. The Board of Directors may exercise this authority without any further approval of stockholders. As of December 31, 2013, the Company had no preferred stock issued or outstanding. | ||||||||||||||||||
Employee Stock Purchase Plan | ||||||||||||||||||
In 2000, the Company approved the ESPP. Under this ESPP, participating employees can authorize the Company to withhold a portion of their base pay during consecutive six-month payment periods for the purchase of shares of the Company's common stock. At the conclusion of the period, participating employees can purchase shares of the Company's common stock at 85% of the lower of the fair market value of the Company's common stock at the beginning or end of the period. Shares are issued under the ESPP for the six-month periods ending June 30 and December 31. Under this plan, 750,000 shares of common stock are authorized for issuance of which 527,340 shares were issued as of December 31, 2013. During the years ended December 31, 2013 and 2012, the Company issued 56,938 shares and 60,028 shares, respectively, under the ESPP. | ||||||||||||||||||
Stock-Based Payment Awards | ||||||||||||||||||
The Company accounts for stock-based payment awards in accordance with the provisions of FASB ASC 718, which requires it to recognize compensation expense for all stock-based payment awards made to employees and directors including stock options, restricted stock units, and employee stock purchases related to the ESPP (“employee stock purchases”). | ||||||||||||||||||
FASB ASC 718 requires companies to estimate the fair value of stock-based payment awards, except restricted stock units, on the date of grant using an option-pricing model. The value of the portion of the award that is ultimately expected to vest is recognized as expense over the requisite service periods in its consolidated statements of income. | ||||||||||||||||||
Upon adoption of FASB ASC 718, the Company elected to retain its method of valuation for stock-based payment awards using the Black-Scholes option-pricing model (“Black-Scholes model”). The determination of fair value of stock-based payment awards on the date of grant using an option-pricing model is affected by its stock price as well as assumptions regarding a number of highly complex and subjective variables. These variables include, but are not limited to its expected stock price volatility over the term of the awards and actual and projected stock option exercise behaviors. The Company records stock compensation expense on a straight-line basis over the requisite service period for all awards granted since the adoption of FASB ASC 718. | ||||||||||||||||||
Stock Option Plans | ||||||||||||||||||
1996 Stock Option and Grant Plan | ||||||||||||||||||
In 1996, the Company adopted the 1996 Stock Option and Grant Plan (the “1996 Stock Plan”) pursuant to which the Board of Directors could grant stock options to employees, directors and consultants. The 1996 Stock Plan authorized grants of options to purchase 4,072,480 shares of authorized but unissued common stock. In 2000, the 1996 Stock Plan was replaced by the 2000 Stock Option and Incentive Plan. As of December 31, 2013, there were no options to purchase shares outstanding under the 1996 Stock Plan. | ||||||||||||||||||
Amended and Restated 2000 Stock Option and Incentive Plan | ||||||||||||||||||
The Third Amended and Restated 2000 Stock Option and Incentive Plan (as amended, the “2000 Plan”) was adopted by the Board of Directors on April 13, 2011. Such amendment to the 2000 Plan was approved by the stockholders at the Company's 2011 Annual Meeting. The 2000 Plan made the following changes, among others, to the Second Amended and Restated 2000 Stock Option and Incentive Plan (the “Plan”): | ||||||||||||||||||
the aggregate number of shares authorized for issuance under the Plan was increased by 3,700,000 shares to 13,067,675 shares of Common Stock; | ||||||||||||||||||
the current limitation that no more than 3,750,000 shares of restricted stock awards, unrestricted stock awards, and performance share awards may be issued under the Plan was replaced with a fungible share provision deducting from shares available for grant under the Plan 1.79 shares for each share that underlies an award granted under the Company's 2000 Plan for deferred stock awards of restricted stock units, restricted stock awards, unrestricted stock awards, performance share awards or other awards under the Company's 2000 Plan for which the full value of such share is transferred by the Company to the award recipient; and | ||||||||||||||||||
other clarifying and updating changes. | ||||||||||||||||||
The Company currently has 13,067,675 shares of its common stock reserved for the issuance of awards under the 2000 Plan. As of December 31, 2013, there were options to purchase 6,690,845 shares, and 463,973 restricted stock units outstanding. | ||||||||||||||||||
Through December 31, 2013 and 2012, incentive stock options to purchase 10,218,057 and 8,990,395 shares and non-qualified stock options to purchase 11,028,074 and 8,906,684 shares, respectively, had been granted to employees and directors under the Stock Plans. Generally, both the incentive stock options and non-qualified stock options become fully vested over a range of one to four-year periods. | ||||||||||||||||||
During the years ended December 31, 2013, 2012 and 2011, 3,349,052, 1,220,934 and 1,030,500 options, respectively, were granted to employees and directors at exercise prices equal to or greater than fair market value of the Company's common stock on the date of grant. | ||||||||||||||||||
During 2013, 2012 and 2011, 259,931, 349,295 and 188,750 restricted stock units, respectively, were granted to certain employees and directors under the 2000 Plan. | ||||||||||||||||||
Earnings per share | ||||||||||||||||||
Basic earnings per share is based upon net income divided by the number of weighted average common shares outstanding during the period. The calculation of diluted earnings per share assumes conversion of stock options and restricted stock units into common stock using the treasury method. The weighted average number of shares used to compute basic and diluted earnings per share consists of the following: | ||||||||||||||||||
Year ended December 31, | ||||||||||||||||||
2013 | 2012 | 2011 | ||||||||||||||||
Basic | 30,384,010 | 28,799,377 | 28,451,386 | |||||||||||||||
Effect of assumed conversion of employee and director stock options and restricted stock units | 1,529,789 | 992,730 | 1,367,348 | |||||||||||||||
Diluted | 31,913,799 | 29,792,107 | 29,818,734 | |||||||||||||||
Excluded from the shares used in calculating the diluted earnings per common share in the above table are options to purchase approximately 2,547,580 shares, 4,700,033 shares and 3,653,317 shares of common stock for the years ended December 31, 2013, 2012 and 2011, respectively, as the impact of these shares would be anti-dilutive. | ||||||||||||||||||
General Option Information | ||||||||||||||||||
The following is a summary of stock option and the restricted stock unit activity: | ||||||||||||||||||
Stock Options | Restricted Stock Units | |||||||||||||||||
Weighted | ||||||||||||||||||
Stock | Average | Restricted | ||||||||||||||||
Options | Exercise | Stock Units | Grant Date | |||||||||||||||
Outstanding | Price | Outstanding | Fair Value | |||||||||||||||
Balance at December 31, 2010 | 7,826,200 | $ | 4.38 | 467,600 | $ | 3.61 | ||||||||||||
Granted | 1,030,500 | 5.64 | 188,750 | 5.64 | ||||||||||||||
Exercised | -105,625 | 3.79 | - | - | ||||||||||||||
Vested (RSU's) | - | - | -116,900 | - | ||||||||||||||
Cancelled / forfeited | -231,500 | 5.27 | - | - | ||||||||||||||
Balance at December 31, 2011 | 8,519,575 | 4.52 | 539,450 | 4.32 | ||||||||||||||
Granted | 1,220,934 | 3.6 | 349,295 | 3.57 | ||||||||||||||
Exercised | -648,000 | 3.94 | - | - | ||||||||||||||
Vested (RSU's) | - | - | -164,090 | - | ||||||||||||||
Cancelled / forfeited | -1,014,000 | 6.36 | -47,462 | 4.21 | ||||||||||||||
Balance at December 31, 2012 | 8,078,509 | 4.25 | 677,193 | 3.97 | ||||||||||||||
Granted | 3,349,052 | 4.44 | 259,931 | 4.62 | ||||||||||||||
Exercised | -3,410,483 | 3.2 | - | - | ||||||||||||||
Vested (RSU's) | - | - | -281,650 | - | ||||||||||||||
Cancelled / forfeited | -1,326,233 | 5.26 | -191,501 | 4.07 | ||||||||||||||
Balance at December 31, 2013 | 6,690,845 | $ | 3.42 | 463,973 | $ | 4.32 | ||||||||||||
For 2013 and included in the table above are grants of 1,715,164 options and 135,650 restricted stock units related to the spin-off of HART. Pursuant to the spin-off, share amounts and exercise prices of Harvard Bioscience options, as well as share amounts of Harvard Bioscience restricted stock units were adjusted so that the intrinsic value held by the holder pertaining to the existing option or award was maintained immediately following the spin-off. | ||||||||||||||||||
The Company's policy is to issue stock available from its registered but unissued stock pool through its transfer agent to satisfy stock option exercises and vesting of the restricted stock units. | ||||||||||||||||||
The following table summarizes information concerning currently outstanding and exercisable options as of December 31, 2013 (Aggregate Intrinsic Value, in thousands): | ||||||||||||||||||
Options Outstanding | Options Exercisable | |||||||||||||||||
Weighted | Weighted | |||||||||||||||||
Average | Weighted | Average | Weighted | |||||||||||||||
Range of | Shares | Remaining | Average | Aggregate | Shares | Remaining | Average | Aggregate | ||||||||||
Exercise | Outstanding at | Contractual Life | Exercise | Intrinsic | Exercisable at | Contractual Life | Exercise | Intrinsic | ||||||||||
Price | Dec. 31, 2013 | in Years | Price | Value | Dec. 31, 2013 | in Years | Price | Value | ||||||||||
$ | 1.43-2.15 | 306,358 | 4.03 | $ | 1.86 | $ | 870 | 306,358 | 4.03 | $ | 1.86 | $ | 870 | |||||
2.28-2.28 | 981,082 | 5.37 | 2.28 | 2,372 | 981,082 | 5.37 | 2.28 | 2,372 | ||||||||||
2.45-2.45 | 13,172 | 1.43 | 2.45 | 30 | 13,172 | 1.43 | 2.45 | 30 | ||||||||||
2.56-2.56 | 994,618 | 7.82 | 2.56 | 2,128 | 198,402 | 7.82 | 2.56 | 425 | ||||||||||
2.59-3.54 | 836,338 | 4.66 | 3.03 | 1,397 | 723,635 | 4.66 | 3.1 | 1,158 | ||||||||||
3.64-3.64 | 935,371 | 8.89 | 3.64 | 991 | - | 0 | - | - | ||||||||||
3.68-3.99 | 486,706 | 3.3 | 3.87 | 404 | 486,706 | 3.3 | 3.87 | 404 | ||||||||||
4.04-4.04 | 865,617 | 7.2 | 4.04 | 571 | 444,865 | 7.2 | 4.04 | 294 | ||||||||||
4.21-4.31 | 807,500 | 9.88 | 4.31 | 315 | - | 0 | - | - | ||||||||||
5.73-6.57 | 464,083 | 0.22 | 5.75 | - | 464,083 | 0.22 | 5.75 | - | ||||||||||
$ | 1.43-6.57 | 6,690,845 | 6.34 | $ | 3.42 | $ | 9,078 | 3,618,303 | 4.56 | $ | 3.3 | $ | 5,553 | |||||
The aggregate intrinsic value in the preceding table represents the total pre-tax intrinsic value, based on the Company's closing stock price of $4.70 as of December 31, 2013, which would have been received by the option holders had all option holders exercised their options as of that date. The weighted average exercise prices above were adjusted to reflect the effect of the spin-off of HART on the Company's outstanding options. Pursuant to the spin-off, share amounts and exercise prices of Harvard Bioscience options were adjusted so that the intrinsic value held by the holder pertaining to the existing option was maintained immediately following the spin-off. The aggregate intrinsic value of options exercised for the years ended December 31, 2013, 2012 and 2011 was approximately $5.1 million, $0.3 million and $8,450, respectively. The total number of in-the-money options that were exercisable as of December 31, 2013 was 3,154,220. | ||||||||||||||||||
For the year ended December 31, 2013, the total compensation costs related to unvested awards not yet recognized is $3.4 million and the weighted average period over which it is expected to be recognized is 2.31 years. | ||||||||||||||||||
Valuation and Expense Information under Stock-Based-Payment Accounting | ||||||||||||||||||
Stock-based compensation expense related to stock options, restricted stock units and the employee stock purchase plan for the years ended December 31, 2013, 2012 and 2011 was allocated as follows: | ||||||||||||||||||
Year Ended December 31, | ||||||||||||||||||
2013 | 2012 | 2011 | ||||||||||||||||
(in thousands) | ||||||||||||||||||
Cost of product revenues | $ | 131 | $ | 87 | $ | 76 | ||||||||||||
Sales and marketing | 223 | 154 | 152 | |||||||||||||||
General and administrative | 2,200 | 2,990 | 2,570 | |||||||||||||||
Research and development | 45 | 25 | 21 | |||||||||||||||
Discontinued operations | 71 | 65 | 44 | |||||||||||||||
Total stock-based compensation | $ | 2,670 | $ | 3,321 | $ | 2,863 | ||||||||||||
The Company did not capitalize any stock-based compensation. | ||||||||||||||||||
The weighted-average estimated fair value per share of stock options granted during 2013, 2012 and 2011 was $2.41, $1.84 and $2.94, respectively, using the Black Scholes option-pricing model with the following weighted-average assumptions: | ||||||||||||||||||
Years Ended December 31, | ||||||||||||||||||
2013 | 2012 | 2011 | ||||||||||||||||
Volatility | 57.18 | % | 55.09 | % | 54.24 | % | ||||||||||||
Risk-free interest rate | 1.42 | % | 0.8 | % | 2.01 | % | ||||||||||||
Expected holding period | 5.67 | years | 5.98 | years | 5.94 | years | ||||||||||||
Dividend Yield | 0 | % | 0 | % | 0 | % | ||||||||||||
The Company used historical volatility to calculate the expected volatility as of December 31, 2013. Historical volatility was determined by calculating the mean reversion of the daily adjusted closing stock price. The risk-free interest rate assumption is based upon observed Treasury bill interest rates (risk free) appropriate for the term of the Company's stock options. The expected life of stock options represents the period of time options are expected to be outstanding and were based on historical experience. The vesting period ranges from one to four years and the contractual life is ten years. | ||||||||||||||||||
Stock-based compensation expense recognized in the consolidated statement of income for the years ended December 31, 2013, 2012 and 2011 is based on awards ultimately expected to vest and has been reduced for annualized estimated forfeitures of 6.54%, 5.38% and 5.04%, respectively. Stock-based-payment accounting requires forfeitures to be estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. Forfeitures were estimated based on historical experience. |
Related_Party_Transactions
Related Party Transactions | 12 Months Ended |
Dec. 31, 2013 | |
Related Party Transactions [Abstract] | ' |
Related Party Transactions Disclosure [Text Block] | ' |
20. Related Party Transactions | |
In connection with the HART spin-off, the Company entered into various commercial agreements with HART. These agreements include: (i) a Separation and Distribution Agreement to effect the separation and spin-off distribution and provide other agreements to govern the Company's relationship with HART after the spin-off; (ii) an Intellectual Property Matters Agreement, which governs various intellectual property related arrangements between the Company and HART, including the separation of intellectual property rights between the Company and HART, as well as certain related cross-licenses between the two companies; (iii) a Product Distribution Agreement, which provides that each company will become the exclusive distributor for the other party for products such other party develops for sale in the markets served by the other; (iv) a Tax Sharing Agreement, which governs the Company's and HART's respective rights, responsibilities and obligations with respect to tax liabilities and benefits, tax attributes, the preparation and filing of tax returns, the control of audits and other tax proceedings and other matters regarding taxes for periods before, during and after the spin-off; and (v) a Transition Services Agreement, which provides for certain services to be performed on a transitional basis by the Company to facilitate HART's transition into a separate public reporting company. As part of the Transition Services Agreement, and for one year following the spin-off date, the Company will provide certain support services to HART, including, among others, accounting, payroll, human resources and information technology services, with the charges for the transition services generally intended to allow the Company to fully recover the costs directly associated with providing the services, plus all out-of-pocket costs and expenses. | |
The Company's operating expenses were reduced by $0.1 million for the year ended December 31, 2013, as a result of the fees the Company charged to HART for services provided pursuant to the Transition Services Agreement. In addition, the Company's rent expense was reduced by $26,000 for the year ended December 31, 2013, as a result of sublease rent charged to HART pursuant to a sublease between the two companies. Refer to Note 13 for further details on the sublease. | |
David Green, who is currently a Director of the Company and was also formerly the Company's President and interim CEO, is currently the Chairman and CEO of HART. | |
Segment_Reporting
Segment Reporting | 12 Months Ended | ||||||
Dec. 31, 2013 | |||||||
Segment and Related Information Disclosure [Abstract] | ' | ||||||
Segment Reporting Disclosure [Text Block] | ' | ||||||
21. Segment and Related Information | |||||||
Operating segments are determined by products and services provided by each segment, internal organization structure, the manner in which operations are managed, criteria used by the Chief Operating Decision Maker (“CODM”) to assess the segment performance, as well as resource allocation and the availability of discrete financial information. Following the spin-off of HART, the Company's former Regenerative Medicine Device (“RMD”) segment, the Company has one operating segment. As such, segment results and consolidated results are the same. | |||||||
The following tables summarize selected financial information of the Company's continuing operations by geographic location: | |||||||
Revenues originating from the following geographic areas consist of: | |||||||
Year ended December 31, | |||||||
2013 | 2012 | 2011 | |||||
(in thousands) | |||||||
United States | $ | 63,810 | $ | 65,190 | $ | 64,185 | |
United Kingdom | 23,123 | 27,137 | 26,160 | ||||
Rest of the world | 18,238 | 18,844 | 18,519 | ||||
Total revenues | $ | 105,171 | $ | 111,171 | $ | 108,864 | |
Long-lived assets by geographic area consist of the following: | |||||||
December 31, | |||||||
2013 | 2012 | ||||||
(in thousands) | |||||||
United States | $ | 14,128 | $ | 16,744 | |||
United Kingdom | 2,343 | 2,441 | |||||
Rest of the world | 6,913 | 6,591 | |||||
Total long-lived assets (1) | $ | 23,384 | $ | 25,776 | |||
(1) Total long-lived assets includes property, plant and equipment, net and amortizable intangible assets, net. | |||||||
Net assets by geographic area consist of the following: | |||||||
December 31, | |||||||
2013 | 2012 | ||||||
(in thousands) | |||||||
United States | $ | 37,497 | $ | 51,218 | |||
United Kingdom | 32,214 | 29,741 | |||||
Rest of the world | 24,774 | 23,254 | |||||
Total net assets | $ | 94,485 | $ | 104,213 |
Allowance_for_Doubtful_Debts
Allowance for Doubtful Debts | 12 Months Ended | ||||||||
Dec. 31, 2013 | |||||||||
Allowance For Doubtful Debts Disclosure [Abstract] | ' | ||||||||
Allowance For Doubtful Debts Disclosure [Text Block] | ' | ||||||||
22. Allowance for Doubtful Accounts | |||||||||
Allowance for doubtful accounts is based on the Company's assessment of the collectability of customer accounts. A rollforward of allowance for doubtful accounts is as follows: | |||||||||
Charged (credited) to | |||||||||
Beginning | Bad Debt | Charged to | Ending | ||||||
Balance | Expense | Allowance (1) | Balance | ||||||
(in thousands) | |||||||||
Year ended December 31, 2011 | $ | 273 | 67 | -38 | $ | 302 | |||
Year ended December 31, 2012 | 302 | -31 | -77 | 194 | |||||
Year ended December 31, 2013 | $ | 194 | 172 | -8 | $ | 358 | |||
(1) Consists of accounts written off, net of recoveries. |
Warranties
Warranties | 12 Months Ended | |||||||||||
Dec. 31, 2013 | ||||||||||||
Warranties Disclosure [Abstract] | ' | |||||||||||
Warranties Disclosure [Text Block] | ' | |||||||||||
23. Warranties | ||||||||||||
A rollforward of product warranties is as follows: | ||||||||||||
Beginning | Ending | |||||||||||
Balance | Payments | Additions | Balance | |||||||||
(in thousands) | ||||||||||||
Year ended December 31, 2011 | $ | 158 | -58 | 44 | $ | 144 | ||||||
Year ended December 31, 2012 | 144 | -136 | 214 | 222 | ||||||||
Year ended December 31, 2013 | $ | 222 | -179 | 262 | $ | 305 |
Quarterly_Financial_Informatio
Quarterly Financial Information (unaudited) | 12 Months Ended | |||||||||||||||
Dec. 31, 2013 | ||||||||||||||||
Quarterly Financial Information Disclosure [Abstract] | ' | |||||||||||||||
Quarterly Financial Information (unaudited) Disclosure [Text Block] | ' | |||||||||||||||
24. Quarterly Financial Information (unaudited) | ||||||||||||||||
The following quarterly 2013 and 2012 financial information has been restated to reflect HART's operations as discontinued operations for all periods presented. The operations of HART have been combined with the Company's other discontinued operations. | ||||||||||||||||
Statement of Operations Data: | ||||||||||||||||
First | Second | Third | Fourth | Fiscal | ||||||||||||
2013 | Quarter | Quarter | Quarter | Quarter | Year | |||||||||||
(in thousands, except per share data) | ||||||||||||||||
Revenues | $ | 26,086 | $ | 26,094 | $ | 25,137 | $ | 27,854 | $ | 105,171 | ||||||
Cost of product revenues | 13,826 | 14,005 | 13,838 | 15,806 | 57,475 | |||||||||||
Gross profit | 12,260 | 12,089 | 11,299 | 12,048 | 47,696 | |||||||||||
Total operating expenses | 10,934 | 11,343 | 10,885 | 12,997 | 46,159 | |||||||||||
Operating income (loss) | 1,326 | 746 | 414 | -949 | 1,537 | |||||||||||
Other (expense) income, net | -95 | -330 | -358 | -319 | -1,102 | |||||||||||
Income (loss) from continuing operations before income taxes | 1,231 | 416 | 56 | -1,268 | 435 | |||||||||||
Income tax expense (benefit) | 299 | 321 | 105 | -1,013 | -288 | |||||||||||
Income (loss) from continuing operations | 932 | 95 | -49 | -255 | 723 | |||||||||||
Loss from discontinued operations, net of tax | -836 | -281 | -935 | -501 | -2,553 | |||||||||||
Net income (loss) | $ | 96 | $ | -186 | $ | -984 | $ | -756 | $ | -1,830 | ||||||
Earnings (loss) per share: | ||||||||||||||||
Basic earnings (loss) per common share from continuing operations | $ | 0.03 | $ | 0 | $ | 0 | $ | -0.01 | $ | 0.02 | ||||||
Discontinued operations | -0.03 | -0.01 | -0.03 | -0.01 | -0.08 | |||||||||||
Basic earnings (loss) per common share | $ | 0 | $ | -0.01 | $ | -0.03 | $ | -0.02 | $ | -0.06 | ||||||
Diluted earnings (loss) per common share from continuing operations | $ | 0.03 | $ | 0 | $ | 0 | $ | -0.01 | $ | 0.02 | ||||||
Discontinued operations | -0.03 | -0.01 | -0.03 | -0.01 | -0.08 | |||||||||||
Diluted earnings (loss) per common share | $ | 0 | $ | -0.01 | $ | -0.03 | $ | -0.02 | $ | -0.06 | ||||||
Statement of Operations Data: | ||||||||||||||||
First | Second | Third | Fourth | Fiscal | ||||||||||||
2012 | Quarter | Quarter | Quarter | Quarter | Year | |||||||||||
(in thousands, except per share data) | ||||||||||||||||
Revenues | $ | 28,322 | $ | 28,496 | $ | 26,104 | $ | 28,249 | $ | 111,171 | ||||||
Cost of product revenues | 14,939 | 14,901 | 14,135 | 14,856 | 58,831 | |||||||||||
Gross profit | 13,383 | 13,595 | 11,969 | 13,393 | 52,340 | |||||||||||
Total operating expenses | 11,321 | 11,121 | 10,813 | 11,255 | 44,510 | |||||||||||
Operating income | 2,062 | 2,474 | 1,156 | 2,138 | 7,830 | |||||||||||
Other (expense) income, net | -385 | -226 | -178 | -149 | -938 | |||||||||||
Income from continuing operations before income taxes | 1,677 | 2,248 | 978 | 1,989 | 6,892 | |||||||||||
Income tax expense | 605 | 698 | 278 | 817 | 2,398 | |||||||||||
Income from continuing operations | 1,072 | 1,550 | 700 | 1,172 | 4,494 | |||||||||||
(Loss) income from discontinued operations, net of tax | -543 | -776 | -833 | 28 | -2,124 | |||||||||||
Net income (loss) | $ | 529 | $ | 774 | $ | -133 | $ | 1,200 | $ | 2,370 | ||||||
Earnings per share: | ||||||||||||||||
Basic earnings per common share from continuing operations | $ | 0.04 | $ | 0.05 | $ | 0.02 | $ | 0.04 | $ | 0.16 | ||||||
Discontinued operations | -0.02 | -0.03 | -0.03 | 0 | -0.07 | |||||||||||
Basic earnings (loss) per common share | $ | 0.02 | $ | 0.02 | $ | -0.01 | $ | 0.04 | $ | 0.09 | ||||||
Diluted earnings per common share from continuing operations | $ | 0.04 | $ | 0.05 | $ | 0.02 | $ | 0.04 | $ | 0.15 | ||||||
Discontinued operations | -0.02 | -0.03 | -0.03 | 0 | -0.07 | |||||||||||
Diluted earnings (loss) per common share | $ | 0.02 | $ | 0.02 | $ | -0.01 | $ | 0.04 | $ | 0.08 |
Summary_of_Significant_Account
Summary of Significant Accounting Policies (Policies) | 12 Months Ended | ||||||
Dec. 31, 2013 | |||||||
Recently Issued Accounting Pronouncements [Abstract] | ' | ||||||
Recently Issued Accounting Pronouncements Disclosure [Text Block] | ' | ||||||
(r) Recently Issued Accounting Pronouncements | |||||||
In July 2013, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2013-11, “Income Taxes (Topic 740): Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists”, which requires an entity to present an unrecognized tax benefit as a reduction of a deferred tax asset for a net operating loss (NOL) carryforward, or similar tax loss or tax credit carryforward, rather than as a liability when the uncertain tax position would reduce the NOL or other carryforward under the tax law. The ASU is effective prospectively for fiscal years, and interim periods within those years, beginning after December 15, 2013. The Company believes the adoption of this new guidance will not have a material impact on its consolidated financial position or results of operations. | |||||||
In February 2013, the FASB issued additional guidance in ASU 2013-02, “Reporting Amounts Reclassified Out of Accumulated Other Comprehensive Income.” The new guidance requires the presentation of effects on net income line items of significant amounts reclassified out of accumulated other comprehensive income, but only if the item reclassified is required under U.S. GAAP to be reclassified to net income in its entirety in the same reporting period. The Company shall provide this information either on the face of the statements or in the notes to the consolidated financial statements. The guidance is effective for fiscal years beginning after December 15, 2012. The adoption of this guidance, which is related to disclosure only, did not have an impact on the Company's consolidated financial position, results of operations or cash flows. | |||||||
Summary of Significant Accounting Policies [Abstract] | ' | ||||||
Principles of Consolidation [Policy Text Block] | ' | ||||||
(a) Principles of Consolidation | |||||||
The consolidated financial statements include the accounts of Harvard Bioscience, Inc. and its wholly-owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. | |||||||
Use of Estimates [Policy Text Block] | ' | ||||||
(b) Use of Estimates | |||||||
The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires the use of management estimates. Such estimates include the determination and establishment of certain accruals and provisions, including those for inventory obsolescence, catalog cost amortization periods, income tax and reserves for bad debts. In addition, certain estimates are required in order to determine the value of assets and liabilities associated with acquisitions. Estimates are also required to evaluate the value and recoverability of existing long-lived and intangible assets, including goodwill. On an ongoing basis, the Company reviews its estimates based upon currently available information. Actual results could differ materially from those estimates. | |||||||
Cash and Cash Equivalents [Policy Text Block] | ' | ||||||
(c) Cash and Cash Equivalents | |||||||
For purposes of the consolidated balance sheets and statements of cash flows, the Company considers all highly liquid instruments with original maturities of three months or less to be cash equivalents. | |||||||
Allowance for Doubtful Accounts [Policy Text Block] | ' | ||||||
(d) Allowance for Doubtful Accounts | |||||||
Allowance for doubtful accounts is based on the Company's assessment of collectability of customer accounts. The Company regularly reviews the allowance by considering factors such as historical experience, credit quality, age of the accounts receivable balances and other factors that may affect a customer's ability to pay. | |||||||
Inventories [Policy Text Block] | ' | ||||||
(e) Inventories | |||||||
The Company values its inventories at the lower of the actual cost to purchase (first-in, first-out method) and/or manufacture the inventories or the current estimated market value of the inventories. The Company regularly reviews inventory quantities on hand and records a provision to write down excess and obsolete inventories to its estimated net realizable value if less than cost, based primarily on historical inventory usage and estimated forecast of product demand. | |||||||
Property, Plant and Equipment [Policy Text Block] | ' | ||||||
(f) Property, Plant and Equipment | |||||||
Property, plant and equipment are stated at cost and depreciated using the straight-line method over the estimated useful lives of the assets as follows: | |||||||
Buildings | 40 | years | |||||
Machinery and equipment | 3 | - | 10 | years | |||
Computer equipment and software | 3 | - | 7 | years | |||
Furniture and fixtures | 5 | - | 10 | years | |||
Automobiles | 3 | - | 6 | years | |||
Property and equipment held under capital leases and leasehold improvements are amortized using the straight line method over the shorter of the lease term or estimated useful life of the asset. | |||||||
Catalog Costs [Policy Text Block] | ' | ||||||
(g) Catalog Costs | |||||||
Significant costs of product catalog design, development and production are capitalized and amortized over the expected useful life of the catalog (usually one to three years). | |||||||
Income Taxes [Policy Text Block] | ' | ||||||
(h) Income Taxes | |||||||
Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to be applied to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. | |||||||
The Company recognizes the effect of income tax positions only if those positions are more likely than not of being sustained. Recognized income tax positions are measured at the largest amount that is more than 50% likely of being realized. Changes in recognition are reflected in the period in which the judgement occurs. | |||||||
Foreign Currency Transaction [Policy Text Block] | ' | ||||||
(i) Foreign Currency Translation | |||||||
The functional currency of the Company's foreign subsidiaries is generally their local currency. All assets and liabilities of its foreign subsidiaries are translated at exchange rates in effect at period-end. Income and expenses are translated at rates which approximate those in effect on the transaction dates. The resulting translation adjustment is recorded as a separate component of stockholders' equity in accumulated other comprehensive income in the consolidated balance sheets. Gains and losses resulting from foreign currency transactions are included in net income. | |||||||
Earnings Per Share [Policy Text Block] | ' | ||||||
(j) Earnings per Share | |||||||
Basic earnings per share is computed by dividing net income by the weighted average number of shares of common stock outstanding during the periods presented. The computation of diluted earnings per share is similar to the computation of basic earnings per share, except that the denominator is increased for the assumed exercise of dilutive options and other potentially dilutive securities using the treasury stock method unless the effect is antidilutive. Since the Company is reporting discontinued operations, it used income from continuing operations as the control number in determining whether those potential dilutive securities are dilutive or antidilutive. | |||||||
Comprehensive Income Loss [Policy Text Block] | ' | ||||||
(k) Comprehensive Income | |||||||
The Company follows the provisions of Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 220, “Comprehensive Income”. FASB ASC 220 requires companies to report all changes in equity during a period, resulting from net income (loss) and transactions from non-owner sources, in a financial statement in the period in which they are recognized. The Company has chosen to disclose comprehensive income, which encompasses net income (loss), foreign currency translation adjustments, gains and losses on derivatives, the underfunded status of its pension plans, and pension minimum additional liability adjustments, net of tax, in the consolidated statements of comprehensive income. | |||||||
Revenue Recognition [Policy Text Block] | ' | ||||||
(l) Revenue Recognition | |||||||
The Company follows the provisions of FASB ASC 605, “Revenue Recognition”. The Company recognizes product revenue when persuasive evidence of a sales arrangement exists, the price to the buyer is fixed or determinable, delivery has occurred, and collectibility of the sales price is reasonably assured. Sales of some of its products include provisions to provide additional services such as installation and training. Revenues on these products are recognized when the additional services have been performed. Service agreements on its equipment are typically sold separately from the sale of the equipment. Revenues on these service agreements are recognized ratably over the life of the agreement, typically one year, in accordance with the provisions of FASB ASC 605-20, “Revenue Recognition—Services”. | |||||||
The Company accounts for shipping and handling fees and costs in accordance with the provisions of FASB ASC 605-45-45, “Revenue Recognition—Principal Agent Considerations”, which requires all amounts charged to customers for shipping and handling to be classified as revenues. The costs incurred related to shipping and handling is classified as cost of product revenues. Warranties and product returns are estimated and accrued for at the time sales are recorded. The Company has no obligations to customers after the date products are shipped or installed, if applicable, other than pursuant to warranty obligations and service or maintenance contracts. The Company provides for the estimated amount of future returns upon shipment of products or installation, if applicable, based on historical experience. | |||||||
Goodwill and Other Intangible Assets [Policy Text Block] | ' | ||||||
(m) Goodwill and Other Intangible Assets | |||||||
Goodwill and other intangible assets include goodwill, unamortizable intangible assets and amortizable intangible assets. Amortizable intangible assets (those intangible assets with definite estimated useful lives) are initially recorded at fair value and amortized, using the straight-line method, over their estimated useful lives. At December 31, 2013, amortizable intangible assets include existing technology, trade names, distribution agreements, customer relationships and patents. These amortizable intangible assets are amortized on a straight-line basis over 7 to 15 years, 15 years, 5 years, 5 to 15 years and 5 to 15 years, respectively. | |||||||
Goodwill and unamortizable intangible assets acquired in a business combination and determined to have an indefinite useful life are not amortized, but instead are tested for impairment annually or more frequently if events or changes in circumstances indicate that the asset might be impaired, in accordance with the provisions of FASB ASC 350, “Intangibles—Goodwill and Other”. | |||||||
For the purpose of its goodwill analysis, and following the spin-off of HART, the Company has one reporting unit. The Company conducted its annual impairment analysis in the fourth quarter of fiscal year 2013. The goodwill impairment test is a two-step process. The first step of the impairment analysis compares the Company's fair value to its carrying value to determine if there is any indication of impairment. Step two of the analysis compares the implied fair value of goodwill to its carrying amount in a manner similar to a purchase price allocation for business combination. If the carrying amount of goodwill exceeds its implied fair value, an impairment loss is recognized equal to that excess. For indefinite-lived intangible assets if the carrying amount exceeds the fair value of the asset, the Company would write down the indefinite-lived intangible asset to fair value. | |||||||
At December 31, 2013, the Company compared its carrying value to its overall market capitalization, noting the fair value of the Company significantly exceeded the carrying value. The Company concluded that none of its goodwill was impaired. | |||||||
The Company evaluates indefinite-lived intangible assets for impairment annually and when events occur or circumstances change that may reduce the fair value of the asset below its carrying amount. Events or circumstances that might require an interim evaluation include unexpected adverse business conditions, economic factors, unanticipated technological changes or competitive activities, loss of key personnel and acts by governments and courts. At December 31, 2013 the Company concluded that none of its indefinite-lived intangible assets were impaired. | |||||||
Impairment Of Long-Lived Assets [Policy Text Block] | ' | ||||||
(n) Impairment of Long-Lived Assets | |||||||
The Company assesses recoverability of its long-lived assets that are held for use, such as property, plant and equipment and amortizable intangible assets in accordance with FASB ASC 360, “Property, Plant and Equipment” when events or changes in circumstances indicate that the carrying amount of an asset or asset group may not be recoverable. Recoverability of assets or an asset group to be held and used is measured by a comparison of the carrying amount of an asset or asset group to estimated undiscounted future cash flows expected to be generated by the asset or the asset group. Cash flow projections are based on trends of historical performance and management's estimate of future performance. If the carrying amount of the asset or asset group exceeds the estimated future cash flows, an impairment charge is recognized by the amount by which the carrying amount of the asset or asset group exceeds its estimated fair value. At December 31, 2013 the Company concluded that none of its long-lived assets were impaired. | |||||||
Derivatives [Policy Text Block] | ' | ||||||
(o) Derivatives | |||||||
The Company uses interest-rate-related derivative instruments to manage its exposure related to changes in interest rates on its variable-rate debt instruments. The Company does not enter into derivative instruments for any purpose other than cash flow hedging. The Company does not speculate using derivative instruments. The Company recognizes all derivative instruments as either assets or liabilities in the balance sheet at their respective fair values. For derivatives designated in hedging relationships, changes in the fair value are either offset through earnings against the change in fair value of the hedged item attributable to the risk being hedged or recognized in accumulated other comprehensive income (“AOCI”), to the extent the derivative is effective at offsetting the changes in cash flows being hedged until the hedged item affects earnings. | |||||||
The Company only enters into derivative contracts that it intends to designate as a hedge of a forecasted transaction or the variability of cash flows to be received or paid related to a recognized asset or liability (cash flow hedge). For all hedging relationships, the Company formally documents the hedging relationship and its risk-management objective and strategy for undertaking the hedge, the hedging instrument, the hedged transaction, the nature of the risk being hedged, how the hedging instrument's effectiveness in offsetting the hedged risk will be assessed prospectively and retrospectively, and a description of the method used to measure ineffectiveness. The Company also formally assesses, both at the inception of the hedging relationship and on an ongoing basis, whether the derivatives that are used in hedging relationships are highly effective in offsetting changes in cash flows of hedged transactions. For derivative instruments that are designated and qualify as part of a cash flow hedging relationship, the effective portion of the gain or loss on the derivative is reported as a component of other comprehensive income and reclassified into earnings in the same period or periods during which the hedged transaction affects earnings. Gains and losses on the derivative representing either hedge ineffectiveness or hedge components excluded from the assessment of effectiveness are recognized in current earnings. | |||||||
The Company discontinues hedge accounting prospectively when it determines that the derivative is no longer effective in offsetting cash flows attributable to the hedged risk, the derivative expires or is sold, terminated, or exercised, the cash flow hedge is de-designated because a forecasted transaction is not probable of occurring, or management determines to remove the designation of the cash flow hedge. | |||||||
In all situations in which hedge accounting is discontinued and the derivative remains outstanding, the Company continues to carry the derivative at its fair value on the balance sheet and recognizes any subsequent changes in its fair value in earnings. When it is probable that a forecasted transaction will not occur, the Company discontinues hedge accounting and recognizes immediately in earnings gains and losses that were accumulated in other comprehensive income related to the hedging relationship. | |||||||
Fair Value of Financial Instruments [Policy Text Block] | ' | ||||||
p) Fair Value of Financial Instruments | |||||||
The carrying values of the Company's cash and cash equivalents, trade accounts receivable and trade accounts payable and short-term debt approximate their fair values because of the short maturities of those instruments. The fair value of the Company's long-term debt approximates its carrying value and is based on the amount of future cash flows associated with the debt discounted using current borrowing rates for similar debt instruments of comparable maturity. | |||||||
Financial reporting standards define a fair value hierarchy that consists of three levels: | |||||||
Level 1 includes instruments for which quoted prices in active markets for identical assets or liabilities accessible to the Company at the measurement date. | |||||||
Level 2 includes instruments for which the valuations are based on quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable data for substantially the full term of the assets or liabilities. | |||||||
Level 3 includes valuations based on inputs that are unobservable and significant to the overall fair value measurement. | |||||||
Share-based Compensation [Policy Text Block] | ' | ||||||
(q) Stock-based Compensation | |||||||
The Company accounts for stock-based payment awards in accordance with the provisions of FASB ASC 718, “Compensation—Stock Compensation”, which requires it to recognize compensation expense for all stock-based payment awards made to employees and directors including stock options, restricted stock units and employee stock purchases (“employee stock purchases”) related to the Employee Stock Purchase Plan (as amended, the “ESPP”). The Company issues new shares upon stock option exercises, upon vesting of the restricted stock units and under the Company's ESPP. | |||||||
Stock-based compensation expense recognized is based on the value of the portion of stock-based payment awards that is ultimately expected to vest and has been reduced for estimated forfeitures. The Company values stock-based payment awards, except restricted stock units at grant date using the Black-Scholes option-pricing model (“Black-Scholes model”). The determination of fair value of stock-based payment awards on the date of grant using an option-pricing model is affected by its stock price as well as assumptions regarding a number of highly complex and subjective variables. These variables include, but are not limited to its expected stock price volatility over the term of the awards and actual and projected stock option exercise behaviors. | |||||||
The fair value of restricted stock units are based on the market price of the Company's stock on the date of grant and are recorded as compensation expense ratably over the applicable service period, which ranges from one to four years. Unvested restricted stock units are forfeited in the event of termination of employment with the Company. | |||||||
Stock-based compensation expense recognized under FASB ASC 718 for the years ended December 31, 2013, 2012 and 2011 consisted of stock-based compensation expense related to stock options, the employee stock purchase plan, and the restricted stock units and was recorded as a component of cost of product revenues, sales and marketing expenses, general and administrative expenses, research and development expenses and discontinued operations. | |||||||
Summary_of_Significant_Account1
Summary of Significant Accounting Policies (Tables) | 12 Months Ended | ||||||
Dec. 31, 2013 | |||||||
Summary of Significant Accounting Policies [Abstract] | ' | ||||||
Property Plant And Equipment Useful Life [Table Text Block] | ' | ||||||
Buildings | 40 | years | |||||
Machinery and equipment | 3 | - | 10 | years | |||
Computer equipment and software | 3 | - | 7 | years | |||
Furniture and fixtures | 5 | - | 10 | years | |||
Automobiles | 3 | - | 6 | years |
Inventories_Tables
Inventories (Tables) | 12 Months Ended | ||||||
Dec. 31, 2013 | |||||||
Inventories Disclosure [Abstract] | ' | ||||||
Schedule of Inventory [Table Text Block] | ' | ||||||
December 31, | |||||||
2013 | 2012 | ||||||
(in thousands) | |||||||
Finished goods | $ | 7,039 | $ | 8,023 | |||
Work in process | 752 | 731 | |||||
Raw materials | 7,986 | 9,008 | |||||
Total | $ | 15,777 | $ | 17,762 |
Property_Plant_and_Equipment_T
Property, Plant and Equipment (Tables) | 12 Months Ended | ||||
Dec. 31, 2013 | |||||
Property, Plant and Equipment Disclosure [Abstract] | ' | ||||
Schedule Of Property Plant And Equipment [Table Text Block] | ' | ||||
December 31, | |||||
2013 | 2012 | ||||
(in thousands) | |||||
Land, buildings and leasehold improvements | $ | 3,082 | $ | 2,790 | |
Machinery and equipment | 9,471 | 8,760 | |||
Computer equipment and software | 4,927 | 4,917 | |||
Furniture and fixtures | 1,281 | 1,201 | |||
Automobiles | 59 | 194 | |||
18,820 | 17,862 | ||||
Less: accumulated depreciation | -14,445 | -13,311 | |||
Property, plant and equipment, net | $ | 4,375 | $ | 4,551 |
Acquisitions_Tables
Acquisitions (Tables) | 12 Months Ended | |||
Dec. 31, 2013 | ||||
Acquisition Disclosure [Abstract] | ' | |||
Schedule of Business Acquisitions [Table Text Block] | ' | |||
(in thousands) | ||||
Tangible assets | $ | 1,500 | ||
Liabilities assumed | -1,454 | |||
Net assets assumed | 46 | |||
Goodwill and intangible assets: | ||||
Goodwill | 1,308 | |||
Customer relationships | 474 | |||
Trade name | 180 | |||
Total goodwill and intangible assets | 1,962 | |||
Acquisition purchase price | $ | 2,008 | ||
(in thousands) | ||||
Tangible assets | $ | 30 | ||
Liabilities assumed | - | |||
Net assets assumed | 30 | |||
Goodwill and intangible assets: | ||||
Goodwill | 145 | |||
Customer relationships | 50 | |||
Technology | 200 | |||
Trade name | 95 | |||
Total goodwill and intangible assets | 490 | |||
Acquisition purchase price | $ | 520 | ||
Schedule of Business Acquisitions , Contingent Consideration [Table Text Block] | ' | |||
(in thousands) | ||||
Cash | $ | 500 | ||
Contingent consideration | 20 | |||
Total | $ | 520 |
Discontinued_Operations_Tables
Discontinued Operations (Tables) | 12 Months Ended | ||||||
Dec. 31, 2013 | |||||||
Discontinued Operations [Abstract] | ' | ||||||
Schedule Of Disposal Groups Including Discontinued Operations Income Statement Balance Sheet And Additional Disclosures [Table Text Block] | ' | ||||||
Year ended December 31, | |||||||
2013 | 2012 | 2011 | |||||
(in thousands) | |||||||
Gain on disposal of discontinued operations, UBI | $ | 440 | $ | 1,344 | $ | - | |
(Loss) from discontinued operations, HART | -4,861 | -4,664 | -2,326 | ||||
Income tax (benefit) | -1,868 | -1,196 | -849 | ||||
(Loss) from discontinued operations, net of tax | $ | -2,553 | $ | -2,124 | $ | -1,477 |
Goodwill_and_Other_Intangible_1
Goodwill and Other Intangible Assets (Tables) | 12 Months Ended | ||||||||||||||
Dec. 31, 2013 | |||||||||||||||
Goodwill And Other Intangible Assets Disclosure [Abstract] | ' | ||||||||||||||
Schedule of Intangible Assets and Goodwill [Table Text Block] | ' | ||||||||||||||
Weighted | |||||||||||||||
December 31, | Average | ||||||||||||||
2013 | 2012 | Life | (a) | ||||||||||||
(in thousands) | |||||||||||||||
Amortizable intangible assets: | Gross | Accumulated Amortization | Gross | Accumulated Amortization | |||||||||||
Existing technology | $ | 13,464 | $ | -11,091 | $ | 13,258 | $ | -10,207 | 4.3 | Years | |||||
Tradename | 6,178 | -2,185 | 6,167 | -1,756 | 11 | Years | |||||||||
Distribution agreement/customer relationships | 21,827 | -9,447 | 21,699 | -7,938 | 10.6 | Years | |||||||||
Patents | 271 | -8 | 9 | -7 | 5 | Years | |||||||||
Total amortizable intangible assets | 41,740 | $ | -22,731 | 41,133 | $ | -19,908 | |||||||||
Indefinite-lived intangible assets: | |||||||||||||||
Goodwill | 36,605 | 36,200 | |||||||||||||
Other indefinite-lived intangible assets | 1,289 | 1,276 | |||||||||||||
Total goodwill and other indefinite-lived intangible assets | 37,894 | 37,476 | |||||||||||||
Total intangible assets | $ | 79,634 | $ | 78,609 | |||||||||||
(a) Weighted average life is as of December 31, 2013. | |||||||||||||||
Goodwill Rollforward [Table Text Block] | ' | ||||||||||||||
(in thousands) | |||||||||||||||
Balance at December 31, 2011 | $ | 34,209 | |||||||||||||
Goodwill arising from business combination | 1,453 | ||||||||||||||
Effect of change in foreign currencies | 538 | ||||||||||||||
Balance at December 31, 2012 | $ | 36,200 | |||||||||||||
Effect of change in foreign currencies | 405 | ||||||||||||||
Balance at December 31, 2013 | $ | 36,605 |
Restructuring_and_Other_Exit_C1
Restructuring and Other Exit Costs (Tables) | 12 Months Ended | |||||||||||
Dec. 31, 2013 | ||||||||||||
Restructuring and Related Activities [Abstract] | ' | |||||||||||
Restructuring Plan Table [Table Text Block] | ' | |||||||||||
Severance | ||||||||||||
and Related Costs | ||||||||||||
(in thousands) | ||||||||||||
Restructuring charges | $ | 2,100 | ||||||||||
Cash payments | -666 | |||||||||||
Restructuring balance at December 31, 2013 | $ | 1,434 | ||||||||||
Severance | ||||||||||||
and Related Costs | ||||||||||||
(in thousands) | ||||||||||||
Restructuring charges | $ | 96 | ||||||||||
Cash payments | -96 | |||||||||||
Restructuring balance at December 31, 2013 | $ | - | ||||||||||
Severance | ||||||||||||
and Related Costs | Other | Total | ||||||||||
(in thousands) | ||||||||||||
Restructuring charges | $ | 312 | $ | 11 | $ | 323 | ||||||
Cash payments | -179 | - | -179 | |||||||||
Restructuring balance at December 31, 2012 | $ | 133 | $ | 11 | $ | 144 | ||||||
Cash payments | $ | -84 | $ | -11 | $ | -95 | ||||||
Non-cash reversal of restructuring charges | -46 | - | -46 | |||||||||
Restructuring balance at December 31, 2013 | $ | 3 | $ | - | $ | 3 | ||||||
Severance and | Fixed Asset | |||||||||||
Related Costs | Write offs | Other | Total | |||||||||
(in thousands) | ||||||||||||
Restructuring charges | $ | 78 | $ | 307 | $ | 110 | $ | 495 | ||||
Cash payments | -33 | - | -180 | -213 | ||||||||
Non-cash charges | - | -307 | 70 | -237 | ||||||||
Restructuring balance at December 31, 2011 | 45 | - | - | 45 | ||||||||
Cash payments | -45 | - | - | -45 | ||||||||
Restructuring balance at December 31, 2012 | $ | - | $ | - | $ | - | $ | - | ||||
Years ended December 31, | ||||||||||||
2013 | 2012 | 2011 | ||||||||||
(in thousands) | ||||||||||||
Restructuring charges | $ | 2,150 | $ | 310 | $ | 467 |
Long_Term_Debt_Tables
Long Term Debt (Tables) | 12 Months Ended | ||||
Dec. 31, 2013 | |||||
Long Term Debt Disclosure [Abstract] | ' | ||||
Schedule of Maturities of Long-term Debt [Table Text Block] | ' | ||||
The aggregate amounts of debt maturing during the next five years are as follows: | |||||
(in thousands) | |||||
2014 | $ | 5,000 | |||
2015 | 5,000 | ||||
2016 | 7,500 | ||||
2017 | 5,000 | ||||
2018 | 2,250 | ||||
Total | $ | 24,750 | |||
Schedule of Debt [Table Text Block] | ' | ||||
December 31, | |||||
2013 | 2012 | ||||
(in thousands) | |||||
Long-term debt: | |||||
Term loan | $ | 12,750 | $ | - | |
DDTL | 9,500 | - | |||
Revolving line | 2,500 | 12,950 | |||
Total debt | 24,750 | 12,950 | |||
Less: current installments | -5,000 | - | |||
Long-term debt | $ | 19,750 | $ | 12,950 |
Derivative_Tables
Derivative (Tables) | 12 Months Ended | ||||||||
Dec. 31, 2013 | |||||||||
Derivative Instruments and Hedging Activities Disclosure [Abstract] | ' | ||||||||
Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block] | ' | ||||||||
31-Dec-13 | 31-Dec-13 | ||||||||
Notional | Fair | ||||||||
Amount | Value (a) | ||||||||
Derivatives designated as hedging instruments under ASC 815 | Balance sheet classification | (in thousands) | |||||||
Interest rate swap | Other liabilities-non current | $ | 17,500 | $ | -49 | ||||
(a) See note 12 for the fair value measurements related to these financial instruments. | |||||||||
Schedule of effect of derivative instruments on the consolidated statements of operations [Table Text Block] | ' | ||||||||
For the Year ended December 31, 2013 | |||||||||
(In thousands) | Amount of gain or (loss) recognized in OCI on derivative (effective portion) | Location of gain or (loss) reclassified from AOCI into income (effective portion) | Amount of gain or (loss) reclassified from AOCI into income (effective portion) | ||||||
Interest rate swaps | $ | -49 | Interest expense | $ | -67 |
Fair_Value_Measurements_Tables
Fair Value Measurements (Tables) | 12 Months Ended | |||||||||
Dec. 31, 2013 | ||||||||||
Fair Value Disclosures [Abstract] | ' | |||||||||
Schedule Of Fair Value Assets And Liabilities Measured On Recurring Basis [Table Text Block] | ' | |||||||||
Fair Value as of December 31, 2013 | ||||||||||
(In thousands) | Level 1 | Level 2 | Level 3 | Total | ||||||
Liabilities: | ||||||||||
Interest rate swap agreements | $ | - | $ | 49 | $ | - | $ | 49 |
Leases_Tables
Leases (Tables) | 12 Months Ended | ||
Dec. 31, 2013 | |||
Leases Disclosure [Abstract] | ' | ||
Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block] | ' | ||
Operating | |||
Leases | |||
(in thousands) | |||
2014 | $ | 1,228 | |
2015 | 1,073 | ||
2016 | 763 | ||
2017 | 422 | ||
2018 | 160 | ||
Thereafter | 70 | ||
Net minimum lease payments | $ | 3,716 |
Accrued_Expenses_Tables
Accrued Expenses (Tables) | 12 Months Ended | ||||
Dec. 31, 2013 | |||||
Accrued Liabilities Current [Abstract] | ' | ||||
Schedule of Accrued Liabilities [Table Text Block] | ' | ||||
December 31, | |||||
2013 | 2012 | ||||
(in thousands) | |||||
Accrued compensation and payroll | $ | 1,349 | $ | 1,389 | |
Accrued legal and professional fees | 927 | 869 | |||
Accrued severance | 1,434 | 133 | |||
Warranty costs | 305 | 222 | |||
Other | 1,063 | 892 | |||
Total | $ | 5,078 | $ | 3,505 |
Income_Taxes_Tables
Income Taxes (Tables) | 12 Months Ended | ||||||
Dec. 31, 2013 | |||||||
Income Tax [Abstract] | ' | ||||||
Schedule of Components of Income Tax Expense (Benefit) [Table Text Block] | ' | ||||||
Year ended December 31, | |||||||
2013 | 2012 | 2011 | |||||
(in thousands) | |||||||
Current income tax expense: | |||||||
Federal and state | $ | 47 | $ | 70 | $ | 111 | |
Foreign | 413 | 1,705 | 1,156 | ||||
460 | 1,775 | 1,267 | |||||
Deferred income tax (benefit) expense: | |||||||
Federal and state | -594 | 931 | 478 | ||||
Foreign | -154 | -308 | -166 | ||||
-748 | 623 | 312 | |||||
Total income tax (benefit) expense | $ | -288 | $ | 2,398 | $ | 1,579 | |
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block] | ' | ||||||
Years ended December 31, | |||||||
2013 | 2012 | 2011 | |||||
(in thousands) | |||||||
Computed "expected" income tax expense | $ | 147 | $ | 2,343 | $ | 2,335 | |
Increase (decrease) in income taxes resulting from: | |||||||
Permanent differences, net | 482 | -25 | 109 | ||||
Foreign tax rate differential | -64 | -435 | -333 | ||||
State income taxes, net of federal income tax benefit | 31 | 135 | 113 | ||||
Non-deductible stock compensation expense | 1 | 254 | 345 | ||||
Impact of prior year pension deductions | -294 | - | - | ||||
Tax credits | -615 | -127 | -558 | ||||
Release of uncertain tax position liability due to | |||||||
expiration of statute of limitations | - | - | -528 | ||||
Change in valuation allowance allocated to income | |||||||
tax expense (benefit) | 31 | 281 | 63 | ||||
Other | -7 | -28 | 33 | ||||
Total income tax (benefit) expense | $ | -288 | $ | 2,398 | $ | 1,579 | |
Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block] | ' | ||||||
Years ended December 31, | |||||||
2013 | 2012 | 2011 | |||||
(in thousands) | |||||||
Domestic | $ | -2,549 | $ | 681 | $ | 339 | |
Foreign | 2,984 | 6,211 | 6,529 | ||||
Total | $ | 435 | $ | 6,892 | $ | 6,868 | |
Schedule of Deferred Tax Assets and Liabilities [Table Text Block] | ' | ||||||
2013 | 2012 | ||||||
(in thousands) | |||||||
Deferred tax assets: | |||||||
Accounts receivable | $ | 65 | $ | 62 | |||
Inventory | 1,405 | 1,251 | |||||
Operating loss and credit carryforwards | 12,978 | 8,829 | |||||
Accrued expenses | 409 | 107 | |||||
Pension liabilities | 985 | 1,366 | |||||
Contingent consideration | 2,593 | 2,413 | |||||
Other accrued liabilities | 1,867 | 3,761 | |||||
Total gross deferred assets | 20,302 | 17,789 | |||||
Less: valuation allowance | -1,249 | -1,307 | |||||
Deferred tax assets | $ | 19,053 | $ | 16,482 | |||
Deferred tax liabilities: | |||||||
Intangible assets | $ | 4,242 | $ | 4,057 | |||
Property, plant and equipment | 70 | 115 | |||||
Other accrued liabilities | 238 | 264 | |||||
Total deferred tax liabilities | 4,550 | 4,436 | |||||
Net deferred tax assets | $ | 14,503 | $ | 12,046 | |||
Summary of Income Tax Contingencies [Table Text Block] | ' | ||||||
(in thousands) | |||||||
Balance at December 31, 2011 | $ | 191 | |||||
Additions based on tax positions of prior years | - | ||||||
Balance at December 31, 2012 | 191 | ||||||
Additions based on tax positions of prior years | - | ||||||
Balance at December 31, 2013 | $ | 191 |
Employee_Benefit_Plans_Tables
Employee Benefit Plans (Tables) | 12 Months Ended | ||||||||
Dec. 31, 2013 | |||||||||
Employee Benefit Plans Disclosure [Abstract] | ' | ||||||||
Schedule Of Costs Of Retirement Plans [Table Text Block] | ' | ||||||||
Year ended December 31, | |||||||||
2013 | 2012 | 2011 | |||||||
(in thousands) | |||||||||
Components of net periodic benefit cost: | |||||||||
Service cost | $ | 288 | $ | 314 | $ | 298 | |||
Interest cost | 797 | 819 | 836 | ||||||
Expected return on plan assets | -524 | -570 | -608 | ||||||
Net amortization loss | 305 | 248 | 159 | ||||||
Curtailment gain | -197 | - | - | ||||||
Net periodic benefit cost | $ | 669 | $ | 811 | $ | 685 | |||
Schedule of Changes in Projected Benefit Obligations [Table Text Block] | ' | ||||||||
December 31, | |||||||||
2013 | 2012 | ||||||||
(in thousands) | |||||||||
Change in benefit obligation: | |||||||||
Balance at beginning of year | $ | 19,643 | $ | 16,866 | |||||
Service cost | 272 | 303 | |||||||
Interest cost | 797 | 819 | |||||||
Participants' contributions | 56 | 60 | |||||||
Actuarial (gain) loss | -329 | 1,547 | |||||||
Benefits paid | -431 | -663 | |||||||
Currency translation adjustment | 395 | 711 | |||||||
Balance at end of year | $ | 20,403 | $ | 19,643 | |||||
Schedule of Changes in Fair Value of Plan Assets [Table Text Block] | ' | ||||||||
December 31, | |||||||||
2013 | 2012 | ||||||||
(in thousands) | |||||||||
Change in fair value of plan assets: | |||||||||
Balance at beginning of year | $ | 13,704 | $ | 12,006 | |||||
Actual return on plan assets | 1,125 | 944 | |||||||
Participants' contributions | 56 | 60 | |||||||
Employer contributions | 801 | 873 | |||||||
Benefits paid | -431 | -663 | |||||||
Currency translation adjustment | 285 | 484 | |||||||
Balance at end of year | $ | 15,540 | $ | 13,704 | |||||
Schedule of Net Funded Status [Table Text Block] | ' | ||||||||
December 31, | |||||||||
2013 | 2012 | ||||||||
(in thousands) | |||||||||
Change in benefit obligation: | |||||||||
Funded status | $ | -4,863 | $ | -5,939 | |||||
Unrecognized net loss | N/A | N/A | |||||||
Net amount recognized | $ | -4,863 | $ | -5,939 | |||||
Schedule of Amounts Recognized in Balance Sheet [Table Text Block] | ' | ||||||||
December 31, | |||||||||
2013 | 2012 | ||||||||
(in thousands) | |||||||||
Deferred income tax assets | $ | 985 | $ | 1,366 | |||||
Other long term liabilities | -4,863 | -5,939 | |||||||
Net amount recognized | $ | -3,878 | $ | -4,573 | |||||
Schedule of Amounts Recognized in Other Comprehensive Income (Loss) [Table Text Block] | ' | ||||||||
December 31, | |||||||||
2013 | 2012 | ||||||||
(in thousands) | |||||||||
Underfunded status of pension plans | $ | -3,878 | $ | -4,573 | |||||
Net amount recognized | $ | -3,878 | $ | -4,573 | |||||
Schedule of Assumptions Used [Table Text Block] | ' | ||||||||
Year ended December 31, | |||||||||
2013 | 2012 | 2011 | |||||||
Discount rate | 4.43% | 4.09% | 4.70% | ||||||
Expected return on assets | 3.79% | 4.02% | 4.40% | ||||||
Rate of compensation increase | 2.99% | 3.51% | 3.50% | ||||||
Schedule of Allocation of Plan Assets [Table Text Block] | ' | ||||||||
December 31, | |||||||||
2013 | 2012 | ||||||||
(in thousands) | |||||||||
Asset category: | |||||||||
Equity securities | $ | 7,404 | 48% | $ | 6,918 | 50% | |||
Debt securities | 6,061 | 39% | 5,049 | 37% | |||||
Cash and cash equivalents | 1,488 | 9% | 969 | 7% | |||||
Other | 587 | 4% | 768 | 6% | |||||
Total | $ | 15,540 | 100% | $ | 13,704 | 100% | |||
December 31, | |||||||||
2013 | 2012 | ||||||||
(in thousands) | |||||||||
Quoted Prices in Active Markets for Identical Assets (Level 1) | $ | 1,488 | $ | 969 | |||||
Significant Other Observable Inputs (Level 2) | 13,465 | 11,967 | |||||||
Significant Other Unobservable Inputs (Level 3) | 587 | 768 | |||||||
Total | $ | 15,540 | $ | 13,704 | |||||
Schedule of Effect of Significant Unobservable Inputs, Changes in Plan Assets [Table Text Block] | ' | ||||||||
December 31, | |||||||||
2013 | 2012 | ||||||||
(in thousands) | |||||||||
Balance at beginning of year | $ | 768 | $ | 1,042 | |||||
Purchases during the year | - | - | |||||||
Unrealized loss | -181 | -274 | |||||||
Balance at end of year | $ | 587 | $ | 768 |
Accumulated_Other_Comprehensiv1
Accumulated Other Comprehensive Income (Tables) | 12 Months Ended | |||||||||||||||
Dec. 31, 2013 | ||||||||||||||||
Accumulated Other Comprehensive Income [Abstract] | ' | |||||||||||||||
Accumulated Other Comprehensive Income [Table Text Block] | ' | |||||||||||||||
Foreign currency | Derivatives | |||||||||||||||
translation | qualifying as | Defined benefit | ||||||||||||||
(in thousands) | adjustments | hedges | pension plans | Total | ||||||||||||
Balance at December 31, 2012 | $ | -290 | $ | - | $ | -4,573 | $ | -4,863 | ||||||||
Other comprehensive income (loss) before reclassifications | 1,573 | -116 | 452 | 1,909 | ||||||||||||
Amounts reclassified from AOCI | - | 67 | 243 | 310 | ||||||||||||
Net other comprehensive income (loss) | 1,573 | -49 | 695 | 2,219 | ||||||||||||
Balance at December 31, 2013 | $ | 1,283 | $ | -49 | $ | -3,878 | $ | -2,644 | ||||||||
Reclassification out of Accumulated Other Comprehensive Income [Table Text Block] | ' | |||||||||||||||
Affected line item in the | Year Ended December 31, | |||||||||||||||
(in thousands) | Statements of Operations | 2013 | 2012 | 2011 | ||||||||||||
Amounts Reclassified From AOCI | ||||||||||||||||
Derivatives qualifying as hedges | ||||||||||||||||
Realized loss on derivatives qualifying as hedges | Interest expense | $ | 67 | $ | - | $ | - | |||||||||
Income tax | Income tax (benefit) expense | - | - | - | ||||||||||||
67 | - | - | ||||||||||||||
Defined benefit pension plans | ||||||||||||||||
Amortization of net losses included in net periodic pension costs | General and administrative expenses | 305 | 248 | 159 | ||||||||||||
Income tax | Income tax (benefit) expense | -62 | -57 | -40 | ||||||||||||
243 | 191 | 119 | ||||||||||||||
Total reclassifications | $ | 310 | $ | 191 | $ | 119 |
Capital_Stock_Tables
Capital Stock (Tables) | 12 Months Ended | |||||||||||||||||
Dec. 31, 2013 | ||||||||||||||||||
Capital Stock Disclosure [Abstract] | ' | |||||||||||||||||
Schedule Of Stock Options And Restricted Stock Units Activity Rollforward [Table Text Block] | ' | |||||||||||||||||
Stock Options | Restricted Stock Units | |||||||||||||||||
Weighted | ||||||||||||||||||
Stock | Average | Restricted | ||||||||||||||||
Options | Exercise | Stock Units | Grant Date | |||||||||||||||
Outstanding | Price | Outstanding | Fair Value | |||||||||||||||
Balance at December 31, 2010 | 7,826,200 | $ | 4.38 | 467,600 | $ | 3.61 | ||||||||||||
Granted | 1,030,500 | 5.64 | 188,750 | 5.64 | ||||||||||||||
Exercised | -105,625 | 3.79 | - | - | ||||||||||||||
Vested (RSU's) | - | - | -116,900 | - | ||||||||||||||
Cancelled / forfeited | -231,500 | 5.27 | - | - | ||||||||||||||
Balance at December 31, 2011 | 8,519,575 | 4.52 | 539,450 | 4.32 | ||||||||||||||
Granted | 1,220,934 | 3.6 | 349,295 | 3.57 | ||||||||||||||
Exercised | -648,000 | 3.94 | - | - | ||||||||||||||
Vested (RSU's) | - | - | -164,090 | - | ||||||||||||||
Cancelled / forfeited | -1,014,000 | 6.36 | -47,462 | 4.21 | ||||||||||||||
Balance at December 31, 2012 | 8,078,509 | 4.25 | 677,193 | 3.97 | ||||||||||||||
Granted | 3,349,052 | 4.44 | 259,931 | 4.62 | ||||||||||||||
Exercised | -3,410,483 | 3.2 | - | - | ||||||||||||||
Vested (RSU's) | - | - | -281,650 | - | ||||||||||||||
Cancelled / forfeited | -1,326,233 | 5.26 | -191,501 | 4.07 | ||||||||||||||
Balance at December 31, 2013 | 6,690,845 | $ | 3.42 | 463,973 | $ | 4.32 | ||||||||||||
Table Of Assumptions [Table Text Block] | ' | |||||||||||||||||
Years Ended December 31, | ||||||||||||||||||
2013 | 2012 | 2011 | ||||||||||||||||
Volatility | 57.18 | % | 55.09 | % | 54.24 | % | ||||||||||||
Risk-free interest rate | 1.42 | % | 0.8 | % | 2.01 | % | ||||||||||||
Expected holding period | 5.67 | years | 5.98 | years | 5.94 | years | ||||||||||||
Dividend Yield | 0 | % | 0 | % | 0 | % | ||||||||||||
Stock Based Compensation Expense Activity By Function [Table Text Block] | ' | |||||||||||||||||
Year Ended December 31, | ||||||||||||||||||
2013 | 2012 | 2011 | ||||||||||||||||
(in thousands) | ||||||||||||||||||
Cost of product revenues | $ | 131 | $ | 87 | $ | 76 | ||||||||||||
Sales and marketing | 223 | 154 | 152 | |||||||||||||||
General and administrative | 2,200 | 2,990 | 2,570 | |||||||||||||||
Research and development | 45 | 25 | 21 | |||||||||||||||
Discontinued operations | 71 | 65 | 44 | |||||||||||||||
Total stock-based compensation | $ | 2,670 | $ | 3,321 | $ | 2,863 | ||||||||||||
Basic and Diluted Shares [Table Text Block] | ' | |||||||||||||||||
Year ended December 31, | ||||||||||||||||||
2013 | 2012 | 2011 | ||||||||||||||||
Basic | 30,384,010 | 28,799,377 | 28,451,386 | |||||||||||||||
Effect of assumed conversion of employee and director stock options and restricted stock units | 1,529,789 | 992,730 | 1,367,348 | |||||||||||||||
Diluted | 31,913,799 | 29,792,107 | 29,818,734 | |||||||||||||||
Schedule of Summary of Outstanding and Exercisable Options [Table Text Block] | ' | |||||||||||||||||
Options Outstanding | Options Exercisable | |||||||||||||||||
Weighted | Weighted | |||||||||||||||||
Average | Weighted | Average | Weighted | |||||||||||||||
Range of | Shares | Remaining | Average | Aggregate | Shares | Remaining | Average | Aggregate | ||||||||||
Exercise | Outstanding at | Contractual Life | Exercise | Intrinsic | Exercisable at | Contractual Life | Exercise | Intrinsic | ||||||||||
Price | Dec. 31, 2013 | in Years | Price | Value | Dec. 31, 2013 | in Years | Price | Value | ||||||||||
$ | 1.43-2.15 | 306,358 | 4.03 | $ | 1.86 | $ | 870 | 306,358 | 4.03 | $ | 1.86 | $ | 870 | |||||
2.28-2.28 | 981,082 | 5.37 | 2.28 | 2,372 | 981,082 | 5.37 | 2.28 | 2,372 | ||||||||||
2.45-2.45 | 13,172 | 1.43 | 2.45 | 30 | 13,172 | 1.43 | 2.45 | 30 | ||||||||||
2.56-2.56 | 994,618 | 7.82 | 2.56 | 2,128 | 198,402 | 7.82 | 2.56 | 425 | ||||||||||
2.59-3.54 | 836,338 | 4.66 | 3.03 | 1,397 | 723,635 | 4.66 | 3.1 | 1,158 | ||||||||||
3.64-3.64 | 935,371 | 8.89 | 3.64 | 991 | - | 0 | - | - | ||||||||||
3.68-3.99 | 486,706 | 3.3 | 3.87 | 404 | 486,706 | 3.3 | 3.87 | 404 | ||||||||||
4.04-4.04 | 865,617 | 7.2 | 4.04 | 571 | 444,865 | 7.2 | 4.04 | 294 | ||||||||||
4.21-4.31 | 807,500 | 9.88 | 4.31 | 315 | - | 0 | - | - | ||||||||||
5.73-6.57 | 464,083 | 0.22 | 5.75 | - | 464,083 | 0.22 | 5.75 | - | ||||||||||
$ | 1.43-6.57 | 6,690,845 | 6.34 | $ | 3.42 | $ | 9,078 | 3,618,303 | 4.56 | $ | 3.3 | $ | 5,553 |
Segment_and_Related_Informatio
Segment and Related Information (Tables) | 12 Months Ended | ||||||
Dec. 31, 2013 | |||||||
Segment and Related Information Disclosure [Abstract] | ' | ||||||
Schedule of Revenue from External Customers Attributed to Foreign Countries by Geographic Area [Table Text Block] | ' | ||||||
Revenues originating from the following geographic areas consist of: | |||||||
Year ended December 31, | |||||||
2013 | 2012 | 2011 | |||||
(in thousands) | |||||||
United States | $ | 63,810 | $ | 65,190 | $ | 64,185 | |
United Kingdom | 23,123 | 27,137 | 26,160 | ||||
Rest of the world | 18,238 | 18,844 | 18,519 | ||||
Total revenues | $ | 105,171 | $ | 111,171 | $ | 108,864 | |
Schedule of Disclosure on Geographic Areas, Long-Lived Assets in Individual Foreign Countries by Country [Table Text Block] | ' | ||||||
Long-lived assets by geographic area consist of the following: | |||||||
December 31, | |||||||
2013 | 2012 | ||||||
(in thousands) | |||||||
United States | $ | 14,128 | $ | 16,744 | |||
United Kingdom | 2,343 | 2,441 | |||||
Rest of the world | 6,913 | 6,591 | |||||
Total long-lived assets (1) | $ | 23,384 | $ | 25,776 | |||
(1) Total long-lived assets includes property, plant and equipment, net and amortizable intangible assets, net. | |||||||
Net Assets By Geographic Area [Table Text Block] | ' | ||||||
Net assets by geographic area consist of the following: | |||||||
December 31, | |||||||
2013 | 2012 | ||||||
(in thousands) | |||||||
United States | $ | 37,497 | $ | 51,218 | |||
United Kingdom | 32,214 | 29,741 | |||||
Rest of the world | 24,774 | 23,254 | |||||
Total net assets | $ | 94,485 | $ | 104,213 |
Allowance_for_Doubtful_Debts_T
Allowance for Doubtful Debts (Tables) | 12 Months Ended | ||||||||
Dec. 31, 2013 | |||||||||
Allowance For Doubtful Debts Disclosure [Abstract] | ' | ||||||||
Schedule of Credit Losses for Financing Receivables, Current [Table Text Block] | ' | ||||||||
Charged (credited) to | |||||||||
Beginning | Bad Debt | Charged to | Ending | ||||||
Balance | Expense | Allowance (1) | Balance | ||||||
(in thousands) | |||||||||
Year ended December 31, 2011 | $ | 273 | 67 | -38 | $ | 302 | |||
Year ended December 31, 2012 | 302 | -31 | -77 | 194 | |||||
Year ended December 31, 2013 | $ | 194 | 172 | -8 | $ | 358 | |||
(1) Consists of accounts written off, net of recoveries. |
Warranties_Tables
Warranties (Tables) | 12 Months Ended | |||||||||||
Dec. 31, 2013 | ||||||||||||
Warranties Disclosure [Abstract] | ' | |||||||||||
Warranty Rollforward Disclosure [Table Text Block] | ' | |||||||||||
Beginning | Ending | |||||||||||
Balance | Payments | Additions | Balance | |||||||||
(in thousands) | ||||||||||||
Year ended December 31, 2011 | $ | 158 | -58 | 44 | $ | 144 | ||||||
Year ended December 31, 2012 | 144 | -136 | 214 | 222 | ||||||||
Year ended December 31, 2013 | $ | 222 | -179 | 262 | $ | 305 |
Quarterly_Financial_Informatio1
Quarterly Financial Information (unaudited) (Tables) | 12 Months Ended | |||||||||||||||||||||||||||||||
Dec. 31, 2013 | Dec. 31, 2012 | |||||||||||||||||||||||||||||||
Quarterly Financial Data [Abstract] | ' | ' | ||||||||||||||||||||||||||||||
Schedule of Quarterly Financial Information [Table Text Block] | ' | ' | ||||||||||||||||||||||||||||||
First | Second | Third | Fourth | Fiscal | First | Second | Third | Fourth | Fiscal | |||||||||||||||||||||||
2013 | Quarter | Quarter | Quarter | Quarter | Year | 2012 | Quarter | Quarter | Quarter | Quarter | Year | |||||||||||||||||||||
(in thousands, except per share data) | (in thousands, except per share data) | |||||||||||||||||||||||||||||||
Revenues | $ | 26,086 | $ | 26,094 | $ | 25,137 | $ | 27,854 | $ | 105,171 | Revenues | $ | 28,322 | $ | 28,496 | $ | 26,104 | $ | 28,249 | $ | 111,171 | |||||||||||
Cost of product revenues | 13,826 | 14,005 | 13,838 | 15,806 | 57,475 | Cost of product revenues | 14,939 | 14,901 | 14,135 | 14,856 | 58,831 | |||||||||||||||||||||
Gross profit | 12,260 | 12,089 | 11,299 | 12,048 | 47,696 | Gross profit | 13,383 | 13,595 | 11,969 | 13,393 | 52,340 | |||||||||||||||||||||
Total operating expenses | 10,934 | 11,343 | 10,885 | 12,997 | 46,159 | Total operating expenses | 11,321 | 11,121 | 10,813 | 11,255 | 44,510 | |||||||||||||||||||||
Operating income (loss) | 1,326 | 746 | 414 | -949 | 1,537 | Operating income | 2,062 | 2,474 | 1,156 | 2,138 | 7,830 | |||||||||||||||||||||
Other (expense) income, net | -95 | -330 | -358 | -319 | -1,102 | Other (expense) income, net | -385 | -226 | -178 | -149 | -938 | |||||||||||||||||||||
Income (loss) from continuing operations before income taxes | 1,231 | 416 | 56 | -1,268 | 435 | Income from continuing operations before income taxes | 1,677 | 2,248 | 978 | 1,989 | 6,892 | |||||||||||||||||||||
Income tax expense (benefit) | 299 | 321 | 105 | -1,013 | -288 | Income tax expense | 605 | 698 | 278 | 817 | 2,398 | |||||||||||||||||||||
Income (loss) from continuing operations | 932 | 95 | -49 | -255 | 723 | Income from continuing operations | 1,072 | 1,550 | 700 | 1,172 | 4,494 | |||||||||||||||||||||
Loss from discontinued operations, net of tax | -836 | -281 | -935 | -501 | -2,553 | (Loss) income from discontinued operations, net of tax | -543 | -776 | -833 | 28 | -2,124 | |||||||||||||||||||||
Net income (loss) | $ | 96 | $ | -186 | $ | -984 | $ | -756 | $ | -1,830 | Net income (loss) | $ | 529 | $ | 774 | $ | -133 | $ | 1,200 | $ | 2,370 | |||||||||||
Earnings per share: | ||||||||||||||||||||||||||||||||
Earnings (loss) per share: | ||||||||||||||||||||||||||||||||
Basic earnings per common share from continuing operations | $ | 0.04 | $ | 0.05 | $ | 0.02 | $ | 0.04 | $ | 0.16 | ||||||||||||||||||||||
Basic earnings (loss) per common share from continuing operations | $ | 0.03 | $ | 0 | $ | 0 | $ | -0.01 | $ | 0.02 | Discontinued operations | -0.02 | -0.03 | -0.03 | 0 | -0.07 | ||||||||||||||||
Discontinued operations | -0.03 | -0.01 | -0.03 | -0.01 | -0.08 | Basic earnings (loss) per common share | $ | 0.02 | $ | 0.02 | $ | -0.01 | $ | 0.04 | $ | 0.09 | ||||||||||||||||
Basic earnings (loss) per common share | $ | 0 | $ | -0.01 | $ | -0.03 | $ | -0.02 | $ | -0.06 | ||||||||||||||||||||||
Diluted earnings per common share from continuing operations | $ | 0.04 | $ | 0.05 | $ | 0.02 | $ | 0.04 | $ | 0.15 | ||||||||||||||||||||||
Diluted earnings (loss) per common share from continuing operations | $ | 0.03 | $ | 0 | $ | 0 | $ | -0.01 | $ | 0.02 | Discontinued operations | -0.02 | -0.03 | -0.03 | 0 | -0.07 | ||||||||||||||||
Discontinued operations | -0.03 | -0.01 | -0.03 | -0.01 | -0.08 | Diluted earnings (loss) per common share | $ | 0.02 | $ | 0.02 | $ | -0.01 | $ | 0.04 | $ | 0.08 | ||||||||||||||||
Diluted earnings (loss) per common share | $ | 0 | $ | -0.01 | $ | -0.03 | $ | -0.02 | $ | -0.06 | ||||||||||||||||||||||
Summary_of_Significant_Account2
Summary of Significant Accounting Policy (Details 1) | 12 Months Ended | |
Dec. 31, 2013 | ||
Maximum [Member] | Land, Buildings and Improvements [Member] | ' | |
Property, Plant and Equipment [Line Items] | ' | |
Property, Plant and Equipment useful life | '40 years | |
Maximum [Member] | Machinery and Equipment [Member] | ' | |
Property, Plant and Equipment [Line Items] | ' | |
Property, Plant and Equipment useful life | '10 years | |
Maximum [Member] | Computer Equipment [Member] | ' | |
Property, Plant and Equipment [Line Items] | ' | |
Property, Plant and Equipment useful life | '7 years | |
Maximum [Member] | Furniture and Fixtures [Member] | ' | |
Property, Plant and Equipment [Line Items] | ' | |
Property, Plant and Equipment useful life | '10 years | |
Maximum [Member] | Automobiles [Member] | ' | |
Property, Plant and Equipment [Line Items] | ' | |
Property, Plant and Equipment useful life | '6 years | |
Minimum [Member] | Machinery and Equipment [Member] | ' | |
Property, Plant and Equipment [Line Items] | ' | |
Property, Plant and Equipment useful life | '3 years | |
Minimum [Member] | Computer Equipment [Member] | ' | |
Property, Plant and Equipment [Line Items] | ' | |
Property, Plant and Equipment useful life | '3 years | |
Minimum [Member] | Furniture and Fixtures [Member] | ' | |
Property, Plant and Equipment [Line Items] | ' | |
Property, Plant and Equipment useful life | '5 years | |
Minimum [Member] | Automobiles [Member] | ' | |
Property, Plant and Equipment [Line Items] | ' | |
Property, Plant and Equipment useful life | '3 years | |
Developed Technology Rights [Member] | ' | |
Finite-Lived Intangible Assets [Line Items] | ' | |
Finite-Lived Intangible Assets, Weighted Average Useful Life | '4 years 3 months 18 days | [1] |
Developed Technology Rights [Member] | Maximum [Member] | ' | |
Finite-Lived Intangible Assets [Line Items] | ' | |
Finite-Lived Intangible Assets, Weighted Average Useful Life | '15 years | |
Developed Technology Rights [Member] | Minimum [Member] | ' | |
Finite-Lived Intangible Assets [Line Items] | ' | |
Finite-Lived Intangible Assets, Weighted Average Useful Life | '7 years | |
Trade Names [Member] | ' | |
Finite-Lived Intangible Assets [Line Items] | ' | |
Finite-Lived Intangible Assets, Weighted Average Useful Life | '11 years 0 months 0 days | [1] |
Trade Names [Member] | Maximum [Member] | ' | |
Finite-Lived Intangible Assets [Line Items] | ' | |
Finite-Lived Intangible Assets, Weighted Average Useful Life | '15 years | |
Distribution Agreements [Member] | Maximum [Member] | ' | |
Finite-Lived Intangible Assets [Line Items] | ' | |
Finite-Lived Intangible Assets, Weighted Average Useful Life | '5 years | |
Customer Relationships [Member] | ' | |
Finite-Lived Intangible Assets [Line Items] | ' | |
Finite-Lived Intangible Assets, Weighted Average Useful Life | '10 years 7 months 6 days | [1] |
Customer Relationships [Member] | Maximum [Member] | ' | |
Finite-Lived Intangible Assets [Line Items] | ' | |
Finite-Lived Intangible Assets, Weighted Average Useful Life | '15 years | |
Customer Relationships [Member] | Minimum [Member] | ' | |
Finite-Lived Intangible Assets [Line Items] | ' | |
Finite-Lived Intangible Assets, Weighted Average Useful Life | '5 years | |
Patents [Member] | ' | |
Finite-Lived Intangible Assets [Line Items] | ' | |
Finite-Lived Intangible Assets, Weighted Average Useful Life | '5 years 0 months 0 days | [1] |
Patents [Member] | Maximum [Member] | ' | |
Finite-Lived Intangible Assets [Line Items] | ' | |
Finite-Lived Intangible Assets, Weighted Average Useful Life | '15 years | |
Patents [Member] | Minimum [Member] | ' | |
Finite-Lived Intangible Assets [Line Items] | ' | |
Finite-Lived Intangible Assets, Weighted Average Useful Life | '5 years | |
[1] | (a) Weighted average life is as of December 31, 2013. |
Concentrations_Narratives_Deta
Concentrations (Narratives) (Details) | 12 Months Ended | ||
Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2011 | |
Customers | Customers | Customers | |
Concentration Risk [Line Items] | ' | ' | ' |
Concentration Risk, Customer | '3. Concentrations No customer accounted for more than 10% of the revenues for the years ended December 31, 2013, 2012 and 2011. | ' | ' |
Sales Revenue, Goods, Net [Member] | ' | ' | ' |
Concentration Risk [Line Items] | ' | ' | ' |
Number Of Customers With Benchmark Contribution Of More Than 10% | 0 | 0 | 0 |
Concentration Risk, Percentage | 10.00% | 10.00% | 10.00% |
Accounts Receivable [Member] | ' | ' | ' |
Concentration Risk [Line Items] | ' | ' | ' |
Concentration Risk, Customer | 'At December 31, 2013 and 2012, no customer accounted for more than 10% of net accounts receivable. | ' | ' |
Number Of Customers With Benchmark Contribution Of More Than 10% | 0 | 0 | ' |
Concentration Risk, Percentage | 10.00% | 10.00% | ' |
Inventories_Details_1
Inventories (Details 1) (USD $) | Dec. 31, 2013 | Dec. 31, 2012 |
In Thousands, unless otherwise specified | ||
Inventories Disclosure [Abstract] | ' | ' |
Finished Goods | $7,039 | $8,023 |
Work in Process | 752 | 731 |
Raw Materials | 7,986 | 9,008 |
Total Inventories, Net | $15,777 | $17,762 |
Property_Plant_and_Equipment_D
Property, Plant and Equipment (Details 1) (USD $) | Dec. 31, 2013 | Dec. 31, 2012 |
In Thousands, unless otherwise specified | ||
Property, Plant and Equipment [Line Items] | ' | ' |
Property, Plant and Equipment, Gross | $18,820 | $17,862 |
Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment | -14,445 | -13,311 |
Property, plant and equipment, net | 4,375 | 4,551 |
Land, Buildings and Improvements [Member] | ' | ' |
Property, Plant and Equipment [Line Items] | ' | ' |
Property, Plant and Equipment, Gross | 3,082 | 2,790 |
Machinery and Equipment [Member] | ' | ' |
Property, Plant and Equipment [Line Items] | ' | ' |
Property, Plant and Equipment, Gross | 9,471 | 8,760 |
Computer Equipment [Member] | ' | ' |
Property, Plant and Equipment [Line Items] | ' | ' |
Property, Plant and Equipment, Gross | 4,927 | 4,917 |
Furniture and Fixtures [Member] | ' | ' |
Property, Plant and Equipment [Line Items] | ' | ' |
Property, Plant and Equipment, Gross | 1,281 | 1,201 |
Automobiles [Member] | ' | ' |
Property, Plant and Equipment [Line Items] | ' | ' |
Property, Plant and Equipment, Gross | $59 | $194 |
Acquisitions_Narratives_Detail
Acquisitions (Narratives) (Details) (USD $) | 12 Months Ended | 0 Months Ended | 12 Months Ended | 0 Months Ended | 12 Months Ended | |
Dec. 31, 2012 | Feb. 03, 2012 | Dec. 31, 2013 | 31-May-12 | Dec. 31, 2013 | Dec. 31, 2012 | |
NumberOfBusinesses | AHN Biotechnologie GmbH Acquisition [Member] | AHN Biotechnologie GmbH Acquisition [Member] | Modular SFC Acquisition [Member] | Modular SFC Acquisition [Member] | Modular SFC Acquisition [Member] | |
Business Acquisition [Line Items] | ' | ' | ' | ' | ' | ' |
Business Acquisition, Effective Date of Acquisition | ' | ' | 3-Feb-12 | ' | 31-May-12 | ' |
Cash Paid for Acquisition | ' | $2,000,000 | ' | $500,000 | ' | ' |
Business Acquisition Direct Acquisition Costs In Income Statement | ' | ' | ' | ' | $0 | $300,000 |
Number of businesses acquired | 2 | ' | ' | ' | ' | ' |
Acquisitions_Details_1
Acquisitions (Details 1) (USD $) | 0 Months Ended | 0 Months Ended | ||||||
In Thousands, unless otherwise specified | Feb. 03, 2012 | Dec. 31, 2012 | Dec. 31, 2012 | Dec. 31, 2012 | 31-May-12 | 31-May-12 | 31-May-12 | 31-May-12 |
AHN Biotechnologie GmbH Acquisition [Member] | AHN Biotechnologie GmbH Acquisition [Member] | AHN Biotechnologie GmbH Acquisition [Member] | AHN Biotechnologie GmbH Acquisition [Member] | Modular SFC Acquisition [Member] | Modular SFC Acquisition [Member] | Modular SFC Acquisition [Member] | Modular SFC Acquisition [Member] | |
Customer Relationships [Member] | Trade Names [Member] | Unpatented Technology [Member] | Customer Relationships [Member] | Trade Names [Member] | ||||
Business Acquisition [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' |
Tangible Assets Acquired | ' | $1,500 | ' | ' | $30 | ' | ' | ' |
Liabilities Assumed | ' | -1,454 | ' | ' | 0 | ' | ' | ' |
Net Tangible Assets Acquired | ' | 46 | ' | ' | 30 | ' | ' | ' |
Business Acquisition Purchase Price Allocation Intangible Assets [Abstract] | ' | ' | ' | ' | ' | ' | ' | ' |
Purchase Price Allocation, Goodwill Amount | ' | 1,308 | ' | ' | 145 | ' | ' | ' |
Purchase Price Allocation, Amortizable Intangible Assets | ' | ' | 474 | 180 | ' | 200 | 50 | 95 |
Business Acquisition Purchase Price Allocation Total Intangible Assets Amount Including Goodwill | ' | 1,962 | ' | ' | 490 | ' | ' | ' |
Total Acquisition Purchase Price | ' | 2,008 | ' | ' | 520 | ' | ' | ' |
Business Acquisition, Cost of Acquired Entity 1 [Abstract] | ' | ' | ' | ' | ' | ' | ' | ' |
Cash Paid for Acquisition | 2,000 | ' | ' | ' | 500 | ' | ' | ' |
Business Acquisition, Contingent Consideration, at Fair Value | ' | ' | ' | ' | 20 | ' | ' | ' |
Business Acquisition Cost Of Acquired Entity Purchase Price 1 | ' | $2,008 | ' | ' | $520 | ' | ' | ' |
Discontinued_Operations_Narrat
Discontinued Operations (Narratives) (Details) (USD $) | 0 Months Ended | 12 Months Ended | |||||
Oct. 31, 2013 | Nov. 01, 2013 | Oct. 21, 2013 | Jun. 28, 2013 | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2011 | |
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] | ' | ' | ' | ' | ' | ' | ' |
Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent | ' | ' | ' | ' | ($2,553,000) | ($2,124,000) | ($1,477,000) |
Assets transferred as part of HART spin-off | ' | 900,000 | ' | ' | ' | ' | ' |
Transfer of cash and cash equivalents to HART | ' | ' | ' | ' | -15,041,000 | 0 | 0 |
Date of Separation Plan Completed | ' | 'November 1, 2013 | ' | ' | ' | ' | ' |
Dividends Payable Date Of Record Day Month And Year | ' | ' | 21-Oct-13 | ' | ' | ' | ' |
Spin-off distribution ratio spinnee to spinnor | ' | '1 for 4 | ' | ' | ' | ' | ' |
Date Entered Into Commerical Agreements With Spinnee | '31-Oct-13 | ' | ' | ' | ' | ' | ' |
Lost Value Adjustment Maintained To Share And Exercise Price Of Existing Options | ' | 80.00% | ' | ' | ' | ' | ' |
Percent Lost Value Provided Back To Option Holder | ' | 20.00% | ' | ' | ' | ' | ' |
Lost Value Adjustment To Share Amount Of Existing Outstanding Restricted Stock Units | ' | 80.00% | ' | ' | ' | ' | ' |
Percent Lost Value Provided Back To Restricted Stock Unit Holder | ' | 20.00% | ' | ' | ' | ' | ' |
Options Granted due to the Spin-off of HART | ' | ' | ' | ' | 1,715,164 | ' | ' |
Restricted Stock Units Granted due to the Spin-off of HART | ' | ' | ' | ' | 135,650 | ' | ' |
Date of Private Letter Ruling | ' | ' | ' | ' | '22-Mar-13 | ' | ' |
Date of Supplemental Ruling to Private Letter Ruling | ' | ' | ' | '28-Jun-13 | ' | ' | ' |
Percent of Acquired Stock to Create Taxable Spin-off | ' | 50.00% | ' | ' | ' | ' | ' |
Proceeds from sale of discontinued operations | ' | ' | ' | ' | 1,784,000 | 0 | 0 |
Genomic Solutions Division [Member] | ' | ' | ' | ' | ' | ' | ' |
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] | ' | ' | ' | ' | ' | ' | ' |
Business Disposal Purchase Price | ' | ' | ' | ' | 1,000,000 | ' | ' |
Business Disposal Earn-Out Period In Years | ' | ' | ' | ' | 3 | ' | ' |
Business Disposal Earn-Out Percent Of Revenue | ' | ' | ' | ' | 20.00% | ' | ' |
Business Disposal Promissory Note Amount | ' | ' | ' | ' | 4,600,000 | ' | ' |
Business Disposal Promissory Note Interest Basis Points Over LIBOR | ' | ' | ' | ' | 11.00% | ' | ' |
Valuation Allowance For Uncertain Collectability Of Business Disposal Promissory Note | ' | ' | ' | ' | 100.00% | ' | ' |
Union Biometrica Division [Member] | ' | ' | ' | ' | ' | ' | ' |
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] | ' | ' | ' | ' | ' | ' | ' |
Business Disposal Purchase Price | ' | ' | ' | ' | 1 | ' | ' |
Business Disposal Earn-Out Period In Years | ' | ' | ' | ' | 5 | ' | ' |
Business Disposal Earn-Out Percent Of Revenue Up To Six Million | ' | ' | ' | ' | 5.00% | ' | ' |
Business Disposal Earn-Out Percent Of Revenue Above Six Million | ' | ' | ' | ' | 8.00% | ' | ' |
Business Disposal Promissory Note Interest Percent | ' | ' | ' | ' | 12.00% | ' | ' |
Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent | ' | ' | ' | ' | 440,000 | 1,344,000 | 0 |
Harvard Apparatus Regnerative Technology [Member] | ' | ' | ' | ' | ' | ' | ' |
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] | ' | ' | ' | ' | ' | ' | ' |
Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent | ' | ' | ' | ' | -4,861,000 | -4,664,000 | -2,326,000 |
Income Taxes [Member] | ' | ' | ' | ' | ' | ' | ' |
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] | ' | ' | ' | ' | ' | ' | ' |
Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent | ' | ' | ' | ' | ($1,868,000) | ($1,196,000) | ($849,000) |
Goodwill_and_Other_Intangible_2
Goodwill and Other Intangible Assets (Narratives) (Details) (USD $) | 12 Months Ended | ||
Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2011 | |
Goodwill And Other Intangible Assets Disclosure [Abstract] | ' | ' | ' |
Amortization of intangible assets | $2,590,000 | $2,752,000 | $2,746,000 |
Estimated 2013 Amortization Expense | 2,500,000 | ' | ' |
Estimated 2014 Amortization Expense | 2,200,000 | ' | ' |
Estimated 2015 Amortization Expense | 2,100,000 | ' | ' |
Estimated 2016 Amortization Expense | 1,800,000 | ' | ' |
Estimated 2017 Amortization Expense | $1,700,000 | ' | ' |
Goodwill_and_Other_Intangible_3
Goodwill and Other Intangible Assets (Details 1) (USD $) | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2011 | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2013 | Dec. 31, 2012 | ||||
In Thousands, unless otherwise specified | Developed Technology Rights [Member] | Developed Technology Rights [Member] | Trade Names [Member] | Trade Names [Member] | Customer Relationships [Member] | Customer Relationships [Member] | Patents [Member] | Patents [Member] | |||||||
Finite-Lived Intangible Assets [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ||||
Finite-Lived Intangible Assets, Gross | $41,740 | $41,133 | ' | $13,464 | $13,258 | $6,178 | $6,167 | $21,827 | $21,699 | $271 | $9 | ||||
Finite-Lived Intangible Assets, Accumulated Amortization | -22,731 | -19,908 | ' | -11,091 | -10,207 | -2,185 | -1,756 | -9,447 | -7,938 | -8 | -7 | ||||
Finite-Lived Intangible Assets, Weighted Average Useful Life | ' | ' | ' | '4 years 3 months 18 days | [1] | ' | '11 years 0 months 0 days | [1] | ' | '10 years 7 months 6 days | [1] | ' | '5 years 0 months 0 days | [1] | ' |
Goodwill | 36,605 | 36,200 | 34,209 | ' | ' | ' | ' | ' | ' | ' | ' | ||||
Other indefinite lived intangible assets | 1,289 | 1,276 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ||||
Total goodwill and other indefinite lived intangible assets | 37,894 | 37,476 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ||||
Total intangible assets | $79,634 | $78,609 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ||||
[1] | (a) Weighted average life is as of December 31, 2013. |
Goodwill_and_Other_Intangible_4
Goodwill and Other Intangible Assets (Details 2) (USD $) | 12 Months Ended | |
In Thousands, unless otherwise specified | Dec. 31, 2013 | Dec. 31, 2012 |
Goodwill And Other Intangible Assets Disclosure [Abstract] | ' | ' |
Goodwill, Beginning Balance | $36,200 | $34,209 |
Acquired during the period | 0 | 1,453 |
Foreign currency translation adjustments related to goodwill balance | 405 | 538 |
Goodwill, Ending Balance | $36,605 | $36,200 |
Restructuring_and_Other_Exit_C2
Restructuring and Other Exit Cots (Narratives) (Details) (USD $) | 12 Months Ended | ||
In Thousands, unless otherwise specified | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2011 |
Restructuring Cost and Reserve [Line Items] | ' | ' | ' |
Restructuring charges | $2,150 | $310 | $467 |
Restructuring Plan 2012 [Member] | ' | ' | ' |
Restructuring Cost and Reserve [Line Items] | ' | ' | ' |
Restructuring charges | ' | 323 | ' |
Restructuring Plan 2011 [Member] | ' | ' | ' |
Restructuring Cost and Reserve [Line Items] | ' | ' | ' |
Restructuring charges | ' | ' | 495 |
Employee Severance [Member] | Restructuring Plan 2012 [Member] | ' | ' | ' |
Restructuring Cost and Reserve [Line Items] | ' | ' | ' |
Restructuring charges | ' | 312 | ' |
Employee Severance [Member] | Restructuring Plan 2011 [Member] | ' | ' | ' |
Restructuring Cost and Reserve [Line Items] | ' | ' | ' |
Restructuring charges | ' | ' | 78 |
Employee Severance [Member] | Restructuring Plan 2013 [Member] | ' | ' | ' |
Restructuring Cost and Reserve [Line Items] | ' | ' | ' |
Restructuring charges | 96 | ' | ' |
Fixed Assets Write Off [Member] | Restructuring Plan 2011 [Member] | ' | ' | ' |
Restructuring Cost and Reserve [Line Items] | ' | ' | ' |
Restructuring charges | ' | ' | 307 |
Other Costs [Member] | Restructuring Plan 2012 [Member] | ' | ' | ' |
Restructuring Cost and Reserve [Line Items] | ' | ' | ' |
Restructuring charges | ' | 11 | ' |
Other Costs [Member] | Restructuring Plan 2011 [Member] | ' | ' | ' |
Restructuring Cost and Reserve [Line Items] | ' | ' | ' |
Restructuring charges | ' | ' | $110 |
Restructuring_and_Other_Exit_C3
Restructuring and Other Exit Costs (Details 1) (USD $) | 12 Months Ended | ||
In Thousands, unless otherwise specified | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2011 |
Restructuring Reserve [Roll Forward] | ' | ' | ' |
Restructuring charges | $2,150 | $310 | $467 |
Restructuring Reserve, Ending Balance | 0 | ' | ' |
Restructuring Plan 2012 [Member] | ' | ' | ' |
Restructuring Reserve [Roll Forward] | ' | ' | ' |
Restructuring Reserve, Beginning Balance | 144 | ' | ' |
Restructuring charges | ' | 323 | ' |
Restructuring Reserve, Settled with Cash | -95 | -179 | ' |
Restructuring Reserve, Accrual Adjustment | -46 | ' | ' |
Restructuring Reserve, Ending Balance | 3 | 144 | ' |
Restructuring Plan 2011 [Member] | ' | ' | ' |
Restructuring Reserve [Roll Forward] | ' | ' | ' |
Restructuring Reserve, Beginning Balance | ' | 45 | ' |
Restructuring charges | ' | ' | 495 |
Restructuring Reserve, Settled with Cash | ' | -45 | -213 |
Restructuring Reserve, Accrual Adjustment | ' | ' | -237 |
Restructuring Reserve, Ending Balance | ' | 0 | 45 |
Employee Severance [Member] | Restructuring Plan 2012 [Member] | ' | ' | ' |
Restructuring Reserve [Roll Forward] | ' | ' | ' |
Restructuring Reserve, Beginning Balance | 133 | ' | ' |
Restructuring charges | ' | 312 | ' |
Restructuring Reserve, Settled with Cash | -84 | -179 | ' |
Restructuring Reserve, Accrual Adjustment | -46 | ' | ' |
Restructuring Reserve, Ending Balance | 3 | 133 | ' |
Employee Severance [Member] | Restructuring Plan 2011 [Member] | ' | ' | ' |
Restructuring Reserve [Roll Forward] | ' | ' | ' |
Restructuring Reserve, Beginning Balance | ' | 45 | ' |
Restructuring charges | ' | ' | 78 |
Restructuring Reserve, Settled with Cash | ' | -45 | -33 |
Restructuring Reserve, Accrual Adjustment | ' | ' | 0 |
Restructuring Reserve, Ending Balance | ' | 0 | 45 |
Employee Severance [Member] | Restructuring Plan 2013 [Member] | ' | ' | ' |
Restructuring Reserve [Roll Forward] | ' | ' | ' |
Restructuring charges | 96 | ' | ' |
Restructuring Reserve, Settled with Cash | -96 | ' | ' |
Employee Severance [Member] | Restructuring Plan December 2013 [Member] | ' | ' | ' |
Restructuring Reserve [Roll Forward] | ' | ' | ' |
Restructuring charges | 2,100 | ' | ' |
Restructuring Reserve, Settled with Cash | -666 | ' | ' |
Restructuring Reserve, Ending Balance | 1,434 | ' | ' |
Fixed Assets Write Off [Member] | Restructuring Plan 2011 [Member] | ' | ' | ' |
Restructuring Reserve [Roll Forward] | ' | ' | ' |
Restructuring Reserve, Beginning Balance | ' | 0 | ' |
Restructuring charges | ' | ' | 307 |
Restructuring Reserve, Settled with Cash | ' | 0 | 0 |
Restructuring Reserve, Accrual Adjustment | ' | ' | -307 |
Restructuring Reserve, Ending Balance | ' | 0 | 0 |
Other Costs [Member] | Restructuring Plan 2012 [Member] | ' | ' | ' |
Restructuring Reserve [Roll Forward] | ' | ' | ' |
Restructuring Reserve, Beginning Balance | 11 | ' | ' |
Restructuring charges | ' | 11 | ' |
Restructuring Reserve, Settled with Cash | -11 | 0 | ' |
Restructuring Reserve, Accrual Adjustment | 0 | ' | ' |
Restructuring Reserve, Ending Balance | 0 | 11 | ' |
Other Costs [Member] | Restructuring Plan 2011 [Member] | ' | ' | ' |
Restructuring Reserve [Roll Forward] | ' | ' | ' |
Restructuring Reserve, Beginning Balance | ' | 0 | ' |
Restructuring charges | ' | ' | 110 |
Restructuring Reserve, Settled with Cash | ' | 0 | -180 |
Restructuring Reserve, Accrual Adjustment | ' | ' | 70 |
Restructuring Reserve, Ending Balance | ' | $0 | $0 |
Long_Term_Debt_Narratives_Deta
Long Term Debt (Narratives) (Details) (USD $) | 0 Months Ended | 12 Months Ended | 0 Months Ended | 0 Months Ended | 0 Months Ended | ||||||||||
Oct. 31, 2013 | Aug. 07, 2009 | Dec. 31, 2013 | Mar. 29, 2013 | Dec. 31, 2012 | Mar. 29, 2013 | Dec. 31, 2013 | Dec. 31, 2012 | Mar. 29, 2013 | Dec. 31, 2013 | Dec. 31, 2012 | Oct. 31, 2013 | Mar. 29, 2013 | Dec. 31, 2013 | Dec. 31, 2012 | |
Revolving Credit Facility [Member] | Revolving Credit Facility [Member] | Revolving Credit Facility [Member] | Term Loan [Member] | Term Loan [Member] | Term Loan [Member] | Delayed Drawdown Term Loan [Member] | Delayed Drawdown Term Loan [Member] | Delayed Drawdown Term Loan [Member] | Delayed Drawdown Term Loan [Member] | ||||||
Credit Agreement [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Previous Approved Credit Facility | ' | $20,000,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Secured Debt | ' | ' | 24,750,000 | ' | 12,950,000 | 25,000,000 | 2,500,000 | 12,950,000 | 15,000,000 | 12,750,000 | 0 | ' | 15,000,000 | 9,500,000 | 0 |
Line of Credit Facility, Maximum Borrowing Capacity | ' | ' | ' | 50,000,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Maturity Dates | ' | ' | ' | ' | ' | 29-Mar-16 | ' | ' | 29-Mar-18 | ' | ' | ' | 29-Mar-18 | ' | ' |
Basis Spread Over LIBOR | ' | ' | ' | ' | ' | 2.50% | ' | ' | 3.00% | ' | ' | ' | 3.00% | ' | ' |
Minimum percentage of Term Loan and the DDTL that company was required to fix the rate of interest on | ' | ' | 50.00% | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Line of Credit Facility, Remaining Borrowing Capacity | ' | ' | 17,400,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Debt Issuance Costs | ' | ' | 300,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Interest Rate In Excess Of LIBOR On Credit Facility | ' | 3.00% | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Maximum Borrowings Available Under The Current Credit Agreement | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 10,000,000 | ' | ' | ' |
Interest Rate As Of Reporting Date | ' | ' | ' | ' | ' | ' | 3.16% | ' | ' | 3.96% | ' | ' | ' | 3.55% | ' |
DDTL Threshold For Dollar For Dollar Reduction In Revolving Line | ' | ' | ' | 10,000,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Transfer Of Delayed Draw Down Term Loan Capacity To Revolver Capacity | 5,000,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Lender Approval To Fund Acquisition With Cash Promissory Note In Excess Of Threshold | ' | ' | 6,000,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Lender Approval To Fund Acquisition With Equity In Excess Of Threshold | ' | ' | $10,000,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Long_Term_Debt_Details_1
Long Term Debt (Details 1) (USD $) | Dec. 31, 2013 | Mar. 29, 2013 | Dec. 31, 2012 |
In Thousands, unless otherwise specified | |||
Debt Instrument [Line Items] | ' | ' | ' |
Secured Debt | $24,750 | ' | $12,950 |
Current portion, long-term debt | -5,000 | ' | 0 |
Long-term debt | 19,750 | ' | 12,950 |
Revolving Credit Facility [Member] | ' | ' | ' |
Debt Instrument [Line Items] | ' | ' | ' |
Secured Debt | 2,500 | 25,000 | 12,950 |
Term Loan [Member] | ' | ' | ' |
Debt Instrument [Line Items] | ' | ' | ' |
Secured Debt | 12,750 | 15,000 | 0 |
Delayed Drawdown Term Loan [Member] | ' | ' | ' |
Debt Instrument [Line Items] | ' | ' | ' |
Secured Debt | $9,500 | $15,000 | $0 |
Long_Term_Debt_Details_2
Long Term Debt (Details 2) (USD $) | Dec. 31, 2013 |
In Thousands, unless otherwise specified | |
Long Term Debt Disclosure [Abstract] | ' |
Debt repayments of principal in the next twelve months | $5,000 |
Debt repayments of principal in Year Two | 5,000 |
Debt repayments of principal in Year Three | 7,500 |
Debt repayments of principal in Year Four | 5,000 |
Debt repayments of principal in Year Five | 2,250 |
Long-term Debt | $24,750 |
Derivative_Narratives_Details
Derivative (Narratives) (Details) (USD $) | 12 Months Ended | 12 Months Ended | |||
Dec. 31, 2013 | Dec. 31, 2013 | Nov. 30, 2013 | Dec. 31, 2013 | Jun. 05, 2013 | |
Delayed Drawdown Term Loan [Member] | Delayed Drawdown Term Loan [Member] | Term Loan [Member] | Term Loan [Member] | ||
Derivative Instruments And Hedging Activities Disclosure [Line Items] | ' | ' | ' | ' | ' |
Minimum percentage of Term Loan and the DDTL that company was required to fix the rate of interest on | 50.00% | ' | ' | ' | ' |
Notional Amount of Interest Rate Swaps | $17,500,000 | ' | $5,000,000 | ' | $15,000,000 |
LIBOR Fixed Rate | ' | 0.93% | ' | 0.96% | ' |
Deferred losses on derivative instruments accumulated in AOCI expected to be reclassified to earnings | $100,000 | ' | ' | ' | ' |
Derivative Interest Rate Swap Effective Percentage | 100.00% | ' | ' | ' | ' |
Derivative_Details_1
Derivative (Details 1) (Other liabilities-non current [Member], Derivatives qualifying as hedges [Member], USD $) | Dec. 31, 2013 | |
In Thousands, unless otherwise specified | ||
Other liabilities-non current [Member] | Derivatives qualifying as hedges [Member] | ' | |
Derivatives, Fair Value [Line Items] | ' | |
Derivative Liability, Fair Value, Net | ($49) | [1] |
[1] | (a) See note 12 for the fair value measurements related to these financial instruments. |
Derivative_Details_2
Derivative (Details 2) (Derivatives qualifying as hedges [Member], USD $) | 12 Months Ended |
In Thousands, unless otherwise specified | Dec. 31, 2013 |
Derivative Instruments, Gain (Loss) [Line Items] | ' |
Derivative Instruments, Loss Recognized in Other Comprehensive Income (Loss), Effective Portion | ($49) |
Interest Expense [Member] | ' |
Derivative Instruments, Gain (Loss) [Line Items] | ' |
Derivative Instruments, Loss Reclassified from Accumulated OCI into Income, Effective Portion | ($67) |
Fair_Value_Measurements_Detail
Fair Value Measurements (Details) (Derivatives qualifying as hedges [Member], USD $) | Dec. 31, 2013 |
In Thousands, unless otherwise specified | |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] | ' |
Derivative Liabilities | $49 |
Fair Value, Inputs, Level 1 [Member] | ' |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] | ' |
Derivative Liabilities | 0 |
Fair Value, Inputs, Level 2 [Member] | ' |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] | ' |
Derivative Liabilities | 49 |
Fair Value, Inputs, Level 3 [Member] | ' |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] | ' |
Derivative Liabilities | $0 |
Leases_Narratives_Details
Leases (Narratives) (Details) (USD $) | 12 Months Ended | ||
Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2011 | |
sqft | |||
Leases Disclosure [Abstract] | ' | ' | ' |
Operating Leases, Rent Expense, Net | $1,300,000 | $1,300,000 | $1,500,000 |
Square Footage of Real Estate Property | 17,000 | ' | ' |
HART Sublease Rent | $26,000 | ' | ' |
HART Sublease Initial Term | 'P1Y6M0D | ' | ' |
HART Sublease Extended Term | 31-May-17 | ' | ' |
Leases_Details_1
Leases (Details 1) (USD $) | Dec. 31, 2013 |
In Thousands, unless otherwise specified | |
Leases Disclosure [Abstract] | ' |
2013 | $1,228 |
2014 | 1,073 |
2015 | 763 |
2016 | 422 |
2017 | 160 |
Thereafter | 70 |
Operating Leases, Total Future Minimum Payments Due | $3,716 |
Accrued_Expenses_Details_1
Accrued Expenses (Details 1) (USD $) | Dec. 31, 2013 | Dec. 31, 2012 |
In Thousands, unless otherwise specified | ||
Accrued Liabilities Current [Abstract] | ' | ' |
Employee Related Liabilities Current | $1,349 | $1,389 |
Accrued Professional Fees Current | 927 | 869 |
Accrued Severance Current | 1,434 | 133 |
Product Warranty Accrual Current | 305 | 222 |
Other Accrued Liabilities Current | 1,063 | 892 |
Total Accrued Expenses | $5,078 | $3,505 |
Income_Tax_Narratives_Details
Income Tax (Narratives) (Details) (USD $) | 12 Months Ended | |||
Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2011 | Dec. 31, 2010 | |
Income Tax [Abstract] | ' | ' | ' | ' |
Increase (Decrease) In Income Taxes Resulting From Release Of Uncertain Tax Position Liability Due To Expiration Of Statute Of Limitations | $0 | $0 | ($528,000) | ' |
US Federal Income Tax Rate | 34.00% | ' | ' | ' |
Net Operating Loss Carryforward Federal And State | 26,600,000 | ' | ' | ' |
Net Operating Loss Carryforward Foreign | 3,900,000 | ' | ' | ' |
Tax Credit Carryforwards | 5,100,000 | ' | ' | ' |
Net Operating Loss Carryforwards Subject To Annual Limitation | 7,200,000 | ' | ' | ' |
Net Operating Loss Carryforwards Annual Limitation | 700,000 | ' | ' | ' |
Undistributed Foreign Earnings | 49,200,000 | 46,000,000 | 40,900,000 | ' |
Cash In Foreign Subsidiaries | 23,600,000 | 19,200,000 | ' | ' |
Cash Held In Foreign Subsidiaries Used For Foreign Capital Improvements | 900,000 | ' | ' | ' |
Additions Based On Tax Positions Of Prior Years | ' | 0 | 200,000 | 500,000 |
Unrecognized Tax Benefits | 191,000 | 191,000 | 191,000 | ' |
CMA Acquisition [Member] | ' | ' | ' | ' |
Income Tax Disclosure [Line Items] | ' | ' | ' | ' |
Cash Held In Foreign Subsidiaries Used For Acquisitions | ' | 4,400,000 | ' | ' |
AHN Biotechnologie GmbH Acquisition [Member] | ' | ' | ' | ' |
Income Tax Disclosure [Line Items] | ' | ' | ' | ' |
Cash Held In Foreign Subsidiaries Used For Acquisitions | $2,000,000 | ' | ' | ' |
Income_Tax_Details_1
Income Tax (Details 1) (USD $) | 3 Months Ended | 12 Months Ended | |||||||||
In Thousands, unless otherwise specified | Dec. 31, 2013 | Sep. 30, 2013 | Jun. 30, 2013 | Mar. 31, 2013 | Dec. 31, 2012 | Sep. 30, 2012 | Jun. 30, 2012 | Mar. 31, 2012 | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2011 |
Income Tax Expense (benefit) Attributable To Income From Continuing Operations [Abstract] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Current Federal And State Income Tax Expense Benefit Continuing Operations | ' | ' | ' | ' | ' | ' | ' | ' | $47 | $70 | $111 |
Current Foreign Income Tax Expense (benefit) From Continuing Operations | ' | ' | ' | ' | ' | ' | ' | ' | 413 | 1,705 | 1,156 |
Current Income Tax Expense (Benefit), Total | ' | ' | ' | ' | ' | ' | ' | ' | 460 | 1,775 | 1,267 |
Deferred Federal And State Income Tax Expense Benefit Continuing Operations | ' | ' | ' | ' | ' | ' | ' | ' | -594 | 931 | 478 |
Deferred Foreign Income Tax Expense (Benefit) | ' | ' | ' | ' | ' | ' | ' | ' | -154 | -308 | -166 |
Deferred Income Taxes Amount | ' | ' | ' | ' | ' | ' | ' | ' | -748 | 623 | 312 |
Income Tax Expense (Benefit), Total | -1,013 | 105 | 321 | 299 | 817 | 278 | 698 | 605 | -288 | 2,398 | 1,579 |
Effective Tax Rate Reconciliation [Abstract] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Computed "Expected" Income Tax Expense | ' | ' | ' | ' | ' | ' | ' | ' | 147 | 2,343 | 2,335 |
Net Change In Income Tax Expense Benefit Resulting From Permanent Differences | ' | ' | ' | ' | ' | ' | ' | ' | 482 | -25 | 109 |
Increase (Decrease) In Income Taxes Resulting From Foreign Tax Rate Differential | ' | ' | ' | ' | ' | ' | ' | ' | -64 | -435 | -333 |
Increase (Decrease) In Income Taxes Resulting From State Income Taxes, Net Of Federal Income Tax Benefit | ' | ' | ' | ' | ' | ' | ' | ' | 31 | 135 | 113 |
Income Tax Reconciliation, Nondeductible Expense, Share-based Compensation Cost | ' | ' | ' | ' | ' | ' | ' | ' | 1 | 254 | 345 |
Increase (Decrease) In Income Taxes Resulting From Adjustment Of Prior Year Tax Accruals | ' | ' | ' | ' | ' | ' | ' | ' | -294 | 0 | 0 |
Income Tax Reconciliation, Tax Credits | ' | ' | ' | ' | ' | ' | ' | ' | -615 | -127 | -558 |
Increase (Decrease) In Income Taxes Resulting From Release Of Uncertain Tax Position Liability Due To Expiration Of Statute Of Limitations | ' | ' | ' | ' | ' | ' | ' | ' | 0 | 0 | -528 |
Increase (Decrease) In Income Taxes Resulting From Change In Valuation Allowance Allocated To Income Tax Expense Benefit | ' | ' | ' | ' | ' | ' | ' | ' | 31 | 281 | 63 |
Increase (Decrease) In Income Taxes Resulting From Other | ' | ' | ' | ' | ' | ' | ' | ' | -7 | -28 | 33 |
Income Tax Expense (Benefit), Total | -1,013 | 105 | 321 | 299 | 817 | 278 | 698 | 605 | -288 | 2,398 | 1,579 |
Operating Income (Loss) [Abstract] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Income From Continuing Operations, Domestic | ' | ' | ' | ' | ' | ' | ' | ' | -2,549 | 681 | 339 |
Income from continuing operations, Foreign | ' | ' | ' | ' | ' | ' | ' | ' | 2,984 | 6,211 | 6,529 |
Income before income taxes | ($1,268) | $56 | $416 | $1,231 | $1,989 | $978 | $2,248 | $1,677 | $435 | $6,892 | $6,868 |
Income_Tax_Details_2
Income Tax (Details 2) (USD $) | 12 Months Ended | |
In Thousands, unless otherwise specified | Dec. 31, 2013 | Dec. 31, 2012 |
Components Of Deferred Tax Assets And Liabilities [Abstract] | ' | ' |
Deferred Tax Assets, Accounts Receivable | $65 | $62 |
Deferred Tax Assets, Inventory | 1,405 | 1,251 |
Deferred Tax Assets Operating Loss And Credits Carryforwards | 12,978 | 8,829 |
Deferred Tax Assets, Accrued Expenses | 409 | 107 |
Deferred Tax Assets, Pension Liabilities | 985 | 1,366 |
Deferred Tax Assets, Tax Deferred Expense, Reserves And Accruals, Contingencies | 2,593 | 2,413 |
Deferred Tax Assets, Other Accrued Liabilities | 1,867 | 3,761 |
Deferred Tax Assets, Gross | 20,302 | 17,789 |
Deferred Tax Assets, Valuation Allowance | -1,249 | -1,307 |
Deferred Tax Assets, Net | 19,053 | 16,482 |
Deferred Tax Liabilities [Abstract] | ' | ' |
Deferred Tax Liabilities, Intangible Assets | 4,242 | 4,057 |
Deferred Tax Liabilities, Property, Plant and Equipment | 70 | 115 |
Deferred Tax Liabilities, Other | 238 | 264 |
Total Deferred Tax Liabilities | 4,550 | 4,436 |
Net Deferred Tax Assets | 14,503 | 12,046 |
Reconciliation Of Uncertain Tax Liabilities [abstract] | ' | ' |
Beginning Balance | 191 | 191 |
Additions Based On Tax Positions Of Prior Years | ' | 0 |
Increase (Decrease) In Income Taxes Resulting From Release Of Uncertain Tax Position Liability Due To Expiration Of Statute Of Limitations | 0 | 0 |
Ending Balance | $191 | $191 |
Employee_Benefit_Plans_Narrati
Employee Benefit Plans (Narratives) (Details) (USD $) | 12 Months Ended | ||
Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2011 | |
Defined Benefit Plan, Estimated Future Benefit Payments [Abstract] | ' | ' | ' |
Defined Benefit Plan, Expected Future Benefit Payments in Year One | $500,000 | ' | ' |
Defined Benefit Plan, Expected Future Benefit Payments in Year Two | 600,000 | ' | ' |
Defined Benefit Plan, Expected Future Benefit Payments in Year Three | 900,000 | ' | ' |
Defined Benefit Plan, Expected Future Benefit Payments in Year Four | 700,000 | ' | ' |
Defined Benefit Plan, Expected Future Benefit Payments in Year Five | 900,000 | ' | ' |
Defined Benefit Plan, Expected Future Benefit Payments in Five Fiscal Years Thereafter | 4,600,000 | ' | ' |
Defined Benefit Plan, Weighted Average Assumptions Used in Calculating Benefit Obligation [Abstract] | ' | ' | ' |
Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Discount Rate Support, Methodology and Source Data | 'The discount rate assumptions used for pension accounting reflect the prevailing rates available on high-quality, fixed-income debt instruments with terms that match the average expected duration of the Company’s defined benefit pension plan obligations. The Company uses the iBoxx AA 15yr+ index, which matches the average duration of its pension plan liability of approximately 15 years. With the current base of assets in the pension plans, a 0.1% increase/decrease in the discount rate assumption would decrease/increase annual pension expense by approximately $157,000. | ' | ' |
Employee Benefit Plans Disclosure [Abstract] | ' | ' | ' |
Defined Contribution Plan Payments In Current Fiscal Year | 600,000 | 500,000 | 600,000 |
Defined Benefit Plan, Accumulated Benefit Obligation | 19,500,000 | 18,100,000 | ' |
Defined Benefit Plan, Estimated Future Employer Contributions in Next Fiscal Year | 800,000 | ' | ' |
Fair Value Impairment Of Pension Assets | 200,000 | ' | ' |
Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Discount Rate Support, Methodology and Source Data | 'The discount rate assumptions used for pension accounting reflect the prevailing rates available on high-quality, fixed-income debt instruments with terms that match the average expected duration of the Company’s defined benefit pension plan obligations. The Company uses the iBoxx AA 15yr+ index, which matches the average duration of its pension plan liability of approximately 15 years. With the current base of assets in the pension plans, a 0.1% increase/decrease in the discount rate assumption would decrease/increase annual pension expense by approximately $157,000. | ' | ' |
Defined Benefit Plan Increase (Decrease) In Discount Rate Percentage | 0.10% | ' | ' |
Defined Benefit Plan Average Pension Plan Liability | '15 years | ' | ' |
Defined Benefit Plan Increase (Decrease) In Discount Rate Value | 157,000 | ' | ' |
Defined Benefit Plan Increase (Decrease) In Asset Return Percentage | 0.10% | ' | ' |
Defined Benefit Plan Average Remaining Work Lifetime | '15 years | ' | ' |
Defined Benefit Plan Increase (Decrease) In Asset Return Value | $94,000 | ' | ' |
Employee_Benefit_Plans_Details
Employee Benefit Plans (Details 1) (USD $) | 12 Months Ended | ||
In Thousands, unless otherwise specified | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2011 |
Employee Benefit Plans Disclosure [Abstract] | ' | ' | ' |
Service Cost | $288 | $314 | $298 |
Interest Cost | 797 | 819 | 836 |
Expected Return on Plan Assets | -524 | -570 | -608 |
Net Amortization Loss | 305 | 248 | 159 |
Curtailment Gain | -197 | 0 | 0 |
Net Periodic Benefit Cost, Total | 669 | 811 | 685 |
Defined Benefit Plan, Change in Benefit Obligation [Roll Forward] | ' | ' | ' |
Defined Benefit Plan, Benefit Obligation | 19,643 | 16,866 | ' |
Service Cost for Defined Benefit Plan | 272 | 303 | ' |
Interest Cost | 797 | 819 | 836 |
Defined Benefit Plan, Contributions by Plan Participants | 56 | 60 | ' |
Defined Benefit Plan, Actuarial Net (Gains) Losses | -329 | 1,547 | ' |
Defined Benefit Plan, Benefits Paid | -431 | -663 | ' |
Defined Benefit Plan, Foreign Currency Exchange Rate Changes, Benefit Obligation | 395 | 711 | ' |
Defined Benefit Plan, Benefit Obligation | 20,403 | 19,643 | 16,866 |
Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward] | ' | ' | ' |
Defined Benefit Plan, Fair Value of Plan Assets | 13,704 | 12,006 | ' |
Defined Benefit Plan, Actual Return on Plan Assets | 1,125 | 944 | ' |
Defined Benefit Plan, Contributions by Plan Participants | 56 | 60 | ' |
Defined Benefit Plan Payments In Current Fiscal Year | 801 | 873 | ' |
Defined Benefit Plan, Benefits Paid | -431 | -663 | ' |
Defined Benefit Plan, Foreign Currency Exchange Rate Changes, Plan Assets | 285 | 484 | ' |
Defined Benefit Plan, Fair Value of Plan Assets | 15,540 | 13,704 | 12,006 |
Defined Benefit Plan, Funded Status of Plan [Abstract] | ' | ' | ' |
Defined Benefit Plan Funded Status Of Plan | -4,863 | -5,939 | ' |
Defined Benefit Plan, Amounts Recognized in Balance Sheet [Abstract] | ' | ' | ' |
Deferred Income Taxes On Pension Liabilities | 985 | 1,366 | ' |
Pension Defined Benefit Plans, Liabilities | -4,863 | -5,939 | ' |
Defined Benefit Plan, Amounts Recognized in Balance Sheet | -3,878 | -4,573 | ' |
Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract] | ' | ' | ' |
Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent | ($3,878) | ($4,573) | ' |
Employee_Benefit_Plans_Details1
Employee Benefit Plans (Details 2) | 12 Months Ended | ||
Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2011 | |
Defined Benefit Plan, Weighted Average Assumptions Used in Calculating Net Periodic Benefit Cost [Abstract] | ' | ' | ' |
Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Discount Rate | 4.43% | 4.09% | 4.70% |
Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Expected Long-term Return on Assets | 3.79% | 4.02% | 4.40% |
Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Rate of Compensation Increase | 2.99% | 3.51% | 3.50% |
Employee_Benefit_Plans_Details2
Employee Benefit Plans (Details 3) (USD $) | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2011 |
In Thousands, unless otherwise specified | |||
Defined Benefit Plan Disclosure [Line Items] | ' | ' | ' |
Defined Benefit Plan, Fair Value of Plan Assets | $15,540 | $13,704 | $12,006 |
Defined Benefit Plan, Actual Plan Asset Allocations | 100.00% | 100.00% | ' |
Fair Value, Inputs, Level 1 [Member] | ' | ' | ' |
Defined Benefit Plan Disclosure [Line Items] | ' | ' | ' |
Defined Benefit Plan, Fair Value of Plan Assets | 1,488 | 969 | ' |
Fair Value, Inputs, Level 2 [Member] | ' | ' | ' |
Defined Benefit Plan Disclosure [Line Items] | ' | ' | ' |
Defined Benefit Plan, Fair Value of Plan Assets | 13,465 | 11,967 | ' |
Fair Value, Inputs, Level 3 [Member] | ' | ' | ' |
Defined Benefit Plan Disclosure [Line Items] | ' | ' | ' |
Defined Benefit Plan, Fair Value of Plan Assets | 587 | 768 | 1,042 |
Equity Securities [Member] | ' | ' | ' |
Defined Benefit Plan Disclosure [Line Items] | ' | ' | ' |
Defined Benefit Plan, Fair Value of Plan Assets | 7,404 | 6,918 | ' |
Defined Benefit Plan, Actual Plan Asset Allocations | 48.00% | 50.00% | ' |
Debt Securities [Member] | ' | ' | ' |
Defined Benefit Plan Disclosure [Line Items] | ' | ' | ' |
Defined Benefit Plan, Fair Value of Plan Assets | 6,061 | 5,049 | ' |
Defined Benefit Plan, Actual Plan Asset Allocations | 39.00% | 37.00% | ' |
Cash and Cash Equivalents [Member] | ' | ' | ' |
Defined Benefit Plan Disclosure [Line Items] | ' | ' | ' |
Defined Benefit Plan, Fair Value of Plan Assets | 1,488 | 969 | ' |
Defined Benefit Plan, Actual Plan Asset Allocations | 9.00% | 7.00% | ' |
Other Assets [Member] | ' | ' | ' |
Defined Benefit Plan Disclosure [Line Items] | ' | ' | ' |
Defined Benefit Plan, Fair Value of Plan Assets | $587 | $768 | ' |
Defined Benefit Plan, Actual Plan Asset Allocations | 4.00% | 6.00% | ' |
Employee_Benefit_Plans_Details3
Employee Benefit Plans (Details 4) (USD $) | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2011 | Dec. 31, 2013 | Dec. 31, 2012 |
In Thousands, unless otherwise specified | Fair Value, Inputs, Level 3 [Member] | Fair Value, Inputs, Level 3 [Member] | |||
Defined Benefit Plan Disclosure [Line Items] | ' | ' | ' | ' | ' |
Defined Benefit Plan, Fair Value of Plan Assets | $15,540 | $13,704 | $12,006 | $768 | $1,042 |
Defined Benefit Plan Purchases During Year | ' | ' | ' | 0 | 0 |
Defined Benefit Plan Unrealized Loss Gain | ' | ' | ' | -181 | -274 |
Defined Benefit Plan, Fair Value of Plan Assets | $15,540 | $13,704 | $12,006 | $587 | $768 |
Accumulated_Other_Comprehensiv2
Accumulated Other Comprehensive Income (Details) (USD $) | 12 Months Ended | ||
In Thousands, unless otherwise specified | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2011 |
Accumulated Other Comprehensive Income (Loss) [Line Items] | ' | ' | ' |
Opening Balance | ($4,863) | ' | ' |
Other Comprehensive Income (Loss) before Reclassifications | 1,909 | ' | ' |
Reclassification from Accumulated Other Comprehensive Income | 310 | 191 | 119 |
Other Comprehensive Income (Loss), Net of Tax | 2,219 | 859 | -1,826 |
Closing Balance | -2,644 | -4,863 | ' |
Foreign currency translation adjustment [Member] | ' | ' | ' |
Accumulated Other Comprehensive Income (Loss) [Line Items] | ' | ' | ' |
Opening Balance | -290 | ' | ' |
Other Comprehensive Income (Loss) before Reclassifications | 1,573 | ' | ' |
Reclassification from Accumulated Other Comprehensive Income | 0 | ' | ' |
Other Comprehensive Income (Loss), Net of Tax | 1,573 | ' | ' |
Closing Balance | 1,283 | ' | ' |
Derivatives qualifying as hedges [Member] | ' | ' | ' |
Accumulated Other Comprehensive Income (Loss) [Line Items] | ' | ' | ' |
Opening Balance | 0 | ' | ' |
Other Comprehensive Income (Loss) before Reclassifications | -116 | ' | ' |
Reclassification from Accumulated Other Comprehensive Income | 67 | ' | ' |
Other Comprehensive Income (Loss), Net of Tax | -49 | ' | ' |
Closing Balance | -49 | ' | ' |
Defined benefit pension plans [Member] | ' | ' | ' |
Accumulated Other Comprehensive Income (Loss) [Line Items] | ' | ' | ' |
Opening Balance | -4,573 | ' | ' |
Other Comprehensive Income (Loss) before Reclassifications | 452 | ' | ' |
Reclassification from Accumulated Other Comprehensive Income | 243 | ' | ' |
Other Comprehensive Income (Loss), Net of Tax | 695 | ' | ' |
Closing Balance | ($3,878) | ' | ' |
Accumulated_Other_Comprehensiv3
Accumulated Other Comprehensive Income (Details 1) (USD $) | 12 Months Ended | ||
In Thousands, unless otherwise specified | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2011 |
Reclassifications Out of Accumulated Other Comprehensive Income [Line Items] | ' | ' | ' |
Derivatives Reclassification Adjustment from AOCI, net tax | $67 | $0 | $0 |
Pension Plan Reclassification Adjustment from AOCI, net tax | 243 | 191 | 119 |
Reclassification from Accumulated Other Comprehensive Income | 310 | 191 | 119 |
Interest Expense [Member] | ' | ' | ' |
Reclassifications Out of Accumulated Other Comprehensive Income [Line Items] | ' | ' | ' |
Derivatives Reclassification Adjustment from AOCI, before tax | 67 | 0 | 0 |
General and Administrative Expense [Member] | ' | ' | ' |
Reclassifications Out of Accumulated Other Comprehensive Income [Line Items] | ' | ' | ' |
Pension Plan Reclassification Adjustment from AOCI, before tax | 305 | 248 | 159 |
Income Tax Expense (Benefit) [Member] | ' | ' | ' |
Reclassifications Out of Accumulated Other Comprehensive Income [Line Items] | ' | ' | ' |
Derivatives Reclassification Adjustment from AOCI, tax | 0 | 0 | 0 |
Pension Plan Reclassification Adjustment from AOCI, tax | ($62) | ($57) | ($40) |
Capital_Stock_Narratives_Detai
Capital Stock (Narratives) (Details) (USD $) | 12 Months Ended | 127 Months Ended | |||
Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2011 | Dec. 31, 2013 | Dec. 31, 1996 | |
Share-Based Compensation Arrangement By Share-Based Payment Award [Line Items] | ' | ' | ' | ' | ' |
Treasury Stock, Value Acquired, Cost Method | ' | ' | $0 | ' | ' |
Share-based Compensation Arrangement by Share-based Payment Award, Discount from Market Price, Offering Date | 85.00% | ' | ' | ' | ' |
Employee Stock Purchase Plan Shares Authorized | 750,000 | ' | ' | 750,000 | ' |
Stock issued during the year, Shares, Employee Stock Purchase Plans | 56,938 | 60,028 | 49,000 | 527,340 | ' |
Date Of Amendment Of Stock Option And Incentive Plan By Board Of Directors | ' | '4/13/2011 | ' | ' | ' |
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized | 13,067,675 | ' | ' | 13,067,675 | ' |
Increase In Number Of Shares Authorized For Issuance Under Stock Option And Incentive Plan | ' | 3,700,000 | ' | ' | ' |
Limitation Of Number Of Awards That Can Be Issued Under Stock Option And Incentive Plan | 3,750,000 | ' | ' | 3,750,000 | ' |
Fungible Shares Issuance Ratio | 179.00% | ' | ' | ' | ' |
Equity Instruments Other than Options, Grants in Period | 259,931 | 349,295 | 188,750 | ' | ' |
Options, Grants in Period, Gross | 3,349,052 | 1,220,934 | 1,030,500 | ' | ' |
Options, Grants in Period, Weighted Average Grant Date Fair Value | $4.44 | $3.60 | $5.64 | ' | ' |
Deferred Compensation Arrangement with Individual, Maximum Contractual Term | '10 | ' | ' | ' | ' |
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount | 2,547,580 | 4,700,033 | 3,653,317 | ' | ' |
Employee Service Share-based Compensation, Allocation of Recognized Period Costs, Capitalized Amount | 0 | 0 | 0 | ' | ' |
Percentage Of Outstanding Common Stock | 20.00% | ' | ' | 20.00% | ' |
Shares Authorized For Issuance Under 1996 Stock Option And Incentive Plan | 0 | ' | ' | 0 | 4,072,480 |
Shares held in Employee Stock Option Plan, Suspense Shares | 6,690,845 | ' | ' | 6,690,845 | ' |
Restricted Stock Units Outstanding For Issuance Of Awards | 463,973 | ' | ' | 463,973 | ' |
Incentive Stock Options Granted To Date | 10,218,057 | 8,990,395 | ' | 10,218,057 | ' |
Non Qualified Stock Options Granted To Date | 11,028,074 | 8,906,684 | ' | 11,028,074 | ' |
Common Stock Market Value Per Share On Reporting Date | $4.70 | ' | ' | $4.70 | ' |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Total Intrinsic Value | 5,100,000 | 300,000 | 8,450 | ' | ' |
In The Money Stock Options Exercisable At The Reporting Date | 3,154,220 | ' | ' | 3,154,220 | ' |
Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized | $3,400,000 | ' | ' | $3,400,000 | ' |
Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized, Period for Recognition | '2 years 3 months 21 days | ' | ' | ' | ' |
Annualized Estimated Forfeiture Rate | 6.54% | 5.38% | 5.04% | ' | ' |
Weighted Average Estimated Black Scholes Value Of Option Grants | $2.41 | $1.84 | $2.94 | $2.41 | ' |
Options Granted due to the Spin-off of HART | 1,715,164 | ' | ' | 1,715,164 | ' |
Restricted Stock Units Granted due to the Spin-off of HART | 135,650 | ' | ' | 135,650 | ' |
Preferred Stock - Shares Authorized | 5,000,000 | 5,000,000 | ' | 5,000,000 | ' |
Minimum [Member] | ' | ' | ' | ' | ' |
Share-Based Compensation Arrangement By Share-Based Payment Award [Line Items] | ' | ' | ' | ' | ' |
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period, Maximum | '1 year | ' | ' | ' | ' |
Maximum [Member] | ' | ' | ' | ' | ' |
Share-Based Compensation Arrangement By Share-Based Payment Award [Line Items] | ' | ' | ' | ' | ' |
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period, Maximum | '4 years | ' | ' | ' | ' |
Capital_Stock_Details_1
Capital Stock (Details 1) (USD $) | 12 Months Ended | ||
Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2011 | |
Capital Stock Disclosure [Abstract] | ' | ' | ' |
Opening Balance Stock Options Outstanding | 8,078,509 | 8,519,575 | 7,826,200 |
Begining Balance Weighted Average Exercise Price | $4.25 | $4.52 | $4.38 |
Increase In Number Of Shares Authorized For Issuance Under Stock Option And Incentive Plan | ' | 3,700,000 | ' |
Options, Grants in Period, Gross | 3,349,052 | 1,220,934 | 1,030,500 |
Options, Grants in Period, Weighted Average Grant Date Fair Value | $4.44 | $3.60 | $5.64 |
Stock option exercises during the year, Shares | -2,135,000 | -648,000 | -106,000 |
Options, Forfeitures and Expirations in Period | -1,326,233 | -1,014,000 | -231,500 |
Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price | $5.26 | $6.36 | $5.27 |
Closing Balance Stock Options Outstanding | 6,690,845 | 8,078,509 | 8,519,575 |
Closing Balance Weighted Average Exercise Price | $3.42 | $4.25 | $4.52 |
Begining Balance Restricted Stock Units Outstanding | 677,193 | 539,450 | 467,600 |
Equity Instruments Other than Options, Grants in Period | 259,931 | 349,295 | 188,750 |
Equity Instruments Other than Options, Vested in Period | -281,650 | -164,090 | -116,900 |
Closing Balance Restricted Stock Units Outstanding | 463,973 | 677,193 | 539,450 |
Begining Balance Grant Date Fair Value Of Restricted Stock Units | $3.97 | $4.32 | $3.61 |
Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value | $4.62 | $3.57 | $5.64 |
Closing Balance Grant Date Fair Value Of Restricted Stock Units | $4.32 | $3.97 | $4.32 |
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract] | ' | ' | ' |
Fair Value Assumptions, Expected Volatility Rate | 57.18% | 55.09% | 54.24% |
Fair Value Assumptions, Risk Free Interest Rate | 1.42% | 0.80% | 2.01% |
Fair Value Assumptions, Expected Term | '5 years 8 months 2 days | '5 years 11 months 23 days | '5 years 11 months 8 days |
Fair Value Assumptions, Expected Dividend Rate | 0.00% | 0.00% | 0.00% |
Options, Exercises in Period, Weighted Average Exercise Price | $3.20 | $3.94 | $3.79 |
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period, Weighted Average Grant Date Fair Value | $4.07 | $4.21 | ' |
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period | -191,501 | -47,462 | ' |
Preferred Stock - Shares Authorized | 5,000,000 | 5,000,000 | ' |
Stock Issued During Period Gross Stock Options Exercised | 3,410,483 | 648,000 | 105,625 |
Capital_Stock_Details_2
Capital Stock (Details 2) (USD $) | 12 Months Ended | ||
In Thousands, except Share data, unless otherwise specified | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2011 |
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items] | ' | ' | ' |
Share-based Compensation | $2,670 | $3,321 | $2,863 |
Weighted Average Number Diluted Shares Outstanding Adjustment [Abstract] | ' | ' | ' |
Basic | 30,384,010 | 28,799,377 | 28,451,386 |
Weighted Average Number Diluted Shares Outstanding Adjustment | 1,529,789 | 992,730 | 1,367,348 |
Diluted | 31,913,799 | 29,792,107 | 29,818,734 |
Cost of Sales [Member] | ' | ' | ' |
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items] | ' | ' | ' |
Share-based Compensation | 131 | 87 | 76 |
Research and Development Expense [Member] | ' | ' | ' |
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items] | ' | ' | ' |
Share-based Compensation | 45 | 25 | 21 |
Selling and Marketing Expense [Member] | ' | ' | ' |
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items] | ' | ' | ' |
Share-based Compensation | 223 | 154 | 152 |
General and Administrative Expense [Member] | ' | ' | ' |
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items] | ' | ' | ' |
Share-based Compensation | 2,200 | 2,990 | 2,570 |
Discontinued Operations [Member] | ' | ' | ' |
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items] | ' | ' | ' |
Share-based Compensation | $71 | $65 | $44 |
Capital_Stock_Details_3
Capital Stock (Details 3) (USD $) | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2011 | Dec. 31, 2010 | Dec. 31, 2013 | Dec. 31, 2013 | Dec. 31, 2013 | Dec. 31, 2013 | Dec. 31, 2013 | Dec. 31, 2013 | Dec. 31, 2013 | Dec. 31, 2013 | Dec. 31, 2013 | Dec. 31, 2013 | Dec. 31, 2013 |
In Thousands, except Share data, unless otherwise specified | One Dollar Forty Three Cents To Two Dollars Fifteen Cents [Member] | Two Dollars Twenty Eight Cents [Member] | Two Dollars Fourty Five Cents [Member] | Two Dollars Fifty Six Cents [Member] | Two Dollars Fifty Nine Cents To Three Dollars Fifty Four Cents [Member] | Three Dollars Sixty Four Cents [Member] | Three Dollars Sixty Eight Cents To Three Dollars Ninety Nine Cents [Member] | Four Dollars Four Cents [Member] | Four Dollars Twenty One Cents To Four Dollars Thirty One Cents [Member] | Five Dollars Seventy Three Cents To Six Dollars Fifty Seven Cents [Member] | One Dollar Forty Three Cents To Six Dollars Fifty Seven Cents [Member] | ||||
Share-Based Compensation Arrangement By Share-Based Payment Award [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number | 6,690,845 | 8,078,509 | 8,519,575 | 7,826,200 | 306,358 | 981,082 | 13,172 | 994,618 | 836,338 | 935,371 | 486,706 | 865,617 | 807,500 | 464,083 | 6,690,845 |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term | ' | ' | ' | ' | '4 years 0 months 10 days | '5 years 4 months 13 days | '1 year 5 months 4 days | '7 years 9 months 25 days | '4 years 7 months 28 days | '8 years 10 months 20 days | '3 years 3 months 18 days | '7 years 2 months 12 days | '9 years 10 months 17 days | '0 years 2 months 19 days | '6 years 4 months 2 days |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price | ' | ' | ' | ' | $1.86 | $2.28 | $2.45 | $2.56 | $3.03 | $3.64 | $3.87 | $4.04 | $4.31 | $5.75 | $3.42 |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value | ' | ' | ' | ' | $870 | $2,372 | $30 | $2,128 | $1,397 | $991 | $404 | $571 | $315 | $0 | $9,078 |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number | ' | ' | ' | ' | 306,358 | 981,082 | 13,172 | 198,402 | 723,635 | 0 | 486,706 | 444,865 | 0 | 464,083 | 3,618,303 |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term | ' | ' | ' | ' | '4 years 0 months 10 days | '5 years 4 months 13 days | '1 year 5 months 4 days | '7 years 9 months 25 days | '4 years 7 months 28 days | ' | '3 years 3 months 18 days | '7 years 2 months 12 days | ' | '0 years 2 months 19 days | '4 years 6 months 18 days |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price | ' | ' | ' | ' | $1.86 | $2.28 | $2.45 | $2.56 | $3.10 | $0 | $3.87 | $4.04 | $0 | $5.75 | $3.30 |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value | ' | ' | ' | ' | $870 | $2,372 | $30 | $425 | $1,158 | $0 | $404 | $294 | $0 | $0 | $5,553 |
Related_Party_Transactions_Nar
Related Party Transactions (Narratives) (Details) (USD $) | 12 Months Ended |
Dec. 31, 2013 | |
Related Party Transactions [Abstract] | ' |
HART Sublease Rent | $26,000 |
Transition Services Charged to HART | $100,000 |
Segment_and_Related_Informatio1
Segment and Related Information (Narratives) (Details) (USD $) | 3 Months Ended | 12 Months Ended | |||||||||
In Thousands, unless otherwise specified | Dec. 31, 2013 | Sep. 30, 2013 | Jun. 30, 2013 | Mar. 31, 2013 | Dec. 31, 2012 | Sep. 30, 2012 | Jun. 30, 2012 | Mar. 31, 2012 | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2011 |
Segment and Related Information Disclosure [Abstract] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Revenues | $27,854 | $25,137 | $26,094 | $26,086 | $28,249 | $26,104 | $28,496 | $28,322 | $105,171 | $111,171 | $108,864 |
Segment_and_Related_Informatio2
Segment and Related Information (Details 1) (USD $) | 3 Months Ended | 12 Months Ended | |||||||||
In Thousands, unless otherwise specified | Dec. 31, 2013 | Sep. 30, 2013 | Jun. 30, 2013 | Mar. 31, 2013 | Dec. 31, 2012 | Sep. 30, 2012 | Jun. 30, 2012 | Mar. 31, 2012 | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2011 |
Segment Reporting Information [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Revenues | $27,854 | $25,137 | $26,094 | $26,086 | $28,249 | $26,104 | $28,496 | $28,322 | $105,171 | $111,171 | $108,864 |
Net Assets | 94,485 | ' | ' | ' | 104,213 | ' | ' | ' | 94,485 | 104,213 | ' |
Segment, Geographical, United States [Member] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Segment Reporting Information [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Revenues | ' | ' | ' | ' | ' | ' | ' | ' | 63,810 | 65,190 | 64,185 |
Net Assets | 37,497 | ' | ' | ' | 51,218 | ' | ' | ' | 37,497 | 51,218 | ' |
Long-lived assets, net | 14,128 | ' | ' | ' | 16,744 | ' | ' | ' | 14,128 | 16,744 | ' |
Segment, Geographical, United Kingdom [Member] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Segment Reporting Information [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Revenues | ' | ' | ' | ' | ' | ' | ' | ' | 23,123 | 27,137 | 26,160 |
Net Assets | 32,214 | ' | ' | ' | 29,741 | ' | ' | ' | 32,214 | 29,741 | ' |
Long-lived assets, net | 2,343 | ' | ' | ' | 2,441 | ' | ' | ' | 2,343 | 2,441 | ' |
Rest Of The World [Member] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Segment Reporting Information [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Revenues | ' | ' | ' | ' | ' | ' | ' | ' | 18,238 | 18,844 | 18,519 |
Net Assets | 24,774 | ' | ' | ' | 23,254 | ' | ' | ' | 24,774 | 23,254 | ' |
Long-lived assets, net | 6,913 | ' | ' | ' | 6,591 | ' | ' | ' | 6,913 | 6,591 | ' |
Total [Member] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Segment Reporting Information [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Long-lived assets, net | $23,384 | ' | ' | ' | $25,776 | ' | ' | ' | $23,384 | $25,776 | ' |
Allowance_for_doubtful_debts_D
Allowance for doubtful debts (Details 1) (USD $) | 12 Months Ended | ||
In Thousands, unless otherwise specified | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2011 |
Movement in Valuation Allowances and Reserves Roll Forward [Abstract] | ' | ' | ' |
Beginning Balance | $194 | $302 | $273 |
Charged To Bad Debt Expense | 172 | -31 | 67 |
Charged To Allowance | -8 | -77 | -38 |
Ending Balance | $358 | $194 | $302 |
Warranties_Details_1
Warranties (Details 1) (USD $) | 12 Months Ended | ||
In Thousands, unless otherwise specified | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2011 |
Product Warranty Disclosure [Abstract] | ' | ' | ' |
Warranty, Beginning Balance | $222 | $144 | $158 |
Warranty payments | -179 | -136 | -58 |
Warranty additions | 262 | 214 | 44 |
Warranty, Ending Balance | $305 | $222 | $144 |
Quarterly_Financial_Informatio2
Quarterly Financial Information (unaudited) (Details 1) (USD $) | 3 Months Ended | 12 Months Ended | |||||||||
In Thousands, except Per Share data, unless otherwise specified | Dec. 31, 2013 | Sep. 30, 2013 | Jun. 30, 2013 | Mar. 31, 2013 | Dec. 31, 2012 | Sep. 30, 2012 | Jun. 30, 2012 | Mar. 31, 2012 | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2011 |
Income per share: | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Basic earnings per common share | ($0.02) | ($0.03) | ($0.01) | $0 | $0.04 | ($0.01) | $0.02 | $0.02 | ($0.06) | $0.09 | $0.14 |
Diluted Earnings Per Common Share | ($0.02) | ($0.03) | ($0.01) | $0 | $0.04 | ($0.01) | $0.02 | $0.02 | ($0.06) | $0.08 | $0.13 |
Basic earnings per common share from continuing operations | ($0.01) | $0 | $0 | $0.03 | $0.04 | $0.02 | $0.05 | $0.04 | $0.02 | $0.16 | $0.19 |
Income (Loss) from Discontinued Operations, Net of Tax, Per Basic Share | ($0.01) | ($0.03) | ($0.01) | ($0.03) | $0 | ($0.03) | ($0.03) | ($0.02) | ($0.08) | ($0.07) | ($0.05) |
Diluted earnings per common share from continuing operations | ($0.01) | $0 | $0 | $0.03 | $0.04 | $0.02 | $0.05 | $0.04 | $0.02 | $0.15 | $0.18 |
Discontinued operations | ($0.01) | ($0.03) | ($0.01) | ($0.03) | $0 | ($0.03) | ($0.03) | ($0.02) | ($0.08) | ($0.07) | ($0.05) |
Quarterly Financial Information Disclosure [Abstract] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Revenues | $27,854 | $25,137 | $26,094 | $26,086 | $28,249 | $26,104 | $28,496 | $28,322 | $105,171 | $111,171 | $108,864 |
Cost of product revenues | 15,806 | 13,838 | 14,005 | 13,826 | 14,856 | 14,135 | 14,901 | 14,939 | 57,475 | 58,831 | 58,672 |
Gross profit | 12,048 | 11,299 | 12,089 | 12,260 | 13,393 | 11,969 | 13,595 | 13,383 | 47,696 | 52,340 | 50,192 |
Total operating expenses | 12,997 | 10,885 | 11,343 | 10,934 | 11,255 | 10,813 | 11,121 | 11,321 | 46,159 | 44,510 | 41,787 |
Operating income | -949 | 414 | 746 | 1,326 | 2,138 | 1,156 | 2,474 | 2,062 | 1,537 | 7,830 | 8,405 |
Other (expense) income, net | -319 | -358 | -330 | -95 | -149 | -178 | -226 | -385 | -1,102 | -938 | -1,537 |
Income From Continuing Operations, Total | -1,268 | 56 | 416 | 1,231 | 1,989 | 978 | 2,248 | 1,677 | 435 | 6,892 | 6,868 |
Total Income Tax Expense (Benefit) | -1,013 | 105 | 321 | 299 | 817 | 278 | 698 | 605 | -288 | 2,398 | 1,579 |
Net income | -756 | -984 | -186 | 96 | 1,200 | -133 | 774 | 529 | -1,830 | 2,370 | 3,812 |
Income from continuing operations | -255 | -49 | 95 | 932 | 1,172 | 700 | 1,550 | 1,072 | 723 | 4,494 | 5,289 |
Income from discontinued operations, net of tax | ($501) | ($935) | ($281) | ($836) | $28 | ($833) | ($776) | ($543) | ($2,553) | ($2,124) | ' |